

Treatment of chronic migraine and chronic tension-type headache

Final evidence report: Appendices

April 14, 2017

Health Technology Assessment Program (HTA) Washington State Health Care Authority PO Box 42712 Olympia, WA 98504-2712 (360) 725-5126 www.hca.wa.gov/about-hca/health-technology-assessment shtap@hca.wa.gov

Treatment of Chronic Migraine and Chronic Tension-Type Headache

Provided by:



Spectrum Research, Inc.

Final Report APPENDICES

April 14, 2017

TABLE OF CONTENTS


APPENDICES

APPENDIX A. ALGORITHM FOR ARTICLE SELECTION	1
APPENDIX B. SEARCH STRATEGIES	2
APPENDIX C. EXCLUDED ARTICLES	7
APPENDIX D. RISK OF BIAS AND STRENGTH OF EVIDENCE	18
APPENDIX E. STUDY QUALITY: ROB EVALUATION	21
APPENDIX F. STUDY CHARACTERISTICS AND PATIENT DEMOGRAPHICS	31
APPENDIX G. DATA ABSTRACTION TABLES: EFFICACY OUTCOMES	60
APPENDIX H. DATA ABSTRACTION TABLES: SAFETY OUTCOMES	96
APPENDIX I. CLINICAL EXPERTS	. 107

TABLES

APPENDIX TABLE E1. RISK OF BIAS FOR RCTS EVALUATING BONTA IN CHRONIC MIGRAINE
APPENDIX TABLE E2. RISK OF BIAS FOR RCTS EVALUATING BONTA IN CHRONIC TENSION-TYPE HEADACHE
APPENDIX TABLE E3. RISK OF BIAS FOR RCTS EVALUATING BONTA IN CHRONIC DAILY HEADACHE
APPENDIX TABLE E4. RISK OF BIAS FOR RCTS EVALUATING ACUPUNCTURE IN CHRONIC MIGRAINE
APPENDIX TABLE E5. RISK OF BIAS FOR RCTS EVALUATING ACUPUNCTURE IN CHRONIC TENSION-TYPE HEADACHE
APPENDIX TABLE E6. RISK OF BIAS FOR RCTS EVALUATING MANUAL THERAPY IN CHRONIC MIGRAINE
APPENDIX TABLE E7. RISK OF BIAS FOR RCTS EVALUATING MANUAL THERAPY IN CHRONIC TENSION-TYPE HEADACHE
APPENDIX TABLE E8. RISK OF BIAS FOR RCTS EVALUATING MASSAGE IN CHRONIC DAILY HEADACHE
APPENDIX TABLE E9. RISK OF BIAS FOR RCTS EVALUATING TRANSCRANIAL MAGNETIC STIMULATION IN CHRONIC MIGRAINE
APPENDIX TABLE E10. RISK OF BIAS FOR RCTS EVALUATING TRIGGER POINT INJECTION IN CHRONIC TENSION-TYPE HEADACHE
APPENDIX TABLE F1. STUDY CHARACTERISTICS AND PATIENT DEMOGRAPHICS FOR BONTA IN CHRONIC MIGRAINE
APPENDIX TABLE F2. STUDY CHARACTERISTICS AND PATIENT DEMOGRAPHICS FOR ACUPUNCTURE IN CHRONIC MIGRAINE
APPENDIX TABLE F3. STUDY CHARACTERISTICS AND PATIENT DEMOGRAPHICS FOR MANUAL THERAPY IN CHRONIC MIGRAINE
Appendix Table F4. Study Characteristics and Patient Demographics for Transcranial Magnetic Stimulation in Chronic Migraine
APPENDIX TABLE F5. STUDY CHARACTERISTICS AND PATIENT DEMOGRAPHICS FOR BONTA IN CHRONIC TENSION-TYPE HEADACHE4
APPENDIX TABLE F6. STUDY CHARACTERISTICS AND PATIENT DEMOGRAPHICS FOR ACUPUNCTURE IN CHRONIC TENSION-TYPE HEADACHE
APPENDIX TABLE F7. STUDY CHARACTERISTICS AND PATIENT DEMOGRAPHICS FOR MANUAL THERAPY IN CHRONIC TENSION-TYPE HEADACHE
Appendix Table F8. Study Characteristics and Patient Demographics for Trigger Point Injections in Chronic Tension-Type Headache
APPENDIX TABLE F9. STUDY CHARACTERISTICS AND PATIENT DEMOGRAPHICS FOR BONTA IN CHRONIC DAILY HEADACHE

APPENDIX TABLE F10.	STUDY CHARACTERISTICS AND PATIENT DEMOGRAPHICS FOR MASSAGE VS. SHAM IN CHRONIC DAILY HEADACHE 59
APPENDIX TABLE G1.	EFFICACY OUTCOMES FROM RCTS EVALUATING BONTA FOR CHRONIC MIGRAINE
APPENDIX TABLE G2. I	EFFICACY OUTCOMES FROM RCTS EVALUATING BONTA FOR CHRONIC TENSION-TYPE HEADACHE65
APPENDIX TABLE G3. I	EFFICACY OUTCOMES FROM RCTS EVALUATING BONTA FOR CHRONIC DAILY HEADACHE
APPENDIX TABLE G4. I	EFFICACY OUTCOMES FROM RCTS EVALUATING ACUPUNCTURE FOR CHRONIC MIGRAINE71
APPENDIX TABLE G5. I	EFFICACY OUTCOMES FROM RCTS EVALUATING ACUPUNCTURE FOR CHRONIC TENSION-TYPE HEADACHE
	Efficacy outcomes from RCTs Evaluating Manual Therapy for Chronic Migraine and Chronic Tension-Type Headache
APPENDIX TABLE G7.	EFFICACY OUTCOMES FROM RCTS EVALUATING MASSAGE THERAPY FOR CHRONIC DAILY HEADACHE91
	EFFICACY OUTCOMES FROM RCTS EVALUATING TRANSCRANIAL MAGNETIC STIMULATION FOR CHRONIC MIGRAINE
	Efficacy Outcomes Results from RCTs Evaluating Trigger Point Injections for Chronic Tension-Type Headache
APPENDIX TABLE H1. S	SAFETY OUTCOMES FROM RCTS EVALUATING BONTA IN INCLUDED STUDIES
APPENDIX TABLE H2. S	SAFETY OUTCOMES FROM RCTS EVALUATING ACUPUNCTURE
	Safety Outcomes from RCTs Evaluating Manual Therapy for Chronic Migraine and Chronic Tension- Type Headache
APPENDIX TABLE H4.	SAFETY OUTCOMES FROM RCTS EVALUATING MASSAGE THERAPY FOR CHRONIC DAILY HEADACHE100
	Safety Outcomes from RCTs Evaluating Transcranial Magnetic Stimulation for Chronic Migraine
	SAFETY OUTCOMES FROM RCTS EVALUATING TRIGGER POINT INJECTIONS FOR CHRONIC TENSION-TYPE HEADACHE
	UNPUBLISHED SAFETY OUTCOMES FROM NCT01432379: BOTOX® PROPHYLAXIS IN PATIENTS WITH CHRONIC MIGRAINE, PRIMARY AND SECONDARY OUTCOMES
	UNPUBLISHED SAFETY OUTCOMES FROM NCT01432379: BOTOX® PROPHYLAXIS IN PATIENTS WITH CHRONIC MIGRAINE, SERIOUS ADVERSE EVENTS
-	UNPUBLISHED SAFETY OUTCOMES FROM NCT02147561: A SAFETY AND EFFICACY STUDY OF BOTOX® IN KOREAN ADULTS WITH CHRONIC MIGRAINE, PRIMARY OUTCOME
	. UNPUBLISHED SAFETY OUTCOMES FROM NCT02147561: A SAFETY AND EFFICACY STUDY OF BOTOX® IN KOREAN ADULTS WITH CHRONIC MIGRAINE, SERIOUS AND NONSERIOUS ADVERSE EVENTS



APPENDIX A. Algorithm for Article Selection

APPENDIX B. Search Strategies

Below is the search strategy for PubMed. Parallel strategies were used to search other electronic databases listed below. Keyword searches were conducted in the other listed resources.

Search strategy (PubMed)

Search date: Inception through 10/23/2016 Filters: Abstract available, English, Human

	Search terms	Citations
	TRIGGER POINTS	
1.	Headache Disorders[MeSH] OR Headache Disorders, Primary[MeSH] OR Tension- Type Headache[MeSH] OR Migraine Disorders[MeSH] OR Headache/therapy [MeSH] OR "tension headache"[TIAB] OR "migraine"[TIAB] OR migrain*[TIAB] OR tension*[TIAB]	
2.	Injections[MeSH] OR Injections, intramuscular[MeSH] OR inject*[TIAB] OR injection*[TIAB] OR "Injection"[TIAB]	227,743
3.	Trigger Points[MeSH] OR trigger*[TIAB] OR trigger point*[TIAB] OR "trigger"[TIAB] OR "trigger point"[TIAB] OR "trigger points"[TIAB] OR "dry needling"[TIAB] OR "dry needle"[TIAB] OR Anesthetics, local[MeSH] OR Steroids[MeSH]	395,049
4.	#1 AND #2 AND #3	310
	BOTULINUM TOXIN	
5.	Botulinum Toxins, Type A[MeSH] OR "botulinum toxin type a"[TIAB] OR onabotulinumtoxinA[All Fields] OR "botox"[TIAB] OR "botulinum"[TIAB] OR botox*[TIAB] OR botulinum*[TIAB]	8,174
6.	#1 AND #5	394
7	TRANSCRANIAL MAGNETIC STIMULATION	
8.	Transcranial Magnetic Stimulation[MeSH] OR Magnetic Field Therapy[MeSH] OR Magnets[MeSH] OR "transcranial magnetic stimulation"[TIAB] OR "magnetic stimulation"[TIAB] OR "magnetic stimulation therapy"[TIAB] OR "magnetic therapy"[TIAB] OR "transcranial stimulation therapy"[TIAB] OR "transcranial stimulation"[TIAB] OR "transcranial therapy"[TIAB] OR magnetic stimulation*[TIAB] OR transcranial stimulation*[TIAB]	
9.	#1 AND #7	170
	ACUPUNCTURE	
10.	Acupuncture[MeSH] OR Acupuncture Therapy[MeSH] OR "acupuncture"[TIAB] OR "acupuncture therapy"[TIAB] OR "manual acupuncture"[TIAB] OR "electroacupuncture"[TIAB] OR "auricular acupuncture"[TIAB] OR "eye acupuncture"[TIAB] or "scalp acupuncture"[TIAB] OR acupunct*[TIAB] OR acupuncture*[TIAB] OR electroacupunct*[TIAB] OR electro-acupunct*[TIAB]	7,712
11.	#1 AND #9	350

	Search terms	Citations
	CHIROPRACTIC/MANUAL THERAPY	
12.	Musculoskeletal Manipulations[MeSH] OR Manipulation, Spinal[MeSH] OR Manipulation, Chiropractic[MeSH] OR Manipulation, Osteopathic[MeSH] OR "chiropractic"[TIAB] OR "osteopathic manipulation"[TIAB] OR "chiropractic manipulation"[TIAB] OR "cervical manipulation"[TIAB] OR "spinal manipulation"[TIAB] OR "manual therapy"[TIAB] OR chiropract*[TIAB] OR osteopath*[TIAB]	10,118
13.	#1 AND #11	358
	MASSAGE	
14.	Massage[MeSH] OR "massage"[TIAB] OR "massage therapy"[TIAB] OR massage*[TIAB] OR massage therapy*[TIAB]	4832
15.	#1 AND #13	174

Search strategy (EMBASE)

Search date: Inception through 11/10/2016

Filters: age (young adult through elderly), study type (human, controlled study, clinical trial, randomized controlled trial, controlled clinical trial, systematic review), publication type (article)

	Search terms	Citations
	TRIGGER POINTS	
1.	"Headache Disorders"/exp OR "Headache Disorders, Primary"/exp OR "Tension- Type Headache"/exp OR "Migraine Disorders"/exp OR "Headache/therapy"/exp OR "tension headache":ab,ti OR "migraine":ab,ti OR migrain*:ab,ti OR tension*:ab,ti	355,493
2.	Injections/exp OR Injections, intramuscular/exp OR inject*:ab,ti OR injection*:ab,ti OR "Injection":ab,ti	807,364
3.	"Trigger Points"/exp OR trigger*:ab,ti OR "trigger point":ab,ti OR "trigger points":ab,ti OR "dry needling":ab,ti OR "dry needle":ab,ti OR "Anesthetics, local"/exp OR "local anesthetics"/exp OR Steroids/exp	1,770,890
4.	#1 AND #2 AND #3	1,146
	BOTULINUM TOXIN	
5.	"Botulinum Toxins, Type A"/exp OR "botulinum toxin type a":ab,ti OR onabotulinumtoxinA OR "botox":ab,ti OR botox*:ab,ti OR botulinum*:ab,ti	27,186
6.	#1 AND #5	486
	TRANSCRANIAL MAGNETIC STIMULATION	
7.	"Transcranial Magnetic Stimulation"/exp OR "Magnetic Field Therapy"/exp OR Magnets/exp OR "transcranial magnetic stimulation":ab,ti OR "magnetic stimulation":ab,ti OR "magnetic stimulation therapy":ab,ti OR "magnetic	27,005

	Search terms	Citations
	therapy":ab,ti OR "transcranial stimulation therapy":ab,ti OR "transcranial stimulation":ab,ti OR "transcranial therapy":ab,ti OR "magnetic stimulation*":ab,ti OR "transcranial stimulation*":ab,ti	
8.	#1 AND #7	311
	ACUPUNCTURE	
9.	Acupuncture/exp OR "Acupuncture Therapy"/exp OR "acupuncture":ab,ti OR "acupuncture therapy":ab,ti OR "manual acupuncture":ab,ti OR "electroacupuncture":ab,ti OR "auricular acupuncture":ab,ti OR "eye acupuncture":ab,ti or "scalp acupuncture":ab,ti OR acupunct*:ab,ti OR acupuncture*:ab,ti OR electroacupunct*:ab,ti OR electro-acupunct*:ab,ti	40,097
10.	#1 AND #9	740
	CHIROPRACTIC/MANUAL THERAPY	
11.	"Musculoskeletal Manipulations"/exp OR "Manipulation, Spinal"/exp OR "Manipulation, Chiropractic"/exp OR "Manipulation, Osteopathic"/exp OR "chiropractic":ab,ti OR "osteopathic manipulation":ab,ti OR "chiropractic manipulation":ab,ti OR "cervical manipulation":ab,ti OR "spinal manipulation":ab,ti OR "manual therapy":ab,ti OR chiropract*:ab,ti OR osteopath*:ab,ti	34,957
12.	#1 AND #11	586
	MASSAGE	
13.	Massage/exp OR "massage":ab,ti OR "massage therapy":ab,ti OR massage*:ab,ti OR massage therapy*:ab,ti	4,746
14.	#1 AND #13	117

Search strategy (Cochrane)

Search date: Inception through 11/10/2016

	Search terms	Citations
	TRIGGER POINTS	
1.	"Headache Disorders" (MeSH) OR "Headache Disorders, Primary" (MeSH) OR	8293
	"Tension-Type Headache" (MeSH) OR "Migraine Disorders" (MeSH) OR	
	"Headache/therapy" (MeSH) OR "tension headache": ab, ti OR "migraine": ab, ti OR	
	migrain*[TIAB] OR tension*[TIAB]	
2.	Injections(MeSH) OR Injections, intramuscular(MeSH) OR inject*:ab,ti OR	43422
	injection*:ab,ti OR "Injection":ab,ti	
3.	"Trigger Points" (MeSH) OR trigger*:ab,ti OR "trigger point":ab,ti OR "trigger	5649
	points":ab,ti OR "dry needling":ab,ti OR "dry needle":ab,ti OR "Anesthetics,	
	local"(MeSH) OR "local anesthetics"(MeSH) OR Steroids(MeSH)	
4.	#1 AND #2 AND #3	24*

	Search terms	Citations
	BOTULINUM TOXIN	
5.	"Botulinum Toxins, Type A"(MeSH) OR "botulinum toxin type a":ab,ti OR	2126
	onabotulinumtoxinA OR "botox":ab,ti OR botox*:ab,ti OR botulinum*:ab,ti	
6.	#1 AND #5	132
	TRANSCRANIAL MAGNETIC STIMULATION	
7.	"Transcranial Magnetic Stimulation" (MeSH) OR "Magnetic Field Therapy" (MeSH)	2643
	OR Magnets(MeSH) OR "transcranial magnetic stimulation":ab,ti OR "magnetic	
	stimulation":ab,ti OR "magnetic stimulation therapy":ab,ti OR "magnetic	
	therapy":ab,ti OR "transcranial stimulation therapy":ab,ti OR "transcranial	
	stimulation":ab,ti OR "transcranial therapy":ab,ti OR "magnetic	
	stimulation"*:ab,ti OR "transcranial stimulation"*:ab,ti	
8.	#1 AND #7	37
	ACUPUNCTURE	
9.	Acupuncture(MeSH) OR "Acupuncture Therapy"(MeSH) OR "acupuncture":ab,ti	8618
	OR "acupuncture therapy":ab,ti OR "manual acupuncture":ab,ti OR	
	"electroacupuncture":ab,ti OR "auricular acupuncture":ab,ti OR "eye	
	acupuncture":ab,ti or "scalp acupuncture":ab,ti OR acupunct*:ab,ti OR	
10	acupuncture*:ab,ti OR electroacupunct*:ab,ti OR electro-acupunct*:ab,ti	240
10.	#1 AND #9	319
	CHIROPRACTIC/MANUAL THERAPY	
11.	"Musculoskeletal Manipulations" (MeSH) OR "Manipulation, Spinal" (MeSH) OR	1777
	"Manipulation, Chiropractic" (MeSH) OR "Manipulation, Osteopathic" (MeSH) OR	
	"chiropractic":ab,ti OR "osteopathic manipulation":ab,ti OR "chiropractic	
	manipulation":ab,ti OR "cervical manipulation":ab,ti OR "spinal	
	manipulation":ab,ti OR "manual therapy":ab,ti OR chiropract*:ab,ti OR	
12.	osteopath*:ab,ti #1 AND #11	85
12.	MASSAGE	0.5
13.	Massage(MeSH) OR "massage":ab,ti OR "massage therapy":ab,ti OR	2485
15.	massage(inerapy :ab,ti OR massage :ab,ti OR massage therapy :ab,ti OR massage therapy :ab,ti	2403
14.	#1 AND #13	98
14.		50

*"Other review" identified from search was excluded

[†]Method study identified from search was excluded

Parallel strategies were used to search the Cochrane Library, EMBASE, and others listed below. Keyword searches were conducted in the other listed resources. In addition, handsearching of included studies was performed.

Electronic Database Searches

The following databases have been searched for relevant information:

Agency for Healthcare Research and Quality (AHRQ) Cochrane Database of Systematic Reviews Cochrane Registry of Clinical Trials (CENTRAL) Cochrane Review Methodology Database Database of Reviews of Effectiveness (Cochrane Library) EMBASE PubMed Informational Network of Agencies for Health Technology Assessment (INAHTA) NHS Economic Evaluation Database

Additional Economics, Clinical Guideline and Gray Literature Databases

AHRQ - Healthcare Cost and Utilization Project Canadian Agency for Drugs and Technologies in Health Centers for Medicare and Medicaid Services (CMS) Food and Drug Administration (FDA) Google Institute for Clinical Systems Improvement (ICSI) National Guideline Clearinghouse

APPENDIX C. Excluded Articles

Articles excluded as primary studies <u>after full text review</u>, with reason for exclusion.

	Citation	Reason for exclusion after full-text review
	RCTs considered and excluded	
1.	(2014). "Medical devices; neurological devices; classification of the transcranial magnetic stimulator for headache. Final order." <u>Fed</u> <u>Regist</u> 79 (130): 38457-38459.	Regulatory document
2.	Alecrim-Andrade, J., J. A. Maciel-Junior, et al. (2008). "Acupuncture in migraine prevention: a randomized sham controlled study with 6-months posttreatment follow-up." <u>Clin J</u> <u>Pain</u> 24 (2): 98-105.	Included episodic and chronic migraine, did not stratify; baseline characteristics suggest primarily episodic migraine
3.	Alecrim-Andrade, J., J. A. Maciel-Junior, et al. (2006). "Acupuncture in migraine prophylaxis: a randomized sham- controlled trial." <u>Cephalalgia</u> 26 (5): 520-529.	Included episodic and chronic migraine, did not stratify; baseline characteristics suggest primarily episodic migraine
4.	Almaraz, A. C., E. Dilli, et al. (2010). "The effect of prophylactic medications on TMS for migraine aura." <u>Headache</u> 50 (10): 1630- 1633.	Subgroup analysis of Lipton 2010 study, which was excluded because study population did not meet inclusion criteria of interest
5.	Ambrosio, E. M., K. Bloor, et al. (2012). "Costs and consequences of acupuncture as a treatment for chronic pain: a systematic review of economic evaluations conducted alongside randomised controlled trials." <u>Complement Ther Med</u> 20 (5): 364-374.	Systematic review article of economic evaluations, includes conditions beyond chronic headache; 2 headache econ evaluations included episodic and chronic headache, did not stratify
6.	Anand, K. S., A. Prasad, et al. (2006). "Botulinum toxin type A in prophylactic treatment of migraine." <u>Am J Ther</u> 13 (3): 183-187.	Included episodic and chronic migraine, did not stratify
7.	Anderson, R. E. and C. Seniscal (2006). "A comparison of selected osteopathic treatment and relaxation for tension-type headaches." <u>Headache</u> 46 (8): 1273-1280.	< 15 subjects per group
8.	Astin, J. A. and E. Ernst (2002). "The effectiveness of spinal manipulation for the treatment of headache disorders: a systematic review of randomized clinical trials." <u>Cephalalgia</u> 22 (8): 617-623.	Review article, not a formal systematic review
9.	Bendtsen, L., S. Evers, et al. (2010). "EFNS guideline on the treatment of tension-type headache - report of an EFNS task force." <u>Eur J Neurol</u> 17 (11): 1318-1325.	Guideline with minimal detail about studies and evidence base

Citation	Reason for exclusion after full-text review
^{10.} Bhola, R., E. Kinsella, et al. (2015). "Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program." <u>J Headache Pain</u> 16 : 535.	Case series, not designed to primarily assess safety; 69% chronic migraine, not stratified
^{11.} Biondi, D. M. (2005). "Noninvasive treatments for headache." <u>Expert Rev Neurother</u> 5(3): 355-362.	Older systematic review, not a formal analysis; the 1 included acupuncture study does not meet inclusion criteria for HTA
^{12.} Blumenfeld, A. M., J. D. Schim, et al. (2008). "Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine." <u>Headache</u> 48 (2): 210-220.	< 15 subjects per group
 Boline, P. D., K. Kassak, et al. (1995). "Spinal manipulation vs. amitriptyline for the treatment of chronic tension-type headaches: a randomized clinical trial." <u>J Manipulative Physiol Ther</u> 18(3): 148- 154. 	Included episodic and chronic migraine, did not stratify; did not assess outcome measures of interest
14. Bronfort, G., N. Nilsson, et al. (2004). "Non-invasive physical treatments for chronic/recurrent headache." <u>Cochrane Database</u> <u>Syst Rev(3)</u> : Cd001878.	Cochrane systematic review; included studies that did not meet inclusion criteria for HTA
 Bronfort, G., W. J. Assendelft, et al. (2001). "Efficacy of spinal manipulation for chronic headache: a systematic review." <u>J</u> <u>Manipulative Physiol Ther</u> 24(7): 457-466. 	More recent systematic review is Bronfort 2014
16. Bryans, R., M. Descarreaux, et al. (2011). "Evidence-based guidelines for the chiropractic treatment of adults with headache." <u>J Manipulative Physiol Ther</u> 34 (5): 274-289.	Guideline; some included studies did not meet inclusion criteria for HTA
^{17.} Cady, R. and C. Schreiber (2008). "Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues." <u>Headache</u> 48 (6): 900-913.	Included episodic and chronic migraine, did not stratify
^{18.} Carlsson, J. and U. Rosenhall (1990). "Oculomotor disturbances in patients with tension headache treated with acupuncture or physiotherapy." <u>Cephalalgia</u> 10 (3): 123-129.	Did not meet inclusion criteria for outcomes of interest
19. Castien, R., A. Blankenstein, et al. (2013). "The working mechanism of manual therapy in participants with chronic tension-type headache." J Orthop Sports Phys Ther 43 (10): 693-699.	Nonrandomized, comparative study
^{20.} Cernuda-Morollon, E., C. Ramon, et al. (2015). "Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?" <u>Cephalalgia</u> 35 (10): 864- 868.	Case series, not designed to primarily assess safety
21. Chaibi, A. and M. B. Russell (2014). "Manual therapies for primary chronic headaches: a systematic review of randomized controlled trials." <u>J Headache Pain</u> 15: 67.	Systematic review; included studies that did not meet inclusion criteria for HTA

Citation	Reason for exclusion after full-text review
 Chaibi, A., P. J. Tuchin, et al. (2011). "Manual therapies for migraine: a systematic review." <u>J Headache Pain</u> 12(2): 127-133. 	More recent systematic review is Chaibi 2014
^{23.} Conforto, A. B., E. Amaro, Jr., et al. (2014). "Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine." <u>Cephalalgia</u> 34 (6): 464-472.	< 15 subjects per group
^{24.} Cummings, M. (2009). "Modellvorhaben Akupunktura summary of the ART, ARC and GERAC trials." <u>Acupunct Med</u> 27(1): 26-30.	Review of 4 large trials, all of which included episodic and chronic migraine and tension type headache, not stratified
^{25.} Davis, M. A., R. W. Kononowech, et al. (2008). "Acupuncture for tension-type headache: a meta-analysis of randomized, controlled trials." <u>J Pain</u> 9 (8): 667-677.	Systematic review; included studies did not meet inclusion criteria for HTA
26. De Hertogh, W., P. Vaes, et al. (2009). "Preliminary results, methodological considerations and recruitment difficulties of a randomised clinical trial comparing two treatment regimens for patients with headache and neck pain." <u>BMC Musculoskelet Disord</u> 10 : 115.	Did not assess population of interest
^{27.} Deng, Z. Q., H. Zheng, et al. (2012). "Health economic evaluation of acupuncture along meridians for treating migraine in China: results from a randomized controlled trial." <u>BMC Complement Altern Med</u> 12 : 75.	RCTs that included episodic
^{28.} Diener, H. C., D. W. Dodick, et al. (2014). "Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine." <u>Eur J Neurol</u> 21 (6): 851-859.	Pooled analysis of multiple trials for safety outcomes
^{29.} Diener, H. C., K. Kronfeld, et al. (2006). "Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial." <u>Lancet Neurol</u> 5(4): 310-316.	Included episodic and chronic migraine, did not stratify; baseline characteristics suggest primarily episodic migraine
 ^{30.} Dodick, D. W., C. T. Schembri, et al. (2010). "Transcranial magnetic stimulation for migraine: a safety review." <u>Headache</u> 50(7): 1153-1163. 	Review article with focus on safety, includes conditions beyond chronic headache
 ^{31.} Dodick, D. W., A. Mauskop, et al. (2005). "Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study." <u>Headache</u> 45(4): 315-324. 	Subgroup analysis of subjects who were not taking prophylactic headache medication, from Mathew 2005
 ^{32.} Dowson, D. I., G. T. Lewith, et al. (1985). "The effects of acupuncture versus placebo in the treatment of headache." <u>Pain</u> 21(1): 35-42. 	Included episodic and chronic migraine, did not stratify; comparator is "mock transcutaneous nerve stimulation"

Citation	Reason for exclusion after full-text review
^{33.} Endres, H. G., G. Bowing, et al. (2007). "Acupuncture for tension- type headache: a multicentre, sham-controlled, patient-and observer-blinded, randomised trial." <u>J Headache Pain</u> 8(5): 306- 314.	>50% episodic tension type headache, did not stratify
^{34.} Erdemoglu, A. K. and A. Varlibas (2007). "The long-term efficacy and safety of botulinum toxin in refractory chronic tension-type headache." <u>J Headache Pain</u> 8(5): 294-300.	Case series, not designed to primarily assess safety
 Ernst, E. (2004). "Manual therapies for pain control: chiropractic and massage." <u>Clin J Pain</u> 20(1): 8-12. 	Review article, not a formal systematic review
36. Espi-Lopez, G. V., A. Gomez-Conesa, et al. (2014). "Treatment of tension-type headache with articulatory and suboccipital soft tissue therapy: A double-blind, randomized, placebo-controlled clinical trial." J Bodyw Mov Ther 18 (4): 576-585.	>50% episodic tension type headache, did not stratify
37. Espi-Lopez, G. V., C. Rodriguez-Blanco, et al. (2014). "Effect of manual therapy techniques on headache disability in patients with tension-type headache. Randomized controlled trial." <u>Eur J Phys</u> <u>Rehabil Med</u> 50(6): 641-647.	>50% episodic tension type headache, did not stratify
^{38.} Evers, S., J. Vollmer-Haase, et al. (2004). "Botulinum toxin A in the prophylactic treatment of migrainea randomized, double-blind, placebo-controlled study." <u>Cephalalgia</u> 24(10): 838-843.	Included episodic and chronic migraine, did not stratify
^{39.} Facco, E., A. Liguori, et al. (2013). "Acupuncture versus valproic acid in the prophylaxis of migraine without aura: a prospective controlled study." <u>Minerva Anestesiol</u> 79 (6): 634-642.	Included episodic and chronic migraine, did not stratify
 ^{40.} Farinelli, I., G. Coloprisco, et al. (2006). "Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience." <u>J Headache Pain</u> 7(6): 407-412. 	Case series, not designed to primarily assess safety
41. Fernandez-de-Las-Penas, C., C. Alonso-Blanco, et al. (2006). "Are manual therapies effective in reducing pain from tension-type headache?: a systematic review." <u>Clin J Pain</u> 22 (3): 278-285.	Systematic review, included articles did not assess the interventions of interest for HTA
 42. Fernandez-de-las-Penas, C., C. Alonso-Blanco, et al. (2006). "Methodological quality of randomized controlled trials of spinal manipulation and mobilization in tension-type headache, migraine, and cervicogenic headache." <u>J Orthop Sports Phys Ther</u> 36(3): 160-169. 	Review, does not provide enough detail of included literature
 ^{43.} France, S., J. Bown, et al. (2014). "Evidence for the use of dry needling and physiotherapy in the management of cervicogenic or tension-type headache: a systematic review." <u>Cephalalgia</u> 34(12): 994-1003. 	Many articles included in systematic review did not meet criteria for population of interest
^{44.} Garcia-Leiva, J. M., J. Hidalgo, et al. (2007). "Effectiveness of ropivacaine trigger points inactivation in the prophylactic	Case series; < 80% with chronic migraine diagnosis

	Citation	Reason for exclusion after full-text review
	management of patients with severe migraine." <u>Pain Med</u> 8 (1): 65-70.	
45.	Gil-Gouveia, R. and P. J. Goadsby (2009). "Neuropsychiatric side- effects of lidocaine: examples from the treatment of headache and a review." <u>Cephalalgia</u> 29 (5): 496-508.	Review and case series; did not assess population of interest
46.	Goldberg, L. D. (2005). "The cost of migraine and its treatment." <u>Am J Manag Care</u> 11 (2 Suppl): S62-67.	Not a formal economic study
47.	Griggs, C. and J. Jensen (2006). "Effectiveness of acupuncture for migraine: critical literature review." <u>J Adv Nurs</u> 54 (4): 491-501.	Systematic review that assessed quality elements only of publications, did not meet inclusion criteria for HTA
48.	Hansen, P. E. and J. H. Hansen (1985). "Acupuncture treatment of chronic tension headachea controlled cross-over trial." <u>Cephalalgia</u> 5 (3): 137-142.	Unclear if episodic or chronic tension type headache; did not report outcomes of interest
49.	Hao, X. A., C. C. Xue, et al. (2013). "Factors associated with conflicting findings on acupuncture for tension-type headache: qualitative and quantitative analyses." <u>J Altern Complement Med</u> 19 (4): 285-297.	Systematic review; included studies did that not meet inclusion criteria for HTA
50.	Harden, R. N., J. Cottrill, et al. (2009). "Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study." <u>Headache</u> 49 (5): 732-743.	CTTH with cervicogenic pain
51.	He, W., X. Zhao, et al. (2012). "Adverse events following acupuncture: a systematic review of the Chinese literature for the years 1956-2010." <u>J Altern Complement Med</u> 18 (10): 892-901.	Review of adverse events from acupuncture in Chinese studies; population not specified
52.	Hedborg, K. and C. Muhr (2011). "Multimodal behavioral treatment of migraine: an Internet-administered, randomized, controlled trial." <u>Ups J Med Sci</u> 116 (3): 169-186.	Combination therapy
53.	Hesse, J., B. Mogelvang, et al. (1994). "Acupuncture versus metoprolol in migraine prophylaxis: a randomized trial of trigger point inactivation." <u>J Intern Med</u> 235 (5): 451-456.	Included episodic and chronic migraine, did not stratify
54.	Hopton, A. and H. MacPherson (2010). "Acupuncture for chronic pain: is acupuncture more than an effective placebo? A systematic review of pooled data from meta-analyses." <u>Pain Pract</u> 10 (2): 94-102.	Systematic review of pooled data from meta-analysis; included studies did not meet inclusion criteria for HTA
55.	Jackson, J. L., A. Kuriyama, et al. (2012). "Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis." Jama 307 (16): 1736-1745.	Systematic review; included studies that did not meet inclusion criteria for HTA

Citation	Reason for exclusion after
^{56.} Jena, S., C. M. Witt, et al. (2008). "Acupuncture in patients with	full-text review>90% episodic migraine and
headache." <u>Cephalalgia</u> 28 (9): 969-979.	tension type headache, did not stratify
^{57.} Karakurum, B., O. Karaalin, et al. (2001). "The 'dry-needle technique': intramuscular stimulation in tension-type headache." <u>Cephalalgia</u> 21 (8): 813-817.	< 80% with chronic tension- type headache
^{58.} Karst, M., M. Reinhard, et al. (2001). "Needle acupuncture in tension-type headache: a randomized, placebo-controlled study." <u>Cephalalgia</u> 21(6): 637-642.	>30% episodic tension type headache, did not stratify
59. Keeratitanont, K., M. P. Jensen, et al. (2015). "The efficacy of traditional Thai massage for the treatment of chronic pain: A systematic review." <u>Complement Ther Clin Pract</u> 21 (1): 26-32.	Systematic review did not include any studies with population of interest
^{60.} Kim M, Danielsson A, Ekelund A-C, Kemppainen E, Sjogren P, Svanberg T, Szalo G, Samuelsson O. Botulinum toxin type A for prophylactic treatment of chronic migraine. Health Technology Assessment, HTA-centrum; May 2014.	Health technology assessment; excluded studies that met inclusion criteria for this HTA
^{61.} Krishnan, A. and N. Silver (2009). "Headache (chronic tension- type)." <u>BMJ Clin Evid</u> 2009.	Review article
^{62.} Lattes, K., P. Venegas, et al. (2009). "Local infiltration of gonyautoxin is safe and effective in treatment of chronic tension- type headache." <u>Neurol Res</u> 31 (3): 228-233.	Case series; gonyautoxin not FDA-approved for use in the United States
^{63.} Lee, M. S. and E. Ernst (2011). "Acupuncture for pain: an overview of Cochrane reviews." <u>Chin J Integr Med</u> 17 (3): 187-189.	Overview of Cochrane reviews; does not comprehensively assess quality of Cochrane systematic reviews
^{64.} Lenhard, L. and P. M. Waite (1983). "Acupuncture in the prophylactic treatment of migraine headaches: pilot study." <u>N Z</u> <u>Med J</u> 96(738): 663-666.	Included episodic and chronic migraine, did not stratify; combination treatment with naloxone
65. Lenssinck, M. L., L. Damen, et al. (2004). "The effectiveness of physiotherapy and manipulation in patients with tension-type headache: a systematic review." <u>Pain</u> 112 (3): 381-388.	Systematic review, some included studies did not meet inclusion criteria for HTA
 ^{66.} Li, Y., H. Zheng, et al. (2012). "Acupuncture for migraine prophylaxis: a randomized controlled trial." <u>Cmaj</u> 184(4): 401-410. 	Included episodic and chronic migraine, did not stratify
 ^{67.} Liguori, A., F. Petti, et al. (2000). "Comparison of pharmacological treatment versus acupuncture treatment for migraine without auraanalysis of socio-medical parameters." <u>J Tradit Chin Med</u> 20(3): 231-240. 	Population unclear; comparator was different/unclear in 2 of 4 centers

Citation	Reason for exclusion after full-text review
^{68.} Linde, K., G. Allais, et al. (2016). "Acupuncture for the prevention of tension-type headache." <u>Cochrane Database Syst Rev</u> 4: Cd007587.	Cochrane systematic review; included studies that did not meet inclusion criteria for HTA
^{69.} Linde, K., G. Allais, et al. (2009). "Acupuncture for migraine prophylaxis." <u>Cochrane Database Syst Rev(1)</u> : Cd001218. *	Cochrane systematic review; included studies that did not meet inclusion criteria for HTA
^{70.} Linde, K., G. Allais, et al. (2009). "Acupuncture for tension-type headache." <u>Cochrane Database Syst Rev</u> (1): Cd007587.	More recent Cochrane review on this topic is Linde 2016
^{71.} Linde, K., A. Streng, et al. (2007). "Randomized trial vs. observational study of acupuncture for migraine found that patient characteristics differed but outcomes were similar." <u>J Clin</u> <u>Epidemiol</u> 60 (3): 280-287.	Included episodic and chronic migraine, did not stratify
^{72.} Linde, K., C. M. Witt, et al. (2007). "The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain." <u>Pain</u> 128 (3): 264-271.	Pooled analysis of studies that included episodic and chronic migraine and tension type headache, did not stratify
^{73.} Linde, K., A. Streng, et al. (2005). "Acupuncture for patients with migraine: a randomized controlled trial." <u>Jama</u> 293 (17): 2118- 2125.	Included episodic and chronic migraine, did not stratify
^{74.} Lipton, R. B., D. W. Dodick, et al. (2010). "Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial." <u>Lancet Neurol</u> 9(4): 373-380.	Included episodic and chronic migraine, did not stratify
^{75.} MacPherson, H., E. Vertosick, et al. (2014). "Influence of control group on effect size in trials of acupuncture for chronic pain: a secondary analysis of an individual patient data meta-analysis." <u>PLoS One</u> 9 (4): e93739.	Systematic review/meta- analysis of effect of control group selection, includes conditions beyond headache
^{76.} Martelletti, P., R. H. Jensen, et al. (2013). "Neuromodulation of chronic headaches: position statement from the European Headache Federation." <u>J Headache Pain</u> 14 : 86.	Review article, includes conditions beyond chronic headache
 ^{77.} Meissner, K., M. Fassler, et al. (2013). "Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis." JAMA Intern Med 173(21): 1941-1951. 	Systematic review/meta- analysis to assess different types of placebo treatments for migraine prophylaxis
^{78.} Melchart, D., K. Linde, et al. (2001). "Acupuncture for idiopathic headache." <u>Cochrane Database Syst Rev</u> (1): Cd001218.	More recent Cochrane reviews on this topic are Linde 2009 and Linde 2016
^{79.} Melchart, D., K. Linde, et al. (1999). "Acupuncture for recurrent headaches: a systematic review of randomized controlled trials." <u>Cephalalgia</u> 19 (9): 779-786; discussion 765.	More recent Cochrane reviews on this topic are Linde 2009 and Linde 2016

Citation	Reason for exclusion after full-text review
^{80.} Melchart, D., A. Streng, et al. (2005). "Acupuncture in patients with tension-type headache: randomised controlled trial." <u>Bmj</u> 331 (7513): 376-382.	>50% episodic tension type headache, did not stratify
81. Mesa-Jimenez, J. A., C. Lozano-Lopez, et al. (2015). "Multimodal manual therapy vs. pharmacological care for management of tension type headache: A meta-analysis of randomized trials." <u>Cephalalgia</u> 35(14): 1323-1332.	Systematic review, some included studies did not meet inclusion criteria for HTA
^{82.} Millan-Guerrero, R. O., S. Isais-Millan, et al. (2009). "Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study." <u>Eur J Neurol</u> 16 (1): 88-94.	Included episodic and chronic migraine, did not stratify
^{83.} Misra, U. K., J. Kalita, et al. (2012). "High frequency repetitive transcranial magnetic stimulation (rTMS) is effective in migraine prophylaxis: an open labeled study." <u>Neurol Res</u> 34 (6): 547-551.	Case series, not designed to primarily assess safety; did not meet criteria for population of interest
^{84.} Mitchell, M. P., K. Schaecher, et al. (2008). "Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization." <u>J Manag Care Pharm</u> 14(5): 442-450.	Not a formal economic study
85. Moraska, A. F., L. Stenerson, et al. (2015). "Myofascial trigger point-focused head and neck massage for recurrent tension-type headache: a randomized, placebo-controlled clinical trial." <u>Clin J</u> <u>Pain</u> 31 (2): 159-168.	>30% episodic tension type headache, did not stratify
^{86.} Park, J. M., S. U. Park, et al. (2011). "Carthami-Semen acupuncture point injection for chronic daily headache: a pilot, randomised, double-blind, controlled trial." <u>Complement Ther Med</u> 19 Suppl 1 : S19-25.	Injection into acupoints, not trigger points; intervention was Carthami-Semen (Safflower Seed)
^{87.} Porta, M. (2000). "A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache." <u>Curr Rev Pain</u> 4 (1): 31-35.	< 15 subjects per group
 ^{88.} Posadzki, P. and E. Ernst (2011). "Spinal manipulation: an update of a systematic review of systematic reviews." <u>N Z Med J</u> 124(1340): 55-71. 	Systematic review of systematic reviews, many populations from included studies did not meet inclusion criteria for HTA
89. Posadzki, P. and E. Ernst (2011). "Spinal manipulations for the treatment of migraine: a systematic review of randomized clinical trials." <u>Cephalalgia</u> 31 (8): 964-970.	Systematic review, some included studies did not meet inclusion criteria for HTA
90. Posadzki, P. and E. Ernst (2011). "Systematic reviews of spinal manipulations for headaches: an attempt to clear up the confusion." <u>Headache</u> 51(9): 1419-1425.	Systematic review, some populations from included studies did not meet inclusion criteria for HTA

Citation	Reason for exclusion after full-text review
91. Posadzki, P. and E. Ernst (2012). "Spinal manipulations for tension- type headaches: a systematic review of randomized controlled trials." <u>Complement Ther Med</u> 20 (4): 232-239.	Systematic review, some included studies did not meet inclusion criteria for HTA
 92. Quinn, C., C. Chandler, et al. (2002). "Massage therapy and frequency of chronic tension headaches." <u>Am J Public Health</u> 92(10): 1657-1661. 	Case series, not designed to primarily assess safety
93. Richards, K. C., R. Gibson, et al. (2000). "Effects of massage in acute and critical care." <u>AACN Clin Issues</u> 11 (1): 77-96.	Review; did not include any studies with population of interest
^{94.} Robbins, M. S., D. Kuruvilla, et al. (2014). "Trigger point injections for headache disorders: expert consensus methodology and narrative review." <u>Headache</u> 54(9): 1441-1459.	Narrative review article
 ^{95.} Rollnik, J. D., O. Tanneberger, et al. (2000). "Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study." <u>Headache</u> 40(4): 300-305. 	Intervention was Dysport
^{96.} Rothrock, J. F., L. M. Bloudek, et al. (2014). "Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine." <u>Headache</u> 54 (10): 1565-1573.	Not a formal economic study
^{97.} Sabatke, S., R. H. Scola, et al. (2015). "Injection of trigger points in the temporal muscles of patients with miofascial syndrome." <u>Arq</u> <u>Neuropsiquiatr</u> 73 (10): 861-866.	Did not meet criteria for population of interest (fibromyalgia population)
 ^{98.} Shamliyan TA, Kane RL, Taylor FR. AHRQ Comparative Effectiveness Reviews. Migraine in Adults: Preventive Pharmacologic Treatments. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013. 	Health technology assessment; included studies that did not meet inclusion criteria for HTA
 ^{99.} Silberstein, S., N. Mathew, et al. (2000). "Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group." <u>Headache</u> 40(6): 445-450. 	Included subjects with episodic migraine only
 ¹⁰⁽ Silberstein, S. D., A. M. Blumenfeld, et al. (2013). "OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline." <u>J Neurol Sci</u> 331(1-2): 48-56. 	Pooled subgroup analysis of subjects with acute headache medication overuse at baseline, from PREEMPT 1 and 2
¹⁰¹ Silberstein, S. D., D. W. Dodick, et al. (2015). "Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT." <u>J Neurol Neurosurg Psychiatry</u> 86(9): 996-1001.	Pooled subgroup analysis of responders to botox only, from PREEMPT 1 and 2
¹⁰² Streng, A., K. Linde, et al. (2006). "Effectiveness and tolerability of acupuncture compared with metoprolol in migraine prophylaxis." <u>Headache</u> 46 (10): 1492-1502.	Included episodic and chronic migraine, did not stratify; baseline characteristics suggest primarily episodic migraine

Citation	Reason for exclusion after full-text review
 ¹⁰⁵ Sun, Y. and T. J. Gan (2008). "Acupuncture for the management of chronic headache: a systematic review." <u>Anesth Analg</u> 107(6): 2038-2047. 	Systematic review and meta- analysis; most included studies reported episodic and chronic headache, did not stratify
¹⁰² Venancio Rde, A., F. G. Alencar, Jr., et al. (2009). "Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches." <u>Cranio</u> 27(1): 46-53.	Unclear if episodic or chronic migraine and tension-type headache, did not stratify
¹⁰⁵ Venancio Rde, A., F. G. Alencar, et al. (2008). "Different substances and dry-needling injections in patients with myofascial pain and headaches." <u>Cranio</u> 26(2): 96-103.	Unclear if episodic or chronic migraine and tension-type headache, did not stratify
10 Vernon, H., G. Jansz, et al. (2009). "A randomized, placebo- controlled clinical trial of chiropractic and medical prophylactic treatment of adults with tension-type headache: results from a stopped trial." <u>J Manipulative Physiol Ther</u> 32 (5): 344-351.	< 15 subjects per group
 ¹⁰⁷ Vickers, A. J., A. M. Cronin, et al. (2012). "Acupuncture for chronic pain." <u>Arch Intern Med</u> 172(19): 1444-1453. 	Systematic review, includes conditions beyond headache
¹⁰⁸ Vincent, C. A. (1989). "A controlled trial of the treatment of migraine by acupuncture." <u>Clin J Pain</u> 5(4): 305-312.	Included episodic and chronic migraine, did not stratify
10! Voigt, K., J. Liebnitzky, et al. (2011). "Efficacy of osteopathic manipulative treatment of female patients with migraine: results of a randomized controlled trial." <u>J Altern Complement Med</u> 17 (3): 225-230.	Included episodic and chronic migraine, did not stratify
¹¹⁽ Wang, K., P. Svensson, et al. (2007). "Effect of acupuncture-like electrical stimulation on chronic tension-type headache: a randomized, double-blinded, placebo-controlled trial." <u>Clin J Pain</u> 23 (4): 316-322.	Needleless electroacupuncture, not true acupuncture; not widely used or available
¹¹¹ Wang, Y., C. C. Xue, et al. (2015). "Acupuncture for frequent migraine: A randomized, patient/assessor blinded, controlled trial with one-year follow-up." <u>Evidence-Based Complementary and</u> <u>Alternative Medicine</u> 2015, article ID 920353: 14 pgs; doi:10.1155/2015/920353	Included episodic and chronic migraine, did not stratify; baseline characteristics suggest primarily episodic migraine
 ¹¹² Witt, C. M., T. Reinhold, et al. (2008). "Cost-effectiveness of acupuncture treatment in patients with headache." <u>Cephalalgia</u> 28(4): 334-345. 	>90% episodic migraine and tension type headache, did not stratify
¹¹⁵ Wonderling, D., A. J. Vickers, et al. (2004). "Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care." <u>Bmj</u> 328 (7442): 747.	Cost utility study; included episodic and chronic migraine, did not stratify
¹¹² Xue, C. C., L. Dong, et al. (2004). "Electroacupuncture for tension- type headache on distal acupoints only: a randomized, controlled, crossover trial." <u>Headache</u> 44 (4): 333-341.	>45% episodic tension type headache, did not stratify

Citation	Reason for exclusion after full-text review
¹¹⁵ Zhang, C. S., H. Y. Tan, et al. (2015). "Placebo Devices as Effective Control Methods in Acupuncture Clinical Trials: A Systematic Review." <u>PLoS One</u> 10 (11): e0140825.	Systematic review and meta- analysis of placebo as a control, did not meet inclusion criteria for HTA
^{11€} Zhao, H. J., J. Y. Tan, et al. (2015). "Auricular therapy for chronic pain management in adults: A synthesis of evidence." <u>Complement</u> <u>Ther Clin Pract</u> 21 (2): 68-78.	Systematic review and meta- analysis of auricular therapy for a variety of pain conditions, most included studies did not meet inclusion criteria for HTA
¹¹⁷ Zhao, L., Y. Guo, et al. (2011). "Systematic review on randomized controlled clinical trials of acupuncture therapy for neurovascular headache." <u>Chin J Integr Med</u> 17 (8): 580-586.	Systematic review and meta- analysis of "neurovascular headache" RCTs, most included studies did not meet inclusion criteria for HTA
¹¹⁸ Zhao, L., F. W. Zhang, et al. (2011). "Adverse events associated with acupuncture: three multicentre randomized controlled trials of 1968 cases in China." <u>Trials</u> 12 : 87.	Pooled analysis of acupuncture tirals to assess adverse events, most included studies did not meet inclusion criteria for HTA
¹¹⁵ Zheng, H., W. Huang, et al. (2015). "Association of pre- and post- treatment expectations with improvements after acupuncture in patients with migraine." <u>Acupunct Med</u> 33 (2): 121-128.	Subanalysis of Li 2012 study, Included episodic and chronic migraine, did not stratify

APPENDIX D. Risk of Bias and Strength of Evidence

Each study is rated against pre-set criteria that resulted in a Risk of Bias (RoB) assessment and presented in a table. The criteria are listed in the Tables below.

	Studies of Therapy*					
Risk of Bias	Study design	Criteria*				
Low risk: Study adheres to commonly held tenets of high quality design, execution and avoidance of bias	Good quality RCT	Random sequence generation Statement of allocation concealment Intent-to-treat analysis Blind or independent assessment for primary outcome(s) Co-interventions applied equally F/U rate of 80%+ and <10% difference in F/U between groups Controlling for possible confounding‡				
Moderately low risk:	Moderate quality RCT	Violation of one or two of the criteria for good quality RCT				
Study has potential for some bias; study does not meet all criteria for class I, but deficiencies not likely to invalidate results or introduce significant bias	Good quality cohort	Blind or independent assessment for primary outcome(s) Co-interventions applied equally F/U rate of 80%+ and <10% difference in F/U between groups Controlling for possible confounding‡				
Moderately High risk:	Poor quality RCT	Violation of three or more of the criteria for good quality RCT				
Study has significant flaws in design and/or execution	Moderate or poor quality cohort	Violation of any of the criteria for good quality cohort				
that increase potential for bias that may invalidate study results	Case-control	Any case-control design				
High risk: Study has significant potential for bias; lack of comparison group precludes direct assessment of important outcomes	Case series	Any case series design				

* Additional domains evaluated in studies performing a formal test of interaction for subgroup modification (i.e., HTE) based on recommendations from Oxman and Guyatt³:

⁺ Outcome assessment is independent of healthcare personnel judgment. Reliable data are data such as mortality or re-operation.

‡ Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

Is the subgroup variable a characteristic specified at baseline or after randomization? (subgroup hypotheses should be developed a priori)

Did the hypothesis precede rather than follow the analysis and include a hypothesized direction that was subsequently confirmed? Was the subgroup hypothesis one of a smaller number tested?

Determination of Overall Strength of Evidence

Following the assessment of the quality of each individual study included in the report, an overall "strength of evidence" for the relevant question or topic is determined. Methods for determining the overall strength of evidence are variable across the literature and are most applicable to evaluation of therapeutic studies.

SRI's method incorporates the primary domains of quality (CoE), quantity of studies and consistency of results across studies as described by AHRQ.

The following four possible levels and their definition will be reported:

High – High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
 Moderate - Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
 Low - Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and likely to change the estimate.
 Insufficient – Evidence either is unavailable or does not permit a conclusion.

All AHRQ "required" and "additional" domains (risk of bias, consistency, directness, precision, publication bias) are assessed Bodies of evidence consisting of RCTs were initially considered as High strength of evidence, while those comprised of nonrandomized studies began as Low strength of evidence. The strength of evidence could be downgraded based on the limitations described above. There are also situations where the nonrandomized studies could be upgraded, including the presence of plausible unmeasured confounding and bias that would decrease an observed effect or increase an effect if none was observed, and large magnitude of effect (strength of association).

Example methodology outline for determining overall strength of evidence (SoE):

All AHRQ "required" and "additional" domains* are assessed. Only those that influence the baseline grade are listed in table.

<u>Baseline strength</u>: Risk of bias (including control of confounding) is accounted for in the individual article evaluations. HIGH = majority of articles RCTs. LOW = majority of articles cohort studies.

<u>DOWNGRADE</u>: Inconsistency^{**} of results (1 or 2); Indirectness of evidence (1 or 2); *a priori* and no test for interaction (2)

Imprecision of effect estimates (1 or 2); Sub-group analyses not stated

UPGRADE: Large magnitude of effect (1 or 2); Dose response gradient (1)

Outcome	Strength of Evidence	Conclusions & Comments	Baseline	DOWNGRADE	UPGRADE	
Outcome	HIGH	Summary of findings	HIGH RCTs	NO consistent, direct, and precise estimates	NO	
Outcome	MODERATE	Summary of findings	LOW Cohort studies	NO consistent, direct, and precise estimates	YES Large effect	
Outcome	LOW	Summary of findings	HIGH RCTs	YES (2) Inconsistent Indirect	NO	

*<u>Required domains</u>: risk of bias, consistency, directness, precision. Plausible confounding that would decrease observed effect is accounted for in our baseline risk of bias assessment through individual article evaluation. <u>Additional domains</u>: dose-response, strength of association, publication bias.

**Single study = "consistency unknown"

APPENDIX E. Study Quality: RoB evaluation

Appendix Table E1. Risk of Bias for RCTs Evaluating BoNTA in Chronic Migraine

	BONTA vs. Placebo							BONTA vs. Active Comparator			
Methodological Principle	Aurora 2010	Aurora 2011: DBS‡	Dodick 2010‡	Lipton 2011‡	Aurora 2014: DBS§	Aurora 2011, 2014: OL§	Denier 2010	Freitag 2008	Vo 2007	Magalhaes 2010	Mathew 2009‡‡
Study design											
Randomized controlled trial	-						-	-	•	-	
Prospective cohort study											
Retrospective cohort study											
Case-control											
Case-series											
Random sequence generation*	Yes		Yes		Yes	N/A	Yes	Unclear	Yes	Yes	No
Statement of concealed allocation*	Yes	Yes		Yes	N/A	Yes	No	No	No ††	No	
Intention to treat*	Yes		Yes		Yes	N/A	Yes	Yes	No	No ††	No
Independent or blind assessment	Yes		Yes		Yes	Yes	Yes	Yes	Yes	Yes	Yes‡‡
Co-interventions applied equally	Yes	Yes		Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Complete follow-up of <u>></u> 80%	Yes	Yes		Yes	Yes	Yes	No**	No	Unclear	No‡‡	
<10% difference in follow-up between groups	Yes	Yes		Yes	N/A	Yes	Yes	Yes	Unclear	No	
Controlling for possible confounding ⁺	Yes		Yes		Yes	Yes	Yes	Yes	Yes	No††	Yes
Risk of Bias	Low		Low		Low	High	Low	Moderately High	Moderate ly High	Moderately High	Moderate ly High

DBS, double-blind study phase; OL, open-label phase

*Applies to randomized controlled trials only. If authors did not describe a methodologic principle, the study did not receive credit for the criterion.

[†]Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

‡Aurora 2011 (DBS), Dodick 2010, Lipton 2011 report on PREEMPT 1 & 2 studies, pooled analyses of the same population through 24-week follow-up (N=1384).

§Aurora 2011, 2014: PREEMPT 1 & 2 studies, participants underwent a double-blind study through 24 weeks, and then participants were invited to participate in an open-label phase beginning at 24 weeks through 56 weeks. All participants in open-label phase received botulinum toxin at 24, 36, 48 weeks and were followed through 56 weeks after baseline. Authors imputed for missing data for some outcomes.

**Freitag 2008: 60 patients were randomized, but only 41 received treatment; 19 were excluded after randomization due to medication overuse; an additional 5 patients were lost to follow-up and 18 patients per group were available for analysis.

⁺⁺Megalhaes: No statement of concealed allocation; no statement of ITT analysis and follow-up information not well described; limited patient demographic information provided, making it difficult to evaluate comparability of treatment groups at baseline.

^{‡‡}Matthew 2009: Unclear if Physician Global Assessment, the primary outcome measure, occurred via blind or independent assessment; At 12 weeks, 80% of BoNTA and 70% of topiramate recipients had data available; by study completion, only 60% of the BoNTA and 50% of the topiramate groups were available. Authors report using last observation carried forward to account for missing data from patients who discontinued but do not present data for sensitivity analysis or evaluation of the impact for missing data.

Appendix Table E2. Risk of Bias for RCTs Evaluating BoNTA in Chronic Tension-Type Headache

Methodological Principle	Hamdy 2009	Kokoska 2004	Padberg 2004	Schmitt 2001	Silberstein 2006
Study design Randomized controlled trial Prospective cohort study Retrospective cohort study Case-control Case-series			•		
Random sequence generation*	Yes	No†	No	Yes	No
Statement of concealed allocation*	No	Yes	Unclear‡	No	No
Intention to treat*	No	No	No	No	Yes
Independent or blind assessment	Unclear	Yes	Yes	Yes	Yes
Co-interventions applied equally	Yes	Yes	Yes	Yes	Yes
Complete follow-up of <u>></u> 80%	Unclear	Unclear§	Yes	Yes	Yes
<10% difference in follow-up between groups	Unclear	Unclear§	Yes	Yes	Yes
Controlling for possible confounding**	Yes	Yes	Yes	Yes	Yes
Risk of Bias	Moderately High	Moderately High	Moderately High	Moderately Low	Moderately Low

All trials compared BoNTA to placebo. No trials were identified that met the inclusion criteria for the comparison of BoNTA to an active treatment.

*Applies to randomized controlled trials only.

[†]Authors state that allocation occurred by a physician blinded to other allocation procedures, by randomly choosing a slip of paper with the patient's name and treatment arm from a bag; the study did not receive credit for this criterion.

‡Authors state that a pharmacist prepared the drug, coded the syringes, and kept treatment codes. However, it is unclear how the pharmacist received the information.

§Article stated that all patients completed the trial, but that 24 of 40 patients had a full 6 months of follow-up.

**Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

Appendix Table E3. Risk of Bias for RCTs Evaluating BoNTA in Chronic Daily Headache

		BoNTA vs. Placebo			BoNTA vs. Topiramate	
Methodological Principle	Mathew 2005	Ondo 2004: DPS	Ondo 2004: OL	Silberstein 2005	Cady 2011: DBS*	Cady 2011: OL*
Study design						
Randomized controlled trial	•	-		•	-	
Prospective cohort study						
Retrospective cohort study						
Case-control						
Case-series						
Random sequence generation ⁺	Yes	No	N/A	Yes	Unclear	N/A
Statement of concealed allocation ⁺	No	No	N/A	No	Yes	N/A
Intention to treat ⁺	Yes	Yes	N/A	Yes	No	N/A
Independent or blind assessment	Yes	Yes	Yes	Yes	Yes	Yes
Co-interventions applied equally	Yes	Yes	Yes	Yes	Yes	Yes
Complete follow-up of <u>></u> 80%	No	Yes	Yes	No	No	No
<10% difference in follow-up between groups	Yes	Yes	Yes	Yes	Yes	No
Controlling for possible confounding‡	Yes	Unclear§	Yes	Yes	No	No
Risk of Bias	Moderately Low	Moderately High	High	Moderately Low	Moderately High	High

DBS, double-blind study phase; OL, open-label phase

*Cady 2011: Participants underwent a double-blind study through 12 weeks, followed by a 2-week taper. Then, participants who did not have ≥50% treatment response were invited to participate in a 12-week open-label phase, continuing with previously-administered intervention, through 26 weeks; Baseline differences noted – a higher proportion of BoNTA recipients were dissatisfied with their prescription meds, frequency of symptoms and severity of symptoms; credit for ITT not given as authors don't state this was done;

[†]Applies to randomized controlled trials only.

‡Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

SOndo: Fewer HA days for BoNTA group (4.8 ± 0.8) compared with placebo (25.5 ± 0.9) are noted during the run-in phase; authors report performing step-wise regression apparently to evaluate predictive factors versus controlling for potential confounders. It is not clear that differences in baseline frequency of headache were controlled for. While authors state that there were no baseline differences between groups, it is possible that sample size may preclude detection of a statistical difference.

	Acupuncture vs. Usual Care	Acupuncture vs. Topiramate	
Methodological Principle	Vickers 2004	Yang 2011	
Study design Randomized controlled trial Prospective cohort study Retrospective cohort study Case-control Case-series			
Random sequence generation*	Yes	Yes	
Statement of concealed allocation*	Yes	Unclear	
Intention to treat*	No†	Yes	
Independent or blind assessment	No‡	No‡	
Co-interventions applied equally	Yes	Yes	
Complete follow-up of <u>></u> 80%	No	Yes	
<10% difference in follow-up between groups	Yes	Yes	
Controlling for possible confounding§	Yes	Yes	
Risk of Bias	Moderately High	Moderately Low	

Appendix Table E4. Risk of Bias for RCTs Evaluating Acupuncture in Chronic Migraine

*Applies to randomized controlled trials only.

⁺In the acupuncture and usual care group, respectively, 19 and 3 patients did not received treatment after randomization and are not accounted for in any analysis.

‡Outcomes were self-reported (patients kept a daily headache diary) and patients could not be blinded due the nature of the treatments: acupuncture vs. usual care (Vickers 2004) and vs. topiramate (Yang 2011)

§Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

	Acupuncture vs. Sham		Acupuncture vs. Active Control*	
Methodological Principle	Karst 2000	Tavola 1992	Carlsson 1990	Soderberg 2006, 2011
Study design				
Randomized controlled trial	•	•	=	•
Prospective cohort study				
Retrospective cohort study				
Case-control				
Case-series				
Random sequence generation ⁺	Unclear	Unclear	Unclear	Unclear
Statement of concealed allocation ⁺	Unclear	Unclear	Unclear	Unclear
Intention to treat ⁺	Unclear	Unclear	Unclear	Yes
Independent or blind assessment	Yes	Yes	No‡	No‡
Co-interventions applied equally	Yes	Yes	Yes	Unclear
Complete follow-up of <u>></u> 80%	Unclear	Yes	Yes	12 wks.: Yes 26 wks.: No
<10% difference in follow-up between groups	Unclear	Yes	No§	Yes
Controlling for possible confounding**	No††	Yes	No‡‡	No§§
Risk of Bias	Moderately High	Moderately High	Moderately High	Moderately High

Appendix Table E5. Risk of Bias for RCTs Evaluating Acupuncture in Chronic Tension-Type Headache

*Acupuncture was compared with physiotherapy (Carlsson 1990) and with both physical training and relaxation (Soderberg 2006, 2011; this trial had three arms).

[†]Applies to randomized controlled trials only.

‡Outcomes were self-reported (self-assessments and/or daily headache diary) and patients could not be blinded due the nature of the treatments: acupuncture vs. physiotherapy (Carlsson 1990) and vs. physical training and vs. relaxation (Soderberg 2006, 2011)

\$20% difference between acupuncture (74%) and physiotherapy (94%) in the number of patients completing follow-up.

**Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

⁺⁺Authors say that the groups did not differ in any baseline factors, however, the proportion of females in each group was disproportionate 38% vs. 61%.

^{‡‡}The authors say that the social, demographic, and disease characteristics were similar between the treatment groups; however, they do not provide any detailed information for confirmation (they only present demographic data for the study population vs. a reference sample of "normal" patients).

§§The following difference were noted at baseline between groups and were not controlled for:

- Acupuncture vs. Physical Training: headache duration (median 10 years [range, 2-35] vs. 5 years [range, 2-30], respectively).
- Acupuncture vs. Relaxation, respectively: sex (77% vs. 90% female; authors report p=NS), age (median 35 vs. 44 years, p=0.002), and education (higher level, 80% vs. 27%; authors report p=NS).

Appendix Table E6. Risk of Bias for RCTs Evaluating Manual Therapy in Chronic Migraine

	Manual Therapy vs. Amitriptyline
Methodological Principle	Nelson 1998
Study design	
Randomized controlled trial	•
Prospective cohort study	
Retrospective cohort study	
Case-control	
Case-series	
Random sequence generation*	Yes
Statement of concealed allocation*	Yes
Intention to treat*	Yes
Independent or blind assessment	No†
Co-interventions applied equally	Yes
Complete follow-up of <u>></u> 80%	No
<10% difference in follow-up between groups	Yes
Controlling for possible confounding‡	Yes
Risk of Bias	Moderately Low

*Applies to randomized controlled trials only.

[†]Outcomes were self-reported (patients kept a daily headache diary) and patients could not be blinded due the nature of the treatments: manipulation vs. amitriptyline.

‡Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

Appendix Table E7. Risk of Bias for RCTs Evaluating Manual Therapy in Chronic Tension-Type	
Headache	

	Manual Therapy vs. Usual Care
Methodological Principle	Castien 2011
Study design	
Randomized controlled trial	•
Prospective cohort study	
Retrospective cohort study	
Case-control	
Case-series	
Random sequence generation*	Yes
Statement of concealed allocation*	Unclear
Intention to treat*	Yes
Independent or blind assessment	No†
Co-interventions applied equally	Yes
Complete follow-up of ≥80%	Yes
<10% difference in follow-up between groups	Yes
Controlling for possible confounding‡	Yes
Risk of Bias	Moderately Low

*Applies to randomized controlled trials only.

⁺Outcomes were self-reported (patients kept a daily headache diary) and patients could not be blinded due the nature of the treatments: manipulation vs. amitriptyline.

‡Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

Appendix Table E8. Risk of Bias for RCTs Evaluating Massage in Chronic Daily Headache

	Massage vs. Sham Ultrasound
Methodological Principle	Chatchawan 2014
Study design	
Randomized controlled trial	•
Prospective cohort study	
Retrospective cohort study	
Case-control	
Case-series	
Random sequence generation*	Yes
Statement of concealed allocation*	Yes
Intention to treat*	Yes
Independent or blind assessment	Yes
Co-interventions applied equally	Yes
Complete follow-up of <u>></u> 80%	Yes
<10% difference in follow-up between groups	Yes
Controlling for possible confounding ⁺	Yes
Risk of Bias	Low

*Applies to randomized controlled trials only.

⁺Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

	TMS vs. Sham	
Methodological Principle	Misra 2013	Teepker 2010Z
Study design		
Randomized controlled trial	=	•
Prospective cohort study		
Retrospective cohort study		
Case-control		
Case-series		
Random sequence generation*	Yes	Unclear
Statement of concealed allocation*	Unclear	Unclear
Intention to treat*	Yes	Unclear
Independent or blind assessment	Yes	Yes
Co-interventions applied equally	Yes	Yes
Complete follow-up of <u>></u> 80%	Yes	Yes
<10% difference in follow-up between groups	Yes	Unclear
Controlling for possible confounding ⁺	No‡	No§
Risk of Bias	Moderately Low	Moderately High

Appendix Table E9. Risk of Bias for RCTs Evaluating Transcranial Magnetic Stimulation in Chronic Migraine

TMS: Transcranial Magnetic Stimulation.

*Applies to randomized controlled trials only.

⁺Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

[‡]Frequency of attacks per month (mean 20.8 vs. 17.0) and migraine index scores (mean 62.5 vs. 51.1) were higher at baseline in the TMS vs. sham group, respectively (though the authors did not find a statistical difference between groups in these characteristic, p=0.06 for both, the p-value approach significance).

§Authors did not provide a robust description of patient characteristics at baseline.

Appendix Table E10. Risk of Bias for RCTs Evaluating Trigger Point Injection in Chronic Tension-Type	
Headache	

	TPI vs. Sham
Methodological Principle	Karadas 2013
Study design	
Randomized controlled trial	-
Prospective cohort study	
Retrospective cohort study	
Case-control	
Case-series	
Random sequence generation*	Unclear
Statement of concealed allocation*	Unclear
Intention to treat*	Unclear
Independent or blind assessment	Yes
Co-interventions applied equally	Unclear
Complete follow-up of ≥80%	Unclear
<10% difference in follow-up between groups	Unclear
Controlling for possible confounding ⁺	No‡
Risk of Bias	Moderately High

TPI: trigger point injection. *Applies to randomized controlled trials only.

[†]Authors must provide a description of robust baseline characteristics, and control for those that are unequally distributed between treatment groups.

‡Authors did not provide a robust description of patient characteristics at baseline (only age and sex were given).

APPENDIX F. Study Characteristics and Patient Demographics

Appendix Table F1. Study Characteristics and Patient Demographics for BoNTA in Chronic Migraine

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Onabotulinumto	oxinA v	s. Placebo	,				
Aurora 2010 Canada, United States (multi- center) RCT Study period: Jan 2006—July 2008	679	OnabotulinumtoxinA (n=341) Units: 155-195 No. of muscle areas: 7 in head/neck area No. of injection sites: 31- 39 No. of treatments: 2 Injection strategy: Combination of fixed injection sites and 'follow- the-pain' strategyPlacebo (n=338) Same set-up but placebo injection was administeredCointerventions None	Inclusion criteria: History of migraine meeting diagnostic criteria listed in ICHD-II section 1 migraine, * \geq 15 headache days out of 28 days with each day consisting of \geq 4 hours of continuous headache, \geq 50% of days being migraine or probably migraine, \geq 4 distinct headache episodes each lasting \geq 4 hours, 18 to 65 years old Exclusion criteria: Any medical condition that might put patients at increased risk if exposed to BoNTA, diagnosis of other primary or secondary headache disorders, use of any headache prophylactic medication within 28 days of baseline measurements, Beck Depression Inventory (BDI) score > 24 at baseline, fibromyalgia, psychiatric disorders, previous exposure	Age (SD): 41.6 years Female: 87.5% Mean duration of chronicity (SD): 20.5 years Mean frequency of migraine days (SD): 19.1 (4.0) days per 28 days Mean frequency of headache, days (SD): 19.9 (3.7) days per 28 days Patients having migraine with aura (for migraine only): NR Patients who had prior preventative treatments: 61.8 % Patients who overused medications: 68.0 % Mean number of analgesic medications used at baseline: NR		 Mean change from baseline in: frequency of headache days in 28 day period frequency of migraine days in 28 day period frequency of headache episodes in 28 day period frequency of migraine episodes in 28 day period Overall acute headache pain medication use Headache Impact Test-6 (HIT-6) Proportion of patients with severe (≥60) HIT-6 score Migraine Specific Quality of Life Questionnaire 	Allergan, Inc. COI: Several authors have received grants, funding, or other financial support from the manufacturer. Three authors are employees and stockholders for the manufacturer. Two authors are on the advisory board of Allergan.

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
			to any botulinum neurotoxin serotype, pregnancy			 Headache Impact Score (HIS) Adverse events (any; treatment- related; serious; treatment-related serious; discontinuation due to adverse events; death) 	
Aurora 2011, Lipton 2011, Dodick 2010 Canada, US, Croatia, Germany, Switzerland, UK (multicenter) RCT Study period: Jan 2006—July 2008	1384	OnabotulinumtoxinA (n=688) Units: 155-195 No. of muscle areas: 7 in head/neck area No. of injection sites: 31- 39 No. of treatments: 2 Injection strategy: Combination of fixed injection site and 'follow- the-pain' strategy Placebo (n=696) Same set-up but placebo injection was administered Cointerventions None	Inclusion criteria: History of migraine meeting diagnostic criteria listed in ICHD-II section 1 migraine, * \geq 15 headache days out of 28 days with each day consisting of \geq 4 hours of continuous headache, \geq 50% of days being migraine or probably migraine, \geq 4 distinct headache episodes each lasting \geq 4 hours, 18 to 65 years old Exclusion criteria: Any medical condition that might put patients at increased risk if exposed to BoNTA, diagnosis of other primary or secondary headache disorders, use of any headache prophylactic medication within 28 days of baseline measurements, Beck Depression Inventory score > 24 at baseline, fibromyalgia, psychiatric disorders, previous exposure to any botulinum	Mean duration of chronicity (SD): 19.2 years Mean frequency of migraine (SD): 19.0 (4.1) days per 28 days Mean frequency of headache (SD): 19.9 (3.7) days per 28 days	(88.2%, 90.4%) Lipton (2011): 6 mos.‡ Dodick (2010): 6 mos. (> 93%)	 Proportion with ≥50% reduction from baseline AND 	

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
			neurotoxin serotype, pregnancy			 severe (≥60) HIT-6 score Migraine Specific Quality of Life Questionnaire (MSQ v.2) Headache Impact Score (HIS) Adverse events (any; treatment- related; serious; treatment-related serious; discontinuation due to adverse events; death) 	
Aurora 2014 66 sites across North America and Europe Study period: Jan 2006—July 2008 RCT	1384	OnabotulinumtoxinA (n=513) Units: 195 U (max dose) No. of muscle areas: 7 in head/neck area No. of injection sites: 31- 39 No. of treatments: 1 every 12 weeks for 24 weeks (2 cycles) Injection strategy: fixed- site, fixed-dose, intramuscular injections. If needed, 40 U more of BoNTA or placebo was administered among three muscle groups using follow-the-pain strategy. Placebo (n= 492)	Inclusion criteria: Persons aged 18-65 years with a history of migraine (ICHD definition) with headache occurring 15 or above days/4 weeks, with each day having 4 or more hours of continuous headache and 50% or over of headache days being migraine or possible migraine days; 4 or more distinct headache episodes each last 4 or more hours; no prior use of BoNTA. Exclusion criteria: No use of any headache prophylactic medication with 4 weeks prior to baseline, (but overuse of acute medications was not an exclusion criterion during	Age (SD): 41.8 (10.4) years Female: 87% Mean duration of chronicity (SD): 19.5 (12.5) years** Mean frequency of migraine (SD): 19.05 (4.0) days/month Mean frequency of headache (SD): 19.9 (3.7) days/month Patients who had prior preventative treatments: NR Patients who overused medications: 66.7%	patients were entered into	 Proportion with ≥50% reduction from baseline AND mean change from baseline in: frequency of headache days in 28 day period frequency of headache episodes in 28 day period frequency of migraine days in 28 day period frequency of migraine episodes in 28 day period 	

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
		Same procedure but placebo injections were administered Cointerventions None		Mean number of analgesic medications used at baseline: 27.4 (19.5) units		 Overall acute headache pain medication use Headache Impact Test-6 (HIT-6) Proportion of patients with severe (≥60) HIT-6 score Proportion of patients with ≥5- point reduction HIT-6 score Migraine Specific Quality of Life Questionnaire (MSQ v.2) Headache Impact Score (HIS) Adverse events (any; treatment- related; serious; treatment-related serious; discontinuation due to adverse events; death) 	
Deiner 2010 50 North American sites 16 European sites (multicenter)	705	OnabotulinumtoxinA (n=347) Units: 155-195 No. of muscle areas: 7 in head/neck area No. of injection sites: 31- 39 No. of treatments: 2 Injection strategy: Combination of fixed	Inclusion criteria: History of migraine meeting diagnostic criteria listed in ICHD-II section 1 migraine*, ≥ 15 headache days out of 28 days with each day consisting of ≥ 4 hours of continuous headache, ≥ 50% of days being migraine or probably migraine, ≥ 4 distinct headache episodes each	Mean duration of chronicity 18.0 years Mean frequency of migraine (SD): 18.9 (4.0) days per 28	Crossover: At 3 month f/u,	 Mean change from baseline in: frequency of headache days in 28 day period frequency of migraine days in 28 day period frequency of headache 	Allergan, Inc. COI: Several authors have received funding or grants from Allergan and several are consultants for pharmaceutical

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Study period: Feb 2008—Aug 2008 RCT		injection sites and 'follow- the-pain' strategy Placebo (n=358) Same set-up but placebo injection was administered Cointerventions None	<pre>lasting ≥ 4 hours, 18 to 65 years old Exclusion criteria: Any medical condition that might put patients at increased risk if exposed to BoNTA, diagnosis of other primary or secondary headache disorders, use of any headache prophylactic medication within 28 days of baseline measurements, BDI score > 24 at baseline, fibromyalgia, psychiatric disorders, previous exposure to any botulinum neurotoxin serotype, pregnancy</pre>	Mean, frequency of headache (SD): 19.8 (3.7) days per 28 days Patients having migraine with aura (for migraine only): NR Patients who had prior preventative treatments: 65.1% Patients who overused medications: 63% Mean number of analgesic medications used at baseline: NR		 episodes in 28 day period frequency of migraine episodes in 28 day period Overall acute headache pain medication use Headache Impact Test-6 (HIT-6) Proportion of patients with severe (≥60) HIT-6 score Migraine Specific Quality of Life Questionnaire (MSQ v.2) Headache Impact Score (HIS) Adverse events (any; treatment- related; serious; treatment-related serious; discontinuation due to adverse events; death) 	companies. Two authors are on the advisory board of Allergan
Freitag 2008 United States Study period: NR RCT	60 rand, 41 treated	OnabotulinumtoxinA (n=30) Units: 100 U total No. of muscle areas: 5 No. of injection sites: 22 No. of treatments: 1 Injection strategy: Fixed injection sites	Inclusion criteria: Head pain ≥ 15 days per month and headache duration ≥ 4 hours, associated symptoms decreasing in severity but headache frequency increasing, 18-65 years old, stable doses of preventative	Age (range): 42.3 (19-64) years Female: 73.2% Mean duration of chronicity (SD): NR	F/U (% BoNTA, % Placebo): 4 wks, 2 mos, 3 mos, 4 mos (60%, 60%) Crossover: None		Allergan, Inc. COI: Analysis was supported by Allergan, Inc. Dr. Freitag has received research grant support and

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
		Placebo (n=30) Same procedure but placebo injection was administered Cointerventions None	 medications for 60 days prior to study entry Exclusion criteria: Use of botulinum toxin of any serotype, myasthenia gravis, Eaton-Lambert syndrome, any disorder of neuromuscular function, use of agents that might interfere with neuromuscular function, first migraine diagnosis after 50 years old, cluster headaches, basilar or ophthalmoplegic or hemiplegic migraine, migraine aura without headache, painful condition more painful than migraine pain, progressive neurological disorders, structural disorder of the brain from birth or trauma or past infection, injections or oral corticosteroids within 30 days of study, psychiatric disorder, antipsychotic medication, BDI Scores > 24, use of investigational drug or device within 30 days of study, triptans used > 3 days per week, ergotamine or dihydroergotamine > 2 days per week, simple analgesics > 2 tablets per day ≥ 5 days per week 	Mean frequency of migraine (SD): NR Mean frequency of headache (SD): 23 days per 28 days		 Mean change from baseline in total <i>days with</i> <i>headache</i> in 28 day period Headache Index (HAI) score Acute mediation usage Migraine Disability Assessment Scores (MIDAS) Headache Pain Specific Quality of Life questionnaire Adverse events 	

WA – Health Technology Assessment

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Vo 2007***	32	OnabotulinumtoxinA	Inclusion criteria: 18-65 years	Age (SD): 42.4 (7.5) years	F/U (% Total): 4	Mean frequency	Comprehensive
	treated	(n=15)	old, > 5 headache days per	Female: 84.4%	wks, 3 mos	of headache days	Neuroscience
United States	(No.	Units: 135 or 205+++	month, migraine headache		(65.3%)	in 30 day period	Program and The
	rand	No. of muscle areas: 6	with or without aura according	Mean duration of chronicity		 Mean severity of 	Uniformed
Study period:	NR)	No. of injection sites: 22	to IHS classification	(SD): 19.5 (10.6) years	Crossover: None	, headache attacks	Services University
NR		No. of treatments: NR				(VAS 0-10)	of the Health
		Injection strategy: NR	Exclusion criteria: NR	Mean frequency of migraine		Migraine Specific	Science Award
RCT				(SD): 19.4 (7.1) days per		Quality of Life	
		Placebo (n=17)		month		questionnaire	COI: NR
		Same procedure but				(MSQ v.2.1)	
		placebo saline injections		Mean frequency of headache		Adverse events	
		were administered		(SD): NR			
		Cointervention		% of patients having			
		None		migraine with aura (for			
				migraine only): NR			
				% of patients who had prior			
				preventative treatments:			
				NR			
				% of patients who overused			
				medications: NR			
				Mean number of analgesic			
				medications used at			
				baseline: NR			
Onabotulinumt	oxinA vs.	Active Comparator					
Magalhaes	72	OnabotulinumtoxinA	Inclusion criteria: 18 to 60	Age (range): 34.1 (18-56)	F/U: 4 wks, 2	• Reduction of ≥50%	Brazilian
2010		(n=35)	years old, chronic daily	years	mos, 3 mos‡	in number of pain	government grant
		Units: 250	migraines according to ICHD-II	Female: 97.2%		episodes	by CAPES and a
Brazil		No. of muscle areas: NR			Crossover: none	 Reduction in 	CNPq research
		No. of injection sites: 15	Exclusion criteria: History of	Mean duration of chronicity		intensity of pain of	grant
Study period:		No. of treatments: 1	more than one primary	(SD): NR		≥3 on VAS	
June 2006—		Injection strategy: NR	headache according to ICHD-II,			• Reduction of ≥50%	COI: NR
Feb 2008			neurological or systemic	Mean frequency of migraine		in number of pain	
		Amitriptyline (n=37)	diseases that cause headache,	(SD): NR		drug doses	

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
		25-50 mg per day	contraindications for any			 Self- and 	
			medications used in the study,	Mean frequency of headach	e	physician-assessed	
		Cointerventions	use of any antidepressant or	(SD): 24.0 (6.5) days per 90		improvement	
		None	other drug with potential	days		 Adverse events 	
			preventative effects on				
			headache with 3 mos prior to	% of patients who had prior			
			enrollment	preventative treatments:			
				NR			
				% of patients who overused			
				medications: NR			
				Mean number of analgesic			
				medications used at			
				baseline: NR			
				baseline. NK			
Mathew 2009	60	OnabotulinumtoxinA	Inclusion Criteria: Outpatient	Age (SD): 36.8 (10.3) years	F/U (% BoNTA, %	 Improvement of 	Comprehensive
		(n=30)	male or female patients of any	Female: 90%	Topiramate): 9	≥50% Physician	Neuroscience
United States		Units: max 200 at	race between 18 and 65 years		mos (60.0%,	Global Assessment	Program and The
		baseline and month 3	old diagnosed with CM, not	Mean duration of chronicity	50.0%)	 Mean change 	Uniformed
Study period:		(100 U fixed-site and 100	previously treated with BoNTA	(SD): NR		from baseline in:	Services University
10.5 mos		U follow-the-pain)	or topiramate.		Crossover: None	 number of 	of the Health
(dates NR)		No. of muscle areas: NR		Mean frequency of		HA/migraine days	Science Award
		No. of injection sites: NR	Exclusion Criteria: Pregnant or	headache/migraine (SD):		per month,	
RCT		No. of treatments: 1	planning pregnancy during	15.5 (7.1) days per month		 HA/migraine-free 	COI: NR
		Injection strategy: Mixed	study period, breastfeeding or			days per months	
		fixed injection and	were of childbearing potential	% of patients who had prior		 days on HA 	
		follow-the-pain	and not using reliable	preventative treatments:		medication, and	
		approach	contraceptive; patients with	NR		average	
			CTTH; underlying conditions			\circ severity of	
		Placebo/Topiramate	judged to preclude treatment	% of patients who overused		HA/migraine	
		(n=30)	with either test medication;	medications: NR		episodes per	
		Placebo saline injections	patients who previously used			month	
		along with topiramate.	study medications for any	Mean number of analgesic		 Headache Impact 	
			reason; patients unable to	medications used at		Test (HIT)-6	
		Cointervention	discontinue any prohibited	baseline: NR		Migraine Disability	
			meds or agents that might			Assessment	

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
		Either an oral placebo (BoNTA) or topiramate (placebo) with 4-week titration to 100 mg/day with option for extra 4 week titration to 200 mg/day. Continued through the end of the study.	interfere with neuromuscular function; patients with evidence of recent alcohol/drug abuse or acute medication overuse.			 (MIDAS) questionnaire, Migraine Impact Questionnaire (MIQ). Adverse events (any; drug-related; probable/ possible drug-related; discontinuation due to adverse events) 	

BDI, Beck Depression Inventory; BoNTA, onabotulinumtoxinA; CM, chronic migraine; COI, conflict of interest; CTTH, chronic tension-type headache; F/U, follow-up; ICHD-II, International Classification of Headache Disorders 2nd Edition; mg, milligrams; mos., months; NA, not applicable; No, number; NR, not reported; U, units; wks., weeks.

* With the exception of "complicated migraine", i.e. hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous infarction.

⁺ Data for open-label phase was not reported.

‡ Percent follow-up not reported.

§ From Aurora 2011, 513 subjects in the BoNTA group and 492 subjects in the control group completed the open-label phase. From Lipton 2011 and Dodick 2010, data for open-label phase was not reported.

** Data is only reported for participants who completed all 5 cycles of treatment.

++513 subjects in the BoNTA group and 492 subjects in the control group completed the open-label phase.

‡‡ Number of patients that entered open-label phase was not reported.

§§ Patients overusing medication were excluded from the study.

*** Study drew participants from an Army Medical Center Neurology clinic.

+++Patients less than 65 kg received 135 U while patients 65 kg or greater received 205 U.

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Acupuncture vs	. Active Co	mparator	1				
Vickers 2004 UK Study period: Nov 1999-Nov 2001 RCT	401 rand, 379 treated	Acupuncture (n=161) No. of treatments: Up to 12 treatments over 3 months Type of needle: NR Acupoints: Individualized to each patient No. of needles: NR No. of insertions per needle: NR Insertion depth: NR Time length of treatment: NR Control (n=140) Patients randomized to the control group received usual care from their practitioner and were not referred to acupuncture.	Inclusion criteria: patients 18- 65 with migraine or tension- type headache (following IHS criteria) who reported avg. of at least 2 headaches per month Exclusion criteria: onset of headache disorder less than one year before or at age 50 or older, pregnancy, malignancy, cluster headache, suspicion that headache disorder had a specific etiology, cranial neuralgias, acupuncture treatment in the previous 12 months	chronicity (SD): 21.5 (13.9) years Mean frequency of migraine (SD): NR	Acupuncture, % Control): 3 mos. (75%, 75%), 12 mos. (75%, 75%) Crossover: None	 Proportion of patients with ≥ 35% improvement Headache score Proportion of patients with ≥ 50% improvement in Headache Frequency (reduction in days with headache) Proportion of patients who used any prophylactic medication in past month Mean headache days/month Mean headache severity (0-10 VAS) SF-36 health status questionnaire Adverse events (serious and nonserious, discontinuation due to adverse events) 	Sponsor: NHS R&D National Coordinating Centre for Health Technology Assessment (NCCHTA) grant: 96/40/15 COI: One author (Nadia Ellis) provides acupuncture as part of her private physiotherapy practice

Appendix Table F2. Study Characteristics and Patient Demographics for Acupuncture in Chronic Migraine

Study	N Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Yang 2011, 2013* Faiwan Study period: NR RCT	 Acupuncture (n=33) No. of treatments: twi per week for 12 wks. Type of needle: Carbo and Viva; 32 (Chinese) gauge, 0.25 x 40mm, sterile disposable stee needles Acupoints: fixed and classic (BL-2, GB-20 (E: HN-5) No. of needles: 7 No. of insertions per needle: NR Insertion depth: standard to each point according to classic acupuncture point Time length of treatment: 30 mins Topiramate (n=33) 4 week titration, beginning with 25mg/day increased b 25mg/day weekly to maximum 100mg/day followed by 8 week maintenance period. Cointerventions None 	 Inclusion criteria: Age 18-65, a diagnosis based on the published guidelines of the Task Force of the International Headache Society Clinical Trials Subcommittee for controlled trials of prophylactic treatment of CM in adults criteria A–C during the 3 months before trial entry, and an established migraine history for at least 1 year Exclusion criteria: HA experience for 15 or more days per month or no response to triptans or ergots on at least 8 days during baseline period, headaches other than CM, migraine prophylaxis agents used in past 3 months, migraine onset after age 50 or over 60 years of age at onset of CM, history of hepatic disorder, 	Age (SD): 47.85 (6.9) years Female: 89.3% Mean duration of chronicity: 13.35 (4) years Mean frequency of migraine (SD): NR Mean frequency of headache, days (SD): 21.15 (1.5) per month Patients having migraine with aura: NR Patients who had prior preventative treatments: NR Patients who overused medications: 74.2% Mean number of days with analgesic medication intake at baseline (SD): 14.8 (2.45 units per month	F/U: NR† Crossover: None	 Proportion of patients with ≥ 50% improvement in Headache Frequency (reduction in days with headache) Mean headache days per month Migraine disability assessment (MIDAS) Short Form 36 Beck Depression Inventory-II Hospital Anxiety and Depression Scale Adverse events (serious and nonserious, death, discontinuation due to adverse events) 	Sponsor: Taiwan Department of Health Clinical Trial and Research Center for Excellence, grant from Kuang Tien General Hospital COI: None stated

CM, chronic migraine; COI, conflict of interest; F/U, follow-up; HA, headache; mg, milligrams; min, minutes; mos, months; No, number; NR, not reported; SD, standard deviation; wks, weeks

* Yang 2013 is a secondary analysis of the Yang 2011; it was included for KQ3 only addressing differential efficacy in subpopulations.

+ Percent follow-up not reported.

Appendix Table F3. Study Characteristics and Patient Demographics for Manual Therapy in Chronic Migraine

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Manual Therap	y/Mani	pulation vs. Amitriptyline v	s. Combined Therapy				
Nelson 1998	218	Spinal Manipulation (n=77)	Inclusion criteria : 18 to 65 years old, migraine headaches	Age (SD): 37.9 (10.8) years Female: 78.9%	F/U (% Manual Therapy, %	 Change in headache index 	Sponsor: NR
United States		No. sessions: 14 sessions over 8 weeks	for ≥ 1 year, ≥ 4 headache days per month	Mean duration of	Amitriptyline, % Combined Care):	(HI) score (derived from	COI: NR
Study period:		(no more than 2		chronicity:	4 wks (75.3%,	daily headache	
NR		sessions per week)	Exclusion criteria: Migraine	 1-5 years: 12.8% 5 10 years: 22.0% 	71.4%, 76.1%)	pain over a 4	
RCT		Length of sessions: NR Segments targeted: Cervical and thoracic	headache according to IHS classification, women that are pregnant or nursing, patients	 5-10 years: 22.9% > 10 years: 64.2% 	Crossover: None	week period)Proportion of patients with	
		spinal segments Description of	underactive chiropractic or medical care within previous	Frequency of migraine (SD): 52.9% of days per		>20%, >40%, and >60%	
		technique: High- velocity, low-amplitude,	month, contraindications to SMT or amitriptyline therapy	month		reduction in HI scores	
		short-lever arm		Patients who had prior preventative treatments:		Headache frequency (% of	
		Amitriptyline (n=70) 3 visits with clinician.		NR		days with headache)	
		25 mg once daily for first week, 50 mg daily		Patients who overused medications: NR		 Headache severity on VAS 	
		during second week, 75				 SF-36 global 	
		mg in third week, and		Mean number of analgesic		score	
		max of 100 mg for remaining 5 weeks		medications used at baseline (SD): 2.1 (1.8) pills per day		Medication intake (OTC	
		Combine Treatment		per day		pills/day)Adverse events	
		(n=71)* Patients received both				(discontinuation due to	
		SMT and amitriptyline therapy.				complications)	
		Cointerventions					
		None					

COI, conflict of interest; F/U, follow-up; IHS, International Headache Society; max, maximum; mg, milligrams; mos, months; NR, not reported; SD, standard deviation; SMT, spinal manipulation therapy; wks, weeks.

*This group did not meet our inclusion criteria and was not included in the results of this report.

Appendix Table F4. Study Characteristics and Patient Demographics for Transcranial Magnetic Stimulation in Chronic Migraine

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
rTMS vs Sham		,			•		
Misra 2013 India Study period: NR RCT	100	High rate rTMS (n=50)Device: Magstim Rapid-2Coil diameter: 7 cmLocation of coil:anterioposteriorly parallel tomidline on left frontal cortexNo. pulses: 600Length of session: 412.4 secondsHz used per pulse: 10HzNo. sessions: 3 sessions onalternate daysSham (n=50)Same procedure but sham coilwas used	Inclusion criteria: > 15 years old, > 4 headache attacks per month for ≥ 3 months Exclusion criteria: Pregnancy, liver or kidney diseases, malignancy, severe hypertension, pacemaker or metallic implants, history of seizure or structural brain lesions, focal neurological deficit	Age (SD): 35.3 (10.2) years Female: 88% Mean duration of chronicity (SD): 10.5 (7.)3 years Frequency of migraine (SD): 18.9 (9.9) days per month Duration of attacks (SD): 0.96 (0.58) days % Patients with migraine with aura patients: 7% % Patients with prior preventative treatments: 98% % Patients overusing medications: 28%* Mean no. analgesics used (SD): 19.1 (17.4) units per month [†]		 Proportion with >50% reduction in headache frequency Proportion with >50% improvement in pain severity (0- 100 VAS) Proportion of patients with headache severity rated: normal, mild, moderate, severe Proportion of patients with functional disability rated: normal, mild, moderate, severe Mean headache frequency (attacks/mo.) Mean headache severity (0-3, worst) Mean functional disability (0-3, worse) Analgesic use per month Patient satisfaction Adverse events 	Sponsor: None; authors state the trial was "an investigator- initiated single- center trial without any external funding." COI: None

WA – Health Technology Assessment

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
						discontinuation due to adverse events)	
Teepker 2010 Germany Study period: NR RCT	32	Low frequency rTMS (n=14) Device: MagPro compact Coil diameter: 13 cm Location of coil: Right dorsolateral prefrontal cortex No. pulses: NR Length of session: NR Hz used per pulse: 1 Hz No. sessions: 5 Sham (n=13) Same procedure but sham 'figure-of-eight' (11 cm diameter) coil was used	Inclusion criteria: ≥ 4 migraine attacks per month Exclusion criteria: Any prophylactic treatment of migraine, cardiac or cerebral pacemaker, metal in the cranium, epilepsy, pregnancy, severe psychiatric or neurological diseases, complex migraine forms	Age (SD) : 35.5 (10.2) Female: 68.8% Mean duration of chronicity (SD): NR Frequency of migraine (SD): 15.9 (8.2) days per month Duration of attacks (SD): NR % Patients with migraine with aura patients: 40.69 % Patients with prior preventative treatments NR % Patients overusing medications: NR Mean no. analgesics used (SD): 14.7 (10.7) pills per month	mos (84.4%) Crossover: None	 Mean migraine frequency – attacks (attacks per 8 week period) Mean migraine frequency – days (days per 8 week period) Mean headache migraine severity (0- 10 VAS over 8 week period) Medication intake (mean pills per 8 weeks) Adverse events (various, discontinuation due to adverse events) 	Sponsor: NR COI: NR

cm, centimeters; COI, conflict of interest; F/U, follow-up; Hz, hertz; mos, months; No., number; NR, not reported; rTMS, repetitive transcranial magnetic stimulation; SD, standard deviation; wks, weeks.

* All medication overuse patients were overusing analgesics.

+ Refers to number of rescue analgesics used.

Appendix Table F5. Study Characteristics and Patient Demographics for BoNTA in Chronic Tension-Type Headache

Study	N In	nterventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Onaboutlinum	toxinA vs. Plac	cebo					
Onaboutlinum Hamdy 2009 Egypt Study period: Aug 2006— Aug 2007 RCT	28 O (r U (1 N N N N N In m ai ai te id ta pi te id ta sa w V C	cebo mabotulinumtoxinA n=14) Inits: Mean(SD) 50.14 13.51) range 30-80 IU‡ 10. of muscle areas: 6 10. of injection sites: 7 10. of treatments: 1 njection strategy: Two nethods; fixed-site nd follow-the-pain pproach. Potential ender points dentified by history- aking and manual alpation lacebo (n=14) ame procedure but aline placebo injection vas administered. ointerventions lone	Inclusion Criteria: A diagnosis of CTTH (according to IHS), had headache on equal or more than 15 days per month on avg. for at least 3 mos, headache duration of 1-10 years, history of failed treatment in the previous 3 mos with at least one prophylactic drug, ability to distinguish between the different headache types Exclusion Criteria: patients with migraine or other forms of primary or secondary headaches, planned or actual pregnancy, lactation, or women of childbearing age using inadequate contraceptive measures, any type of substance use disorder, drug induced headache, and patients with medication overuse in the last 2 years, previous exposure to BoNTA, any neuromuscular disease, or treatment with drugs affecting neuromuscular junction, prior injection of anesthetic or steroid into the	Age (SD): 36.57 (7.61) years Female: 67.8% Mean duration of chronicity in Years (SD): 4.79 (2.57) years Mean frequency of headache (SD): 19.56 (3.46) days per month Mean headache duration (SD): 8.68 (1.06) hours/day Patients who had prior preventative treatments: 100% Patients who overused medications: 0% Mean number of analgesic medications used at baseline (SD): 10.92 (2.46) days per month	F/U : 3 mos§ Crossover: None	 Headache days per month Headache severity (VAS) Headache Disability Index (HDI) Number of days with acute headache medication use per month Adverse events (serious, non- serious) 	Sponsor: NR COI: Authors state there were none

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
			serious physical or psychiatric disease.				
Kokoska 2004	40	OnabotulinumtoxinA	Inclusion Criteria: All persons	Age (range) : 46.45 (19-	F/U: 6 mos**	 Mean number of 	Sponsor: Allergan,
		(n=20)	over 18 with episodic or	80) years		headache	Inc.
United States		Units: 50 U	chronic frontal headache (IHS	Female: 77.5 %	Crossover: none	episodes per	
		No. of muscle areas: 3	definition) with a frequency			month	COI: NR
Study period:		No. of injection sites:	equal or greater than	Mean duration of		 Mean change in 	
July 1998—		10 (5 U each)	1/month and a frontal pain	chronicity (SD): NR		headache	
June 2000		No. of treatments: 1	distribution			intensity	
		Injection strategy:		Mean frequency of		 Adverse events 	
RCT		Fixed-site	Exclusion Criteria: History of	headache: 23.3 episodes			
			stroke, migraine alone,	per month			
		Placebo (n=20)	previous use of BoNTA,				
		Same procedure but	previous corrugator or	Patients who had prior			
		saline placebo injection	frontalis muscle surgery,	preventative			
		was administered	previous Bell's palsy, active	treatments: 92.5%			
			lid ptosis or lagophthalmos,				
		Cointerventions	current aminoglycoside	Patients who overused			
		None	therapy, and known adverse	medications: NR			
			reaction to BoNTA or human				
			albumin, pregnant or nursing.	Patients who used			
				analgesic medications at			
				baseline: 95 %			
Padberg 2004	40	OnabotulinumtoxinA	Inclusion criteria: Chronic	Age (SD): 44.6 years	F/U (% BoNTA,	 Mean change in 	Sponsor: In part by
		(n=19)	tension type headache	Female: 70%	% Placebo): 3	headache	Allergan, Inc.
Netherlands		Units: 100 (maximum)	according to IHS criteria		mos (100%,	intensity (VAS)	
		10-20 U per muscle		Mean headache duration	100%)	 Mean number of 	COI: NR
Study period:		No. of muscle areas: 7	Exclusion criteria: Under 18	(SD): 12.8 hours per day		headache days	
Oct 1999—		No. of injection sites:	years old, pregnancy,		Crossover: None	 Mean number of 	
Aug 2001		NR	neuromuscular disorders, use	Frequency of headache,		days on which	
		No. of treatments: 1	of other investigational drugs	percentage of		symptomatic	
RCT		Injection strategy:	within 30 days of screening	days/month (SD): 92.5%		treatment was	
		'Follow the pain'	visit, previous use of	(14.6)		taken	
		strategy	botulinum toxin, migraine			 Mean number of 	
			frequency > 1 attack per	Patients who had prior		symptomatic	
		Placebo (n=21)	month, analgesics or caffeine	preventative		tablets per day	
			abuse	treatments: NR		 Self-assessed 	
						improvement	

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
		Same procedure but placebo injection was administered		Patients who overused medications: NR		Adverse events	
		Cointerventions None		Mean number of analgesic medications used at baseline: 0.65 (0.8) units per day			
Schmitt 2001	60 rand,	OnabotulinumtoxinA (n=30)	Inclusion criteria: Chronic tension-type headache	Age (SD): 45.8 (15.6) years	F/U (% BoNTA, % Placebo): 4	 Proportion of patients with 	Sponsor: NR
Switzerland	59 treated	Units: 20 per injection, 80 total	according to IHS criteria	Female: 60%	wks, (100%, 83%) 8 wks	≥25% decrease in daily pain scores	COI: NR
Study period: NR		No. of muscle areas: 2 No. of injection sites:	Exclusion criteria: Head trauma or whiplash injury,	Mean duration of chronicity (SD): 22.3	(93%, 80%)	 West Haven-Yale Multidimensional 	
RCT		NR No. of treatments: 1 Injection strategy: Fixed injection sites	episodic tension-type headache, severe medical, neurologic, or psychiatric disorder, recent introduction of new headache therapy,	(17.2) years Mean frequency of headache, days (SD): NR	Crossover: None	 Pain Inventory Mean number of pain-free days Mean pain severity on VAS 	
		Placebo (n=29) Same procedure but saline placebo injection was administered	previous treatment with botulinum injections, pregnancy, lactation, alcohol or drug abuse	Patients who had prior preventative treatments: NR		 Mean analgesic intake per month 	
		Cointerventions None		Patients who overused medications: NR			
				Mean number of analgesic medications used at baseline: 24.5 (25.08) units per month			
Silberstein	300	OnabotulinumtoxinA	Inclusion criteria: 18 to 65	Age (range): 42.6 (18-65)	F/U (% Total): 4	 Proportion of 	Sponsor: NR
2006		(n=250) Units:	years old, chronic tension- type headache according to	years Female: 62.3%	wks, 2 mos, 3 mos, 4 mos	patients with ≥50% decrease in	COI: NR; however 3
United States,		 150 U (n=49) 	IHS criteria, stable headache		(93%)	headache days	of the 7 authors
Canada, UK,		 100 U (n=51) 	frequency and severity for ≥ 6	Mean duration of		 Mean change 	listed are cited as
Germany,		 100 Usub (n=52) ## 	mos. prior to screening	chronicity (range): 14.7	Crossover: None	noni bascinc in	being affiliated with
Belgium, and Denmark		 86 Usub (n=51) 50 U (n=47) 	period, ≥ 15 headaches per month for ≥ 6 moss prior to screening period, ability to	(0-54) years		number of headache free days per month	Allergan, Inc.

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Study period: Jan 2000— Feb 2001 RCT		No. of muscle areas: 3 or 5§§ No. of injection sites: 10 No. of treatments: 1 Injection strategy: NR Placebo (n=50) Same procedure but placebo injection was administered into 5 muscle areas Cointerventions None	distinguish tension-type headaches from non-tension- type headaches Exclusion criteria: Medical condition or use of agent that increased risk when using BoNTA, symptomatic medication overuse, > 1 migraine headache per month for ≥ 6 mos. prior to screening period, cluster headache, cranial neuralgias, consistently refractory to multiple acute therapies for treatment of CTTH, use of prophylactic headache medications for < 3 mos. prior to day-30 visit, injection of anesthetics or steroids injected in study targeted muscles in 1 month prior to day-30 visit, previous therapy with botulinum toxin of any serotype, women that were pregnant or nursing	Mean frequency of headache: 24.0 days per 30 days Patients who had prior preventative treatments: 87.9% Patients who overused medications: NA ⁺⁺ Mean number of analgesic medications used at baseline: NR		 Percentage of the day with headache Mean headache severity Concurrent headache medication usage Beck Depression Inventory Headache Pain Specific Quality of Life Questionnaire Tension-Type Headache Impact Questionnaire SF-36 Patient- assessment Global Assessment Scale Adverse events 	

Avg, average; BoNTA, onabotulinumtoxinA; COI, conflict of interest; CTTH, chronic tension-type headache; F/U, follow-up; HA, headache; IHS, International Headache Society; max, maximum; mL, milliliters; mos., months; NA, not applicable; No, number; NR, not reported; SD, standard deviation; U, units; wks., weeks;

[‡] Dosage varied between patients, but each patient received equal dose for each injection site

§ Percent follow-up not reported

** Twenty-four patients had a full 6 month follow up and all patients turned in HA diaries

++ Patients the overused medication were excluded from the study

'Sub' was used as an identifier in the study for the groups in which only 3 muscle groups received treatment. Other groups received treatment in 5 muscle groups

§§ Three groups received injections at 5 muscle areas (50U, 100U, 150U) while two groups received injections at 3 muscle areas (86Usub, 100Usub)

Appendix Table F6. Study Characteristics and Patient Demographics for Acupuncture in Chronic Tension-Type Headache

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Acupuncture vs	. Placebo o						
Karst 2000	39	Acupuncture (n=21)	Inclusion criteria:	Age (SD): 49.0 (14.8)	F/U: last day of tx	 Frequency of 	Sponsor: NR
		No. of treatments: Twice	CTTH according to	years	(NR), 6wks. (NR)	headache	
Germany		per week for 5 weeks	IHS classification	Female: 48.7%		attackes (per	COI: NR
		Type of needle: Seirine B-			Crossover: None	month)	
Study period:		type needle no. 8 (0.3 x	Exclusion criteria:	Mean duration of		 Headache 	
NR		0.3 mm) and no. 3 (0.2 x	Anticoagulation,	chronicity: NR		severity (VAS	
		0.15 mm)	predominantly			0-10)	
Study period		Acupoints: GB 20, L 14, LR	operating factors,	Mean frequency of		 Clinical global 	
NR		3, GB 8, GB 14, GB 21, GB	rebound analgesic	headache (SD): 27.0		impression	
		41, UB 2, UB 10, UB 60	headache syndrome,	(6.5) days/month		Mean	
		No. of needles: Max of 15	symptomatic or	. , , ,		analgesic	
		No. of insertions per	other concomitant	Patients who had		intake/month	
		needle: NR	headaches, history of	prior preventative		 Pressure pain 	
		Insertion depth: NR	or current migraines	treatments: NR		threshold	
		Time length of treatment:				unesnoiu	
		30 min		Patients who			
				overused			
		Placebo (n=18)		medications: NR			
		Blunt placebo needle					
		simulated puncturing		Mean number of			
		sensation without being		analgesic			
		inserted. Elastic foam was		medications used at			
		used to shield needle type		baseline: 9.2 (11.9)			
		used to sillera needle type		units per month			
		Cointervention		units per month			
		None					
Tavola 1992	30	Acupuncture (n=15)	Inclusion Criteria:	Age (SD): 32.9 (11.6)	F/U: 6 mos., 12	Proportion of	Sponsor: NR
		No. of treatments: 1	Diagnosis of muscle-	years	mos.*	patients with	
Italy		treatment per week for 8	tensive and tension-	Female: 86.6%		>33% and	COI: NR
		weeks	type headache,		Crossover: None	>50%	
Study period:		Type of needle: stainless	exclusion of organic	Mean duration of		improvement	
NR		steel, 0.3 mm diameter	pathology, frequency	chronicity (SD): 7.8		over baseline	
		Acupoints: placements	of headache episodes	(7.9) years		on Headache	
RCT		made according to	greater than once a	(, ;cuio		Index	
		traditional Chinese	week having a mean			mack	

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
		medicine criteria on an	intensity not less	Mean frequency of		 Headache 	
		individual basis	than 'moderate,'	headache (SD): 17.5		frequency	
		No. of needles: 6-10	abstainment from	(9.2) days/month		(no./month)	
		No. of insertions per	other therapies			 Headache 	
		needle: NR	previously	Patients who had		intensity	
		Insertion depth: 10-20mm	undertaken (except	prior preventative		 Headache 	
		Time length of treatment:	for non-narcotic	treatments: NR		index (HI)	
		20 minutes	analgesics).			 Frequency of 	
				Patients who		analgesic use	
		Sham (n=15)	Exclusion Criteria:	overused		_	
		No. of treatments: 1	NR	medications: NR			
		treatment per week for 8					
		weeks		Mean number of			
		No. of needles: 6-10		analgesic medications			
		Acupoints: same regions,		used at baseline (SD):			
		but not in specific		11.5 (11.3)			
		acupoints		units/month			
		Insertion depth: 2-4mm					
		Time length of treatment:					
		20 minutes					
		Cointervention					
		None					
Acupuncture vs	. Active Co						
Carlsson 1990	60 rand,	Acupuncture (n=23)	Inclusion Criteria:	Age (SD): 34 (12) years	F/U (%	Sickness	Sponsor: Swedish Fund for
Carisson 1990	58	No. of treatments: 4-5	Females between 18-	% Female: 100%	Acupuncture, %	• Sickness Impact	Scientific Research without
Sweden	treated	Type of needle: NR	60 with duration of	70 T ETHAIE. 10070	Physiotherapy):	Profile	Animal Experiments
Sweden	liealeu	Acupoints: classical	headache of more	Mean duration of	12 mos. (74%,	Mood	Anima Experiments
Study period:		Chinese acupuncture	than 6 months, those	chronicity (SD): 9 (8)	93%)	Adjective	COI: NR
1987—1988		points (GB20, GB21, LI4)	who could speak and	years	5570)	Check List	
1907 1900		No. of needles: 3	read Swedish	years	Crossover: None	Intensity of	
RCT		No. of insertions per		Mean frequency of		headache	
		needle: NR	Exclusion Criteria:	headache (SD): NR		(VAS 0-100),	
		Insertion depth: 10-30mm	patients with			frequency	
		Time length of treatment:	malignant or other	Patients who had		 Analgesic 	
		20 min	serious diseases,	prior preventative		consumption	
			headaches with close	treatments: 96%		Adverse	

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
		Specific for each patient	an organic disorder	Patients who			
		including: relaxation	or generalized	overused			
		techniques, auto-massage,	myalgia, headaches	medications: NR			
		cryotherapy and	as part of				
		transcutaneous electrical	fibromyalgic	Mean number of			
		nerve stimulation.	syndrome	analgesic medications			
		No. of treatments: 1-2		used at baseline: NR			
		sessions per week, 10-12					
		sessions over 2-3 months					
		Time length of treatment:					
		30-45 minutes					
		Crossover					
		None					
Soderberg	90	Acupuncture (n=30)	Inclusion criteria: 18	Age (range): 37.5 (18-	F/U (%	 Headache- 	Sponsor: Vardalsstiftelsen
2011		No. of treatments: 10-12	to 65 years old, CTTH	59) years	Acupuncture, %	free periods	Kommunala
		sessions in 10-12 weeks	according to IHS	Female: 81.1%	Physical Training,	Headache-	Landstingsforbundet for
Sweden		Type of needle: 15 x	classification		% Relaxation	free days	Landstinsangelagenheter, te
(multicenter)		0.25mm and 30 or 40 x		Mean duration of	Training): 3 mos	 Headache 	Renee Eanders Fond, and
Church and a standard.		0.30mm	Exclusion criteria:	chronicity (range): 7.5	(90%, 86.7%,	intensity	GlaxoSmith Kline
Study period: March 1997—		Acupoints: GB 20, GB 14,	Headache that began	(2-37) years	86.7%), 6 mos	(VAS 0-100)	
		LI 14, and ST 44 (PC 6, PC	after age 50, > 1	Mean frequency of	(56.7%, 63.3%,	Minor	COI: NR
Sept 1999		7, SP 6, GB 34, ST 8, EX 2, AMD EX 1 were optional)	migraine per month in the past year,	headache (SD): NR	63.3%)	Symptom	
RCT		No. of needles: 10-12	inability to speak or	neauache (SD): NR	Crossover: None	Evaluation	
NCT.		No. of insertions per	read Swedish, serious	Patients who had	Clossovel. None	Profile	
		needle: 3 per session	somatic or	prior preventative			
		Insertion depth: 2-5 mm	psychiatric disease,	treatments: NR			
		or 10-30 mm based on	drug abuse of use of				
		location	analgesics and	Patients who			
		Time length of treatment:	triptans > 10 days per	overused			
		30 min	month	medications: NR			
		Developed Training (n=20)		Moon number of			
		Physical Training (n=30) 10 sessions done over 2.5-		Mean number of analgesic used at			
		3 months. Sessions were a		-			
		combination of in-clinic		baseline: 9.2 (11.9) units per month			
		and home-training but all					

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
		focused on neck and					
		shoulder muscles					
		Relaxation Training (n=30) 8-10 sessions performed					
		individually with a					
		physiotherapist.					
		Combination of neuromuscular and self-					
		hypnotic techniques, as					
		well as breathing					
		techniques, stress coping					
		mechanisms, and how to					
		relax during the day and					
		during activity.					
		Cointervention					
		None					

COI, conflict of interest; CTTH, chronic tension-type headache; F/U, follow-up; IHS, International Headache Society; max, maximum; min, minutes; mm, millimeters; mos, months; NA, not applicable; No, number; NR, not reported; SD, standard deviation; Tx, treatment; wks, weeks

* Percent follow-up not reported

Appendix Table F7. Study Characteristics and Patient Demographics for Manual Therapy in Chronic Tension-Type Headache

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Manual Thera	py/Manipul	ation vs. Active Comparat	or				
Castien 2011	82 rand,	Spinal manipulation (n=41)	Inclusion criteria: 18 to 65 years old, diagnosed with	Age (SD): 40.4 (10.8) years	F/U (% Manual Therapy, % Usual	 Proportion of patients with 	Sponsor: NR
The Netherlands (multicenter)	80 treated	No. sessions: Max of 9 Length of sessions: 30 min Segments targeted:	CTTH according to IHS classification Exclusion criteria:	Female: 78% Mean duration of chronicity: 12.8 (11.5)	Care): 2 mos (97.6%, 97.6%), 26 wks (92.7%, 90.2%)	50% reduction in headache frequency • Mean headache	COI: NR
Study period: June 2007— Dec 2008		Cervical, thoracic, and lumbar spinal segments Description of	Rheumatoid arthritis, suspected malignancy, pregnancy, intake of triptans, ergotamines, or opioids ≥ 10	years Mean frequency of headache, days (SD):	Crossover: None	frequency (days with headache in 2 week time period)	
RCT		technique: NR Usual Care (n=41)	days per month, simple analgesics \geq 15 days per month for \geq 3 months,	23.9 (6.9) days per month		 Mean headache intensity (0-10 NRS) 	
		General practitioner provided information and advice, first prescribing life-style	manual therapy treatment within 2 months of enrollment	Patients who had prior preventative treatments: NR		 Headache Impact Test-6 Headache Disability 	
		changes. Analgesics or NSAIDs were prescribed and pain		Patients who overused medications: NA*		Inventory • Analgesic/NSAID use	
		medication was changed as needed. Treatment spanned on		Mean number of analgesic medications used at baseline (SD):		 Patient- reported improvement 	
		average 2-3 visits Cointervention		 1.3 (2.8) pills per week NSAIDs 3.2 (4.5) pills per 		Resource useAdverse events	
		None		week analgesics			

AM, Amitriptyline; COI, conflict of interest; CTTH, chronic tension-type headache; F/U, follow-up; IHS, International Headache Society; max, maximum; mg, milligrams; min, minutes; mos, months; NA, not applicable; No, number; NR, not reported; NSAIDs, non-steroidal ant inflammatory drugs; SD, standard deviation; TTH, tension-type headache; wks, weeks *Patients that overused medication were excluded from the study.

Appendix Table F8. Study Characteristics and Patient Demographics for Trigger Point Injections in Chronic Tension-Type Headache

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Trigger Point Ir	njections vs	. Placebo					
Karadas 2013 Turkey Study period: NR	49 rand, 48 treated	Trigger Point Injections (n=24) Injection: 0.5% lidocaine Muscle areas: muscles innervated by trigeminal nerve and cervical nerves originating from C1-C3 No. injections: 2 per muscle area No. sessions: 3 sessions, 1 every 3 days Placebo (n=24) Same procedure but saline injections were administered Cointerventions None	Inclusion criteria: Headache for ≥ 15 days per month, 18 to 65 years old, CTTH for ≥ 6 months, no response to optimal doses of antidepressants for ≥ 3 months Exclusion criteria: Use of prophylactic headache treatment in last 20 days, medication-overuse headache according to ICHD- II, BoNTA therapy, pregnancy, allergy to local anesthetics, malignancy, cervical and cranial surgery, primary headaches other than TTH, nonpharmacological therapy in previous 6 months, > 500 mg/day of caffeine in past month, anemia and bleeding diathesis, major psychiatric disorders, use of antipsychotic, antidepressant or antiepileptic drugs within previous 3 months, neuromuscular dysfunction, agents that affect neuromuscular functions, uncontrolled hypertensions, hypothyroidism, hyperthyroidism	Age (SD): 40.5 (12.6) years Female: 83.0% Mean duration of chronicity: NR Mean frequency of headache (SD): 19.7 (8.5) days per 30 days Mean duration of attacks (SD): NR % Patients with prior preventative treatments: NR % Patients overusing medications: NR Mean no. analgesics used (SD): 9.9 (2.3) pills per month		 Number of painful days in a month Severity of pain Number of analgesics used in a month Hamilton depression scores Hamilton anxiety scores Adverse events (serious and nonserious) 	Sponsor: NR COI: Authors declare no conflicts of interest

BoNTA, botulinum toxin type A; COI, conflict of interest; CTTH, chronic tension-type headache; F/U, follow-up; ICHD-II, International Classification of Headache Disorders 2nd Edition; mg, milligrams; mos, months; NA, not applicable; No., number; NR, not reported; SD, standard deviation; TTH, tension-type headache; wks, weeks.

Appendix Table F9. Study Characteristics and Patient Demographics for BoNTA in Chronic Daily Headache

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Onabotulinumt	oxinA v	s. Placebo or Sham				1	
Mathew	355	OnabotulinumtoxinA	Inclusion criteria: 18 to 65	Age (SD): 43.5 years	F/U (% Total): 9	Proportion of	Sponsor: Allergan,
2005*		(n=173)	years old, > 15 headaches in	Female: 84.5%	mos (77.2%)	patients with	Inc.
		Units: 105-260	30 days, stable medical			≥50% decrease	
United States		No. of muscle areas: NR	condition, stable chronic	Mean duration of	Crossover: None	in the	COI: Three authors
(multicenter)		No. of injection sites:	medication regiments for ≥3	chronicity (SD): 14.5		frequency of	are employed by
		23-58	mos. prior to baseline period,	(12.4) years		headache days	Allergan, Inc., and
Study period:		No. of treatments: 3	compliance with study			and headache	own stock in the
NR		Injection strategy:	instructions, willingness to	Mean frequency of		episodes per	company
		'Follow the pain'	stay on current medications	migraine (SD): 11.0 (7.3)		30-day period	
RCT		strategy	for the course of the study	days per month		 Mean change 	
						from baseline	
		Placebo (n=182)	Exclusion criteria: Medical	Mean frequency of		in frequency of	
		Same procedure but	condition or use of agent	headache, days (SD): 13.1		headache-free	
		saline placebo injection	that increased risk when	(8.0) days per month		days in a 30 day	
		was administered	using BoNTA, infection or			period	
			skin problem at injection site,	Patients who had prior		• Number of days	
		Cointerventions	allergy to study medication,	preventative		that acute	
		None	history of complicated	treatments: 35.8%		headache	
			migraine, a Beck Depression			medication was	
			Inventory (BDI) score > 24,	Patients who overused		used	
			previous therapy with	medications: 47.3%		Number of uses	
			botulinum toxin of any			(intakes) of	
			serotype, injection of	Mean number of		acute headache	
			anesthetics or steroids in	analgesic medications		medication	
			study-targeted muscles with	used at baseline: NR		 Migraine 	
			30 days of baseline period,			Disability	
			overuse or abuse of			Assessment	
			symptomatic medication,			Scale (MIDAS)	
			alcohol, or drugs, chronic use			Headache Pain-	
			within 3 mos. of baseline			Specific Quality	

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
			period of muscle relaxants,			of Life Questionnaire	
			pregnancy			Adverse events	
Ondo 2004	60	OnabotulinumtoxinA	Inclusion criteria: 18 to 80	Age (SD): 47 (11.1) years	F/U (% BoNTA, %	Mean number	Sponsor: NR
		(n=30)	years old, headaches > 15	Female: 81.7%	Placebo): 3 mos	of headache	COI: NR
United States		Units: 200	days per month	Mean duration of	, (96.7%, 96.7%)	free days	
		No. of muscle areas: NR	<i>,</i> .	chronicity (SD): NR	Crossover: At 3	• Global	
Study period:		No. of injection sites:	Exclusion criteria: NR	Mean frequency of	month f/u,	impressions	
NR		NR		headache (SD): 23 (7)	patients were	 Mean use of 	
		No. of treatments: 1		days per month	offered open-label		
RCT		Injection strategy:			BoNTA injections ⁺	headache	
		'Follow the pain'		Patients having		medications	
		strategy		migraine with aura (for		 Beck 	
				migraine only): NR		Depression	
		Placebo (n=30)				Inventory (BDI)	
		Same procedure but		Patients who had prior		 Psychosocial 	
		placebo injection was		preventative		Adjustement to	
		administered		treatments: 66.6%		Illness Scale	
		Cointerventions:		Patients who overused		(PAIS) • Adverse events	
		None		medications: 56.6 %			
				Mean number of			
				analgesic medications			
				used at baseline (SD):			
				45.35 doses (26.3) per			
				month			
Silberstein	702	OnabotulinumtoxinA	Inclusion criteria: 18 to 65	Age (range): 43.4 (18-65)	F/U (% Placebo-	 Proportion of 	Sponsor: Allergan,
2005*		(n=524)	years old, < 15 headache days	years	nonresponders, %	patients with	Inc.
		Units:	in 30 day screening period,	Female: 82.9%	Placebo-	≥50% decrease	
United States		■ 225 U (n=182)	medically stable, no changes	Mean duration of	responders): 6	in headache	COI: One author is
(multicenter)		■ 150 U (n=168)	in long term medication	chronicity (SD): 13.7	mos (71.9%,	days per 30-	on the advisory
Church a serie d		■ 75 U (n=174)	within 3 mos. of enrollment,	(12.2) years	75.6%)	days	panel for Allergan,
Study period:		No. of muscle areas: 7	willingness to stay on current	Mean frequency of	Crease war Name	 Proportion of 	Inc., two authors
July 2001—		No. of injection sites: 20	medications for the course of	migraine, days (SD): 10.5	Crossover: None	patients with	have received
Nov 2003		No. of treatments: 3	the study	(7.5) days per 30 days		≥50% decrease	research fees or
RCT		Injection strategy: Fixed injection sites				in <i>migraine</i>	support from the
RCI		injection sites					sponsor, one author

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Onabotulinum		Placebo (n=178) Same procedure but placebo injection was administered Cointerventions None	Exclusion criteria: Medical condition or use of agent that increased risk when using BoNTA, infection or skin problem at any of the injection sites, allergy to study medication, cluster headaches, chronic paroxysmal hemicranias, analgesic rebound headache, headache secondary to head trauma or whiplash, "complicated" migraine,‡ BDI score > 24, previous therapy with botulinum toxin of any serotype, injection of anesthetics or corticosteroids in study-targeted muscles with 30 days of baseline period, abuse of symptomatic medication, alcohol, or drugs, concurrent or long term use of muscle relaxants within 3 mos. of screening period, women that were pregnant or nursing	Mean frequency of headache, days (SD): 13.8 (8.6) days per 30 days Patients who had prior preventative treatments: 49.6 % Patients who overused medications: 42.1% Mean number of analgesic medications used at baseline: NR		 headaches per 30-days Proportion of patients with ≥50% decrease in 2 or more migraine headaches per 30-days Mean change from baseline in number of headache free days per 30- days Mean frequency of any type of headache and of migraine headache Number of days with acute medication usage Migraine Disability Assessment (MIDAS) Headache Pain Specific Quality of Life Questionnaire Adverse events 	has worked as a principal investigator within Allergan Inc., one author has worked as a consultant for Allergan, Inc., and two authors are stockholders and employees of the sponsor
Cady 2011	59	OnabotulinumtoxinA	Inclusion criteria: Outpatient,	Age (range): 39.6 (19.6-	F/U (% BoNTA, %	Treatment	Funding: Industry
Country NR		(n=29) Units: 100-200	Subject met criteria for CM	64.0) years Female: 91.5%	Topiramate): 4 wks (96.5%,	Responder Rate based on the	, , , , , , , , , , , , , , , , , , , ,

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
		No. of muscle areas: NR	defined by ICHD-II, 18 to 65		90.0%), 3 mos	Global	COI: One author is a
Study period:		No. of injection sites:	years old	Mean duration of	(85.7%, 80.0%)	Physician	consultant for
Sept 2004—		NR		chronicity: 16 years		Assessment	GlaxoSmithKline,
Aug 2006		No. of treatments: 1	Exclusion criteria: Pregnancy,		Crossover: At 3	 Mean change 	Merck and received
		Injection strategy:	headache disorders other	Mean frequency of	month f/u,	from baseline	grants. Several
RCT (3		Combination of fixed	than CM, medical disorders	migraine (SD): 11.1 days	patients who had	in number of	authors received
centers)		injection sites and	that would increase risk with	per 28 days	not reduced no. of	headache days	research grants
		'follow-the-pain'	exposure to BoNTA, liver or		headache days per	per month	from companies
		strategy	renal impairment, ketogenic	Mean frequency of	month by ≥ 50%	 Mean change 	within the industry
			diets, previous used of	headache (SD): 21.1 days	were offered	from baseline	
		Topiramate (n=30)	botulinum toxin of any type	per 28 days	open-label BoNTA	in headache	
		25 mg given daily	or topiramate, alcohol/drug		injections§	free days per	
		increased to 100 mg in	abuse or overuse of acute	Patients who had prior		month	
		weekly incremental	medication	preventative		 Migraine 	
		changes of 25 mg.		treatments: 98.3 %		Impact and	
		Treatment spanned 12				Disability	
		weeks		Patients who overused		Assessment	
				medications: NR**		(MIDAS)	
		Cointerventions				 Headache 	
		None		Mean analgesic usage:		Impact Test-6	
				14.5 days per month		(HIT-6)	
						Money spent	
						on migraine	
						medication	
						 Adverse events 	

BDI, Beck Depression Inventory; BoNTA, onabotulinumtoxinA; COI, conflict of interest; F/U, follow-up; mos., months; No, number; NR, not reported; SD, standard deviation; wks., weeks;

* After baseline, patients went through placebo injections to test for "placebo responders" and "placebo nonresponders"

⁺ Only one patients decided to not to receive open-label injections, however 7 patients total did not complete the phase

‡ Including migrainous infarction, hemiplegic migraine, opthalmoplegic migraine, or basilar migraine

§Of the 27 subjects that did not have at least a 50% reduction in headache days per month, 9 from the topiramate group and 11 from the BoNTA group started the open-label phase

**Assumed to be 0% since medication overuse was an exclusion criteria.

Appendix Table F10. Study Characteristics and Patient Demographics for Massage vs. Sham in Chronic Daily Headache

Study	N	Interventions	Inclusion, Exclusion Criteria	Demographics	F/U %	Outcomes	Funding
Massage vs. Sh	am US	•					
Chatchawan 2014 Thailand Study period: NR RCT	72	Thai Traditional Massage (n=36) TTM massage for 25 minutes, stretching for 5 minutes. Technique was consistent with pattern of royal Thai massage, pressing along meridian lines at massage points for 5-10 second, repeated 3-5 times. Targeted 5 different muscle areas Sham US (n=36) US given using detuned US device. Nine 30 minute sessions over 3 weeks	Inclusion criteria: 20 to 50 years old, CTTH or migraine according to IHS classification, headache diagnosis for ≥ 3 months prior to study, headaches for ≥ 15 days per month and ≥ 2 times per week, VAS score for headache intensity ≥ 4 Exclusion criteria: Headache cause by cervical disorders, skin disease, hemiplegia/paresis, hypertension, antiplatelet drugs, massage therapy within the past month	Mean age (SD): 27.4 (8.1) years Female:76.4 % Mean duration of chronicity: NR Mean frequency of headache* (SD): 16.3 (4.4) days per month % Migraine patients: 42% Mean duration of attacks (SD): 6.5 ± 9.24 hours % Patients with migraine with aura patients: NR % Patients with prior preventative treatments: NR % Patients overusing medications: NR Mean no. analgesics used (SD): NR	F/U (% TTM, % Sham US): 4 wks (97.2%, 100%) Crossover: None	 Headache Intensity on VAS Frequency of pain (times/wk.) Headache Disability Index (HDI) Pressure Point Threshold Cervical range of motion Adverse events 	Sponsor: Under Incubation Researcher Project, Neuroscience Research and Development Group, Kohn Kaen University, and the Back, Neck, and Other Joint Pain Research Group COI: Authors declare no conflicts of interest

COI, conflict of interest; CTTH, chronic tension-type headache; F/U, follow-up; IHS, International Headache Society; mos, months; No, number; NR, not reported; SD, standard deviation; Sx, symptom; TTM, Thai traditional massage; VAS, visual analog score; US, ultrasound; wks, weeks

*Reported migraine and tension-type headache frequency together; value reported here includes migraine population.

APPENDIX G. Data Abstraction Tables: Efficacy Outcomes

Appendix Table G1. Efficacy Outcomes from RCTs Evaluating BoNTA for Chronic Migraine

			Results	mean or %) [*]	Effect Estimate (95% CI) †	p-value ⁺
Author	Outcome	F/U post-tx	Intervention	Control		
BoNTA vs. Placebo			•		•	
Aurora 2010 (PREEMPT 1)	Frequency of headache episodes/month, Δ from baseline	24	-5.2	-5.3	NR	0.344
24 week study period	Frequency headache days/month, Δ from baseline	24	-7.8	-6.4	NR	0.006
z4 week study period	Δ from baseline, frequency of migraine episodes/month	24	-4.8	-4.9	NR	0.206
	Δ from baseline, frequency migraine days/month	24	-7.6	-6.1	NR	0.002
	Δ from baseline, frequency of acute HA medication intake/month	24	-10.3	-10.4	NR	0.795
	Δ from baseline, HIT-6 score	24	-4.7	-2.4	NR	<.001
	% patients with severe (≥60) HIT-6 score from baseline	24	68.9%	79.9%	NR	0.001
	Δ from baseline, HRQoL: restrictive (MSQ)	24	NR	NR	NR	<.001
	Δ from baseline, HRQoL: preventive (MSQ)	24	NR	NR	NR	0.005
	Δ from baseline, HRQoL: emotional (MSQ)	24	NR	NR	NR	0.029
Diener 2010 (PREEMPT 2)	Δ from baseline, frequency of headache episodes/month	24	-5.3	-4.6	NR	p=.003
24 wook study pariod	Δ from baseline, frequency headache days/month	24	-9.0	-6.7	NR	p<.001
24 week study period	Δ from baseline, frequency migraine days/month	24	-8.7	-6.3	NR	p<.001
	Δ from baseline, frequency of acute HA medication intake/month	24	-9.9	-8.4	NR	NS
	Δ from baseline, HIT-6 score	24	-4.9	-2.4	NR	<.001
	% patients with severe (≥60) HIT-6 score from baseline	24	66.3	76.5	NR	p=.003

			Results (mean or %)*		Effect Estimate (95% CI) †	p-value ⁺
Author	Outcome	F/U post-tx	Intervention	Control		
	Δ from baseline, HRQoL: restrictive (MSQ)	24	NR	NR	NR	<.001
	Δ from baseline, HRQoL: preventive (MSQ)	24	NR	NR	NR	<.001
	Δ from baseline, HRQoL: emotional (MSQ)	24	NR	NR	NR	<.001
Aurora 2011, Dodick	Δ from baseline, frequency headache days/month	24	-8.4 (-8.9, -7.9)	-6.6 (-7.1, -6.1)	NR	<.001
2010, Lipton 2011 (PREEMPT 1&2)	Δ from baseline, \geq 50% reduction in frequency headache days/month	24	47.1%	35.1%	NR	<.001
24 week study period	Δ from baseline, frequency headache episodes/month	24	-5.2 (-5.6, -4.8)	-4.9 (-5.3, -4.5)	NR	p=.009
	Δ from baseline, \geq 50% reduction in frequency headache episodes/month	24	48.6%	43.1%	NR	NS
	Δ from baseline, frequency migraine days/month	24	-8.2 (-8.7, -7.7)	-6.2 (-6.7, -5.7)	NR	<.001
	Δ from baseline, \geq 50% reduction in frequency migraine days/month	24	48.2%	36.4%	NR	<.001
	Δ from baseline, frequency of migraine episodes/month	24	-4.9 (-5.3, -4.5)	-4.5 (-4.9, -4.1)	NR	p=.004
	Δ from baseline, \geq 50% reduction in frequency migraine episodes/month	24	48.1%	43.4%	NR	NS
	Δ from baseline, frequency of acute HA medication intake/month	24	-10.1 (-11.4, -8.8)	-9.4 (-10.6, -8.1)	NR	NS
	Δ from baseline, frequency of acute HA medication days/month	24	-6.1 (-6.6, -5.5)	-5.3 (-5.8, -4.8)	NR	p=.016
	Δ from baseline, HIT-6 score	12	-4.7	-2.6	NR	<.001
		24	-4.8 (-5.3, -4.3)	-2.4 (-2.9, -2.0)	NR	<.001
	% patients with severe (≥60) HIT-6 score from baseline	24	67.6% (64.1%, 71.1%)	78.2% (75.1%, 81.2%)	NR	<.001
	Δ from baseline, HRQoL: restrictive (MSQ)	12	16.2	9.9	NR	<.001
		24	17.0 (18.7, 15.2)	8.6 (10.2, 7.0)	NR	<.001
	Δ from baseline, HRQoL: preventive (MSQ)	12	13	8	NR	<.001
		24	13.1 (14.8, 11.4)	6.4 (8.0, 4.9)	NR	<.001

			Results	(mean or %) [*]	Effect Estimate (95% CI) †	p-value†
Author	Outcome	F/U post-tx	Intervention	Control		
	Δ from baseline, HRQoL: emotional (MSQ)	12	18.3	11	NR	<.001
		24	17.9 (20.1, 15.8)	9.5 (11.4, 7.5)	NR	<.001
Aurora 2014	Δ from baseline, frequency headache days/month	24	-8.8 (-9.4, -8.2)	-6.5 (-7.1, -5.9)	NR	<.001
(PREEMPT 1&2)	Δ from baseline, frequency headache episodes/month	24	-5.9 (-6.1, -5.2)	-4.8 (-5.4, -4.4)	NR	<.001
24 week study period	Δ from baseline, frequency migraine days/month	24	-8.6 (-9.2, -8.0)	-6.2 (-6.7, -5.5)	NR	<.001
	Δ from baseline, frequency of migraine episodes/month	24	-5.5 (-5.8, -4.9)	-4.4 (-5.0, -4.1)	NR	<.001
	Δ from baseline, frequency of acute HA medication intake/month	24	-10.4 (-11.8, -8.7)	-9.3 (-11.0, -8.0)	NR	NS
	Δ from baseline, HIT-6 score	24	-5.5 (-6.1, -4.8)	-2.3 (-2.8, -1.8)	NR	<.001
	% patients with severe (≥60) HIT-6 score from baseline	24	62.6% (58.4%, 66.8%)	78.5% (74.8%, 82.1%)	NR	<.001
	Δ from baseline, HRQoL: restrictive (MSQ)	24	18.3 (16.4, 20.3)	8.5 (6.8, 10.3)	NR	<.001
	Δ from baseline, HRQoL: preventive (MSQ)	24	14.4 (12.5, 16.3	6.7 (-5.0, 8.4)	NR	<.001
	Δ from baseline, HRQoL: emotional (MSQ)	24	19.6 (17.2, 22.0)	9.7 (7.5, 11.8)	NR	<.001
Freitag 2007	Δ from baseline, frequency of migraine episodes/month	16	-4.2 (-31%)	-1.3 (-8.9%)	NR	<.001
16 week study	Δ from baseline, ≥50% reduction in migraine episodes	16	6/18 (33%)	3/18 (16.7%)	NR	NR
treatment period	Δ from baseline, HAI (headache index)	16	-6.1 (30.5%)	-3.8 (-21%)	NR	p=.003
	Δ from baseline, frequency headache days/month	16	-4.0	-2.0	NR	p=.018
	Δ from baseline, frequency of acute HA medication intake/month	16	-1.0	0.0	NR	NS
	Δ from baseline, MIDAS	16	-11	+2	NR	NS
	Δ from baseline, Headache Pain Specific QoL	16	14	22	NR	NS
Magalhaes 2010	Δ from baseline, ≥50% reduction in # pain days/90 days	12	67.8%	72.0%	NR	NS
12 week study period	Δ from baseline, ≥3 point VAS reduction in pain intensity/90 days	12	50.0%	55.6%	NR	NS

			Result	s (mean or %) [*]	Effect Estimate (95% CI) †	p-value ⁺
Author	Outcome	F/U post-tx	Intervention	Control		
	Δ from baseline, ≥50% reduction in migraine drug doses/90 days	12	77.0%	71.0%	NR	NS
	Self-reported improvement/90 days	12	84.0%	88.0%	NR	NS
	Physician-reported improvement/90 days	12	88.0%	87.0%	NR	NS
	# pain days at 90 days	12	11.8 ± 7.6	9.7 ± 6.8	NR	NS
Vo 2007	Δ from baseline, frequency of headache episodes/month	12	NR	NR	NR	NS
16 week study period	Δ from baseline, severity of headache episodes/month	12	NR	NR	NR	NS
	Δ from baseline, HRQoL: restrictive (MSQ)	12	NR	NR	NR	NS
	Δ from baseline, HRQoL: preventive (MSQ)	12	NR	NR	NR	NS
	Δ from baseline, HRQoL: emotional (MSQ)	12	NR	NR	NR	NS
BoNTA vs. Active Com	parator					
Magalhaes 2010	Δ from baseline, ≥50% reduction in # pain days/90 days	12	67.8%	72.0%	NR	NS
BoNTA vs. Amitriptyline	Δ from baseline, ≥3 point VAS reduction in pain intensity/90 days	12	50.0%	55.6%	NR	NS
12 week study period	Δ from baseline, ≥50% reduction in migraine drug doses/90 days	12	77.0%	71.0%	NR	NS
<i>,</i> ,	Self-reported improvement/90 days	12	84.0%	88.0%	NR	NS
	Physician-reported improvement/90 days	12	88.0%	87.0%	NR	NS
	# pain days at 90 days	12	11.8 ± 7.6	9.7 ± 6.8	NR	NS
Mathew 2009	Δ from baseline, ≥50% physician-reported treatment	4	NR	NR	NR	NS
BoNTA vs. Topiramate	improvement	12	NR	NR	NR	NS
		24	NR	NR	NR	NS
42 week study period (12 week treatment		36	NR	NR	NR	NS
period)	Δ from baseline, ≥50% reduction in frequency headache	12	10/26 (38.5%)	5/22 (22.7%)	NR	NS
	days/month	24	14/24 (58.3%)	7/22 (31.8%)	NR	NS

			Results (mean or %)*		Effect Estimate (95% CI) †	p-value ⁺
Author	Outcome	F/U post-tx	Intervention	Control		
		36	9/22 (40.9%)	9/21 (42.9%)	NR	NS
	Δ from baseline, severity of headache episodes/month	12	-0.2 ± 0.5	-0.4 ± 0.8	NR	NS
		24	-0.1 ± 0.5	-0.5 ± 0.8	NR	NS
		36	-0.2 ± 0.5	-0.4 ± 0.8	NR	NS
	Δ from baseline, days taking HA medication/month	12	-4.3 ± 4.3	-2.5 ± 4.6	NR	NS
		24	-6.1 ± 5.2	-4.1 ± 5.4	NR	NS
		36	-4.5 ± 5.9	-4.0 ± 6.7	NR	NS
	Δ from baseline, HIT-6 score	12	-3.5 ± 6.2	-6.7 ± 5.9	NR	NS
		24	-5.6 ± 6.4	-10.4 ± 7.1	NR	NS
		36	-3.5 ± 5.2	-8.8 ± 7.4	NR	NS
	Δ from baseline, MIDAS	12	-10.5 ± 24.1	-33.3 ± 53.1	NR	NS
		24	-11.3 ± 22.4	-46.3 ± 75.7	NR	NS
	Δ from baseline, MIQ score	4	-1.2 ± 2.1	-1.0 ± 2.1	NR	NS
		24	-0.5 ± 1.1	-1.3 ± 2.7	NR	NS

BDI, Beck Depression Index; BoNTA, OnabotulinumtoxinA; CI, confidence interval; F/U, follow-up; HA, headache; HDI, Henry Ford Hospital Headache Disability Inventory; HIT-6, Headache Impact Test-6; HRQoL, health related quality of life; MIDAS, Migraine Disability Assessment Scale; MIQ, Migraine Impact Questionnaire; NR, not reported; NS, not significant; PAIS, Psychosocial Adjustment to Illness Scale; PN, placebo non-responder; PR, placebo responder; QoL, quality of life; SD, standard deviation; SF-36, Short Form-36; TTHA, tension-type headache; Tx ,treatment; VAS, visual analog scale; WHYMPI, West Haven-Yale Multidimensional Pain Inventory

* Results are reported as either a mean or a percent. Confidence intervals or standard deviations are reported in parenthesis

+ As reported by the authors.

Appendix Table G2. Efficacy Outcomes from RCTs Evaluating BoNTA for Chronic Tension-Type Headache

			Resu	ults (mean or %)*	Effect Estimate (95% Cl) †	p-value ⁺
Author	Outcome	F/U post-tx	Intervention	Control		
BoNTA vs. Placebo						
Hamdy 2009	Frequency headache days/month	Base-line	19.93 ± 3.75	19.21 ± 3.17	NR	NR
16 week study period		4	15.00 ± 2.25	4 17.50 ± 2.03	NR	p=.005
		12	12.07 ± 1.94	15.92 ± 2.16	NR	p=.000
	Δ from baseline, % reduction in frequency headache days/month	12	37.8%	17.1%	NR	NR
	Headache severity (VAS)	Base-line	6.21 ± 1.05	6.36 ± 1.08	NR	NR
		4	4.79 ± 1.05	5.86 ± 0.86	NR	p=.007
		12	3.50 ± 1.22	5.21 ± 1.19	NR	p=.001
	Δ from baseline, % reduction in headache severity	12	43.7%	18.0%	NR	NR
	HDI score	Base-line	64.43 ± 8.74	60.57 ± 10.27	NR	NR
		4	44.29 ± 14.84	56.14 ± 11.70	NR	p=.027
		12	38.29 ± 19.84	56.57 ± 12.31	NR	p=.007
	Δ from baseline, % reduction in HDI score	12	40.6%	6.6%	NR	NR
	# days with acute HA medications/month	Base-line	11.14 ± 2.59	10.71 ± 2.33	NR	NR
		4	7.43 ± 1.09	9.64 ± 2.02	NR	p=.001
		12	6.43 ± 1.16	8.36 ± 1.65	NR	p=.001
	Δ from baseline, % decrease in # days with acute HA medications	12	42.3%	21.9%	NR	NR
Kokoska 2004	Δ from baseline, average headache intensity score (Likert 0-10 scale)	24	-0.54	-0.11	NR	NR

			Resu	ults (mean or %)*	Effect Estimate (95% CI) †	p-value†
Author	Outcome	F/U post-tx	Intervention	Control		
24 week study period	Δ from baseline, frequency headache days/month	24	-6.3	-4.8	NR	NS
Padberg 2004	Δ from baseline, headache intensity (100mm VAS)	12	-10.6	-7.1	NR	NS
12 week study period	Δ from baseline, ≥45% VAS reduction in pain intensity	12	6/19 (31.6%)	3/21 (14.3%)	NR	NS
	Self-reported improvement from baseline	4	8/19 (42.1%)	11/21 (52.4%)	NR	NS
		8	10/19 (52.6%)	10/21 (47.6%)	NR	NS
		12	9/19 (47.4%)	6/21 (28.6%)	NR	NS
	Δ from baseline, % headache days	12	12 ± 20%	5 ± 14%	NR	NS
	Δ from baseline, % days on which analgesics were taken	12	0.12 ± 0.29%	0.10 ± 0.40%	NR	NS
Schmitt 2001	WHYMPI instrument‡	4	NR	NR	NR	NS
8 week study period		8	NR	NR	NR	NS
	Pain severity (VAS)	Base-line	2.62 ± 1.62	2.81 ± 1.86	NR	NR
		4	2.46 ± 1.91	2.49 ± 2.29	NR	NS
		8	2.31 ± 2.09	2.26 ± 2.19	NR	NS
	Self-reported improvement from baseline	4	7/30 (23.3%)	6/29 (20.7%)	NR	NS
		8	7/30 (23.3%)	7/29 (24.1%)	NR	NS
	Δ from baseline, ≥25% VAS reduction in pain	4	11/30 (36.7%)	8/29 (27.6%)	NR	NS
	intensity	8	15/30 (50.0%)	9/29 (31.0%)	NR	NS
	Monthly amount intake of analgesics	Base-line	23.87 ± 27.53	25.14 ± 22.80	NR	NR
		4	23.30 ± 26.68	25.18 ± 22.55	NR	NS
		8	20.32 ± 26.30	26.52 ± 27.12	NR	NS

			Results (mean or %)*		Effect Estimate (95% CI) †	p-value+
Author	Outcome	F/U post-tx	Intervention	Control		
	# pain-free days	Base-line	3.63 ± 5.12	3.79 ± 5.60	NR	NR
		4	4.87 ± 6.85	6.14 ± 7.84	NR	NS
		8	6.00 ± 8.38	5.59 ± 7.71	NR	NS
Silberstein 2006	Δ from baseline, frequency headache-free days/60 days	8	2.8 (150U group; N=48)	4.5	NR	p=.007
30 week study period	Δ from baseline, ≥50% reduction in TTHA days	12	150U: NR 100U: 15/47 (31.9%) 100U 3s: 15/49 (30.6%) 86U 3s: 15/47 (31.9%) 50U: NR	6/50 (12.0%)	NR	p=NS p=.017 p=.024 p=.017 p=NS
	Δ from baseline, headache severity/60 days	8	150U; N=48: -0.1 100U; N=NR: -0.1 100U 3s; N=NR: -0.2 86U 3s; N=47: -0.2 50U; N=NR: -0.2	-0.1	NR	NS for all groups
	Headache Pain Specific QoL score	8	NR	NR	NR	NS for all groups
Т	Tension-Type HA Impact score	8	NR	NR	NR	NS for all groups
	SF-36	8	NR	NR	NR	NS for all groups

BDI, Beck Depression Index; BoNTA, OnabotulinumtoxinA; CI, confidence interval; F/U, follow-up; HA, headache; HDI, Henry Ford Hospital Headache Disability Inventory; HIT-6, Headache Impact Test-6; HRQoL, health related quality of life; MIDAS, Migraine Disability Assessment Scale; MIQ, Migraine Impact Questionnaire; NR, not reported; NS, not significant; PAIS, Psychosocial Adjustment to Illness Scale; PN, placebo non-responder; PR, placebo responder; QoL, quality of life; SD, standard deviation; SF-36, Short Form-36; TTHA, tension-type headache; Tx ,treatment; VAS, visual analog scale; WHYMPI, West Haven-Yale Multidimensional Pain Inventory

* Results are reported as either a mean or a percent. Confidence intervals or standard deviations are reported in parenthesis

⁺ As reported by the authors

‡ Study reported means and standard deviations for 11 domains of WHYMPI separately

Appendix Table G3. Efficacy Outcomes from RCTs Evaluating BoNTA for Chronic Daily Headache

			Results (mean or %)*		Effect Estimate (95% CI) ⁺	p-value†
Author	Outcome	F/U post-tx	Intervention	Control		
BoNTA vs. Placebo	•					
Mathew 2005	Δ from baseline, frequency headache-free days/month	4	PN (n=134): 3.2±5.8 PR (n=39): 8.8±7.1	PN (n=145): 2.6±5.4 PR (n=37): 8.9±6.0	NR	p=NS p=NS
BoNTA vs. Placebo	Δ from baseline, frequency headache-free days/month	8	PN (n=134): 4.5±7.1 PR (n=39): 10.3±5.7	PN (n=145): 3.6±6.4 PR (n=37): 9.9±5.7	NR	p=NS p=NS
36 week study period (16 week treatment period)	Δ from baseline, frequency headache-free days/month	12	PN (n=134): 4.2±6.5 PR (n=39): 10.4±7.1	PN (n=145): 4.0±6.5 PR (n=37): 10.0±6.0	NR	p=NS p=NS
penou)	Δ from baseline, frequency headache-free days/month	24	PN (n=134): 6.7±7.8 PR (n=39): 12.1±6.4	PN (n=145): 5.2±6.9 PR (n=37): 10.5±4.1	NR	p=NS p=NS
	Δ from baseline, frequency headache-free days/month	32	PN (n=134): 7.8±8.4 PR (n=39): 13.0±6.3	PN (n=145): 6.8±7.2 PR (n=37): 12.8±6.6	NR	p=NS p=NS
	Δ from baseline, ≥50% reduction in frequency headache days/month	24	PN: 32.7% PR: NR	PN: 15.0% PR: NR	NR	p=.027 p=NS
	Δ from baseline, ≥50% reduction in frequency headache days/month	24	40.3% (pooled)	25.3% (pooled)	NR	p=.05
	Δ from baseline, frequency headache days/month	24	PN: -6.1 PR: -9.9	PN: -3.1 PR: -5.6	NR	p=.013 p=.004
	Δ from baseline, frequency headache days/month	24	-7.1 (pooled)	-3.7 (pooled)	NR	p=.001
	Δ from baseline, frequency of acute HA medication intake days	24	PN: -6.0±7.9 PR: -10.2±6.3	PN: -5.0±6.5 PR: -7.8±3.7	NR	p=NS p=NS
Ondo 2004	Self-reported improvement from baseline	12	17/29 (58.6%)	3/29 (10.3%)	NR	p<.05
BoNTA vs. Placebo	Physician-reported improvement from baseline	12	16/29 (55.2%)	2/29 (6.9%)	NR	p<.001
8 week study period	Δ from baseline, frequency of abortive HA medication intake	12	106 ± 76	135 ± 81	NR	NS
	Beck Depression Inventory (BDI) score	12	NR	NR	NR	NS
	Psychosocial Adjustment to Illness Scale (PAIS) score	12	NR	NR	NR	NS

			Result	Effect Estimate (95% Cl)†	p-value ⁺	
Author	Outcome	F/U post-tx	Intervention	Control		
Silberstein 2005 BoNTA vs. Placebo	Δ from baseline, frequency headache-free days/month	24	PN 225U: 6.1±7.1 PN 150U: 7.9±8.4 PN 75U: 7.9±7.8	PN: 8.0 ± 8.8	NR	NS
36 week study period (16 week treatment period)	Δ from baseline, frequency headache-free days/month	24	PR, 225U: 13.1±7.8 PR 150U: 11.4±7.5 PR 75U: 14.0±6.1	PR: 10.8 ± 7.2	NR	NS
	Δ from baseline, ≥50% reduction in frequency headache days/month	24	PN 225U: 25.4% PN, 150U: 35.1% PN 75U: 30.9%	PN: 31.7%	NR	NS
BoNTA vs. Active Com	iparator	-		-		
Cady 2011	Improvement, Physician Global Assessment	4	17/28 (60.7%)	20/27 (74.0%)	NR	NS
BoNTA + placebo		12	19/24 (79.2%)	17/24 (70.8%)	NR	NS
Tablets vs. Topiramate +	Δ from baseline, frequency headache days/month	4	-3.0 (n=28)	-4.4 (n=28)	NR	NS
Placebo Tablets		12	-8.0 (n=24)	-8.1 (n=25)	NR	NS
12 week study period		14	-3.2 (n=11)	-6.5 (n=9)	NR	NS
		26	-6.0 (n=8)	-8.5 (n=4)	NR	NS
	Δ from baseline, MIDAS	12	-38.5 (n=21)	-26.7 (n=21)	NR	NS
	Δ from baseline, HIT-6 score	4	-4.8 (n=25)	-5.9 (n=23)	NR	NS
		12	-6.3 (n=21)	-6.0 (n=19)	NR	NS

BDI, Beck Depression Index; BoNTA, OnabotulinumtoxinA; CI, confidence interval; F/U, follow-up; HA, headache; HDI, Henry Ford Hospital Headache Disability Inventory; HIT-6, Headache Impact Test-6; HRQoL, health related quality of life; MIDAS, Migraine Disability Assessment Scale; MIQ, Migraine Impact Questionnaire; NR, not reported; NS, not significant; PAIS, Psychosocial Adjustment to Illness Scale; PN, placebo non-responder; PR, placebo responder; QoL, quality of life; SD, standard deviation; SF-36, Short Form-36; TTHA, tension-type headache; Tx, treatment; VAS, visual analog scale; WHYMPI, West Haven-Yale Multidimensional Pain Inventory

* Results are reported as either a mean or a percent. Confidence intervals or standard deviations are reported in parenthesis

⁺ As reported by the authors

Appendix Table G4. Efficacy Outcomes from RCTs Evaluating Acupuncture for Chronic Migraine

				sults or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
Acupuncture	vs. Usual Care				1	
Vickers 2004	≥35% improvement in headache score† (protocol definition)	Immediate	41% (65/159)	27% (37/136)	NA	0.014
12 week		9 months	54% (87/161)	32% (45/140)	NA	0.0001
treatment	≥50% improvement in headache days‡	Immediate	23% (36/159)	13% (17/136)	NA	0.024
period	(IHS definition) – any	9 months	30% (49/161)	15% (21/140)	NA	0.002
	≥50% improvement in headache days‡ (IHS definition) – at least mild headache	9 months	35% (56/161)	18% (25/140)	NA	0.001
	≥50% improvement in headache days‡ (IHS definition) – moderate or severe headache	9 months	39% (63/161)	26% (37/140)	NA	0.02
	Any prophylactic medication in past month	Baseline	25% (40/161)	32% (45/140)	NA	NR
		Immediate	21% (34/159)	29% (39/136)	Adjusted MD 7% (-3%, 17%)	0.15
		9 months	14% (22/161)	26% (37/140)	Adjusted MD 13% (4%, 22%)	0.005
	Headache score† (weekly)	Baseline	24.6 ± 14.1 (n=161)	26.7 ± 16.8 (n= 140)	NA	NR
		Immediate	18.0 ± 14.8 (n=159)	23.7 ± 16.8 (n=136)	Adjusted MD 3.9 (1.6, 6.3)	0.001
		9 months	16.2 ± 13.7 (n=161)	22.3 ± 17.0 (n=140)	Adjusted MD 4.6 (2.2, 7.0)	0.0002
	Headache days/month‡ – any	Baseline	15.6 ± 6.6 (n=161)	16.2 ± 6.7 (n= 140)	NA	NR
		Immediate	12.1 ± 7.2 (n=159)	14.3 ± 7.3 (n=136)	Adjusted MD 1.8 (0.7, 2.9)	0.002
		9 months	11.4 ± 7.5 (n=161)	13.6 ± 7.5 (n=140)	Adjusted MD 1.8 (0.6, 2.9)	0.003
	Headache days/month‡ – at least mild	Baseline	13.5 ± 6.3 (n=161)	13.8 ± 6.5 (n= 140)	NA	NR
		9 months	9.1 ± 6.5 (n=161)	10.9 ± 6.6 (n=140)	Adjusted MD 1.6 (0.5, 2.6)	0.004

				ults or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Headache days/month‡ – moderate or severe	Baseline	8.5 ± 65.0 (n=161)	8.9 ± 5.7 (n= 140)	NA	NR
		9 months	5.4 ± 4.8 (n=161)	6.9 ± 5.6 (n=140)	Adjusted MD 1.2 (0.4, 2.1)	0.006
	Scaled pain medication (weekly)	Baseline	16.5 ± 18.1 (n=161)	14.3 ± 17.6 (n= 140)	NA	NR
		Immediate	11.0 ± 13.6 (n=159)	11.4 ± 14.1 (n=136)	Adjusted MD 1.6 (-0.7, 3.9)	0.16
		9 months	8.5 ± 12.2 (n=161)	18.7 ± 12.6 (n=140)	Adjusted MD 1.2 (-0.6, 3.1)	0.19
	Scaled prophylactic medication (weekly)	Baseline	9.0 ± 17.8 (n=161)	13.3 ± 22.2 (n= 140)	NA	NR
		Immediate	7.9 ± 17.6 (n=159)	11.5 ± 21.3 (n=136)	Adjusted MD 0.7 (-2.4, 3.8)	0.7
		9 months	5.0 ± 14.4 (n=161)	11.1 ± 21.3 (n=140)	Adjusted MD 3.9 (0.5, 7.4)	0.026
	Total scaled medication (weekly)	Baseline	25.4 ± 25.1 (n=161)	27.6 ± 28.8 (n= 140)	NA	NR
		Immediate	18.9 ± 21.7 (n=159)	22.9 ± 24.8 (n=136)	Adjusted MD 2.9 (-1, 6.7)	0.14
		9 months	13.4 ± 18.2 (n=161)	19.8 ± 24.4 (n=140)	Adjusted MD 5.2 (5.3, 9.2)	0.009
	SF-36 physical function subscale	Baseline	81.9 ± 21.1 (n=161)	85.3 ± 18.4 (n= 139)	NA	NR
		Immediate	82.6± 20.7 (n=156)	81.7 ± 21.3 (n=134)	Adjusted MD 3.0 (-2.0, 6.2)	0.07
		9 months	82.6 ± 23.3 (n=157)	82.3 ± 20.2 (n=138)	Adjusted MD 2.7 (-0.7, 6.0)	0.12
	SF-36 role functioning physical subscale	Baseline	60.4 ± 40.2 (n=161)	59.4 ± 38.6 (n= 139)	NA	NR
		Immediate	63.5 ± 14.4 (n=154)	56.7 ± 40.8 (n=134)	Adjusted MD 5.0 (-3.6, 3.5)	0.3
		9 months	70.0 ± 39.2 (n=157)	60.3 ± 41.3 (n=138)	Adjusted MD 8.8 (0.6, 17.0)	0.036
	SF-36 role functioning emotional subscale	Baseline	73.2 ± 36.6 (n=160)	69.6 ± 39.4 (n= 140)	NA	NR
		Immediate	72.4 ± 39.7 (n=155)	74.7 ± 36.3 (n=130)	Adjusted MD -5.1 (-13, 2.9)	0.2

				sults or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
		9 months	76.0 ± 37.0 (n=154)	70.1 ± 39.2 (n=136)	Adjusted MD 4.9 (-3.5, 13.4)	0.3
	SF-36 energy/fatigue subscale	Baseline	47.9 ± 19.9 (n=161)	52.2 ± 20.2 (n= 140)	NA	NR
		Immediate	51.3 ± 21.6 (n=154)	51.8 ± 20.8 (n=134)	Adjusted MD 1.9 (-1.8, 5.7)	0.3
		9 months	55.4± 20.7 (n=158)	54.2 ± 20.7 (n=139)	Adjusted MD 4.2 (0.6, 7.7)	0.02
	SF-36 emotional well-being subscale	Baseline	66.0 ± 15.0 (n=161)	67.0 ± 14.1 (n= 140)	NA	NR
		Immediate	66.6 ± 15.3 (n=156)	67.8 ± 14.0 (n=134)	Adjusted MD -0.9 (-3.8, 2.0)	0.5
		9 months	68.3 ± 15.4 (n=158)	68.9 ± 14.7 (n=139)	Adjusted MD 0.0 (-2.9, 2.9)	1.0
	SF-36 social functioning subscale	Baseline	71.0 ± 24.9 (n=161)	73.6 ± 21.6 (n= 140)	NA	NR
		Immediate	73.6 ± 24.8 (n=156)	75.4 ± 22.6 (n=134)	Adjusted MD -0.8 (-5.6, 4.1)	0.8
		9 months	77.9 ± 25.2 (n=158)	74.8 ± 23.2 (n=138)	Adjusted MD 4.2 (-0.8, 9.2)	0.1
	SF-36 pain subscale	Baseline	59.8 ± 23.3 (n=160)	66.3 ± 21.3 (n= 140)	NA	NR
		Immediate	64.3 ± 23.6 (n=156)	64.6 ± 23.5 (n=134)	Adjusted MD 2.4 (-2.5, 7.3)	0.3
		9 months	65.0 ± 24.5 (n=158)	63.7 ± 22.2 (n=139)	Adjusted MD 4.4 (-0.2, 9.0)	0.063
	SF-36 general health subscale	Baseline	60.2 ± 21.1 (n=161)	64.0 ± 21.8 (n= 140)	NA	NR
		Immediate	61.1 ± 21.1 (n=156)	61.8 ± 22.1 (n=134)	Adjusted MD 2.1 (95% CI - 1.0, 5.3)	0.2
		9 months	61.9 ± 22.5 (n=158)	62.5 ± 22.9 (n=139)	Adjusted MD 3.0 (-0.4, 6.5)	0.09
	SF-36 health change subscale	Baseline	52.5 ± 15.4 (n=161)	53.4 ± 17.0 (n= 140)	NA	NR
		Immediate	58.0 ± 18.9 (n=154)	50.6 ± 18.3 (n=133)	Adjusted MD 7.7 (3.5, 12.0)	0.0004
		9 months	62.8 ± 20.1 (n=158)	55.5 ± 18.4 (n=139)	Adjusted MD 7.9 (3.5, 12.3)	0.0004

				ults or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Number of visits to GP	9 months	1.7 ± 2.5 (n=161)	2.3 ± 3.6 (n=140)	Adjusted MD 0.77 (0.56, 1.06)	0.1
	Number of visits to Specialist	9 months	0.22 ± 0.9 (n=161)	0.14 ± 0.6 (n=140)	Adjusted MD 1.13 (0.34, 3.73)	0.8
	Number of visits to Complementary therapist	9 months	2.0 ± 7.1 (n=161)	2.3 ± 6.8 (n=140)	Adjusted MD 0.56 (0.18, 1.72)	0.3
Acupuncture	vs. Topiramate		•	•		•
Yang 2011 12 week	Responders (proportion of patients with ≥50% ↓ from baseline in number of moderate/severe headache days)	3 months post- tx	75.8% (25/33)	30.3% (10/33)	NR	<0.01
treatment period	Responders (proportion of patients with ≥50% ↓ from baseline in number of headache days)	3 months post- tx	63.6% (21/33)	15.2% (5/33)	NR	<0.01
	Δ from baseline, mean headache days/month	3 months post- tx	-10.7 ± 2.8 (n=33)	-7.9 ± 3.6 (n=33)	NR	<0.01
	Δ from baseline, mean moderate/severe headache days/month	3 months post- tx	-10.5 ± 2.8 (n=33)	-7.8 ± 3.6 (n=33)	NR	<0.01
	Δ from baseline, MIDAS score	3 months post- tx	-38.5 ± 10.7 (n=33)	-25.9 ± 9.3 (n=33)	NR	<0.01
	Δ from baseline, BDI-II score	3 months post- tx	-7.7 ± 4.8 (n=33)	-5.6 ± 2.4 (n=33)	NR	0.025
	Δ from baseline, HADS score	3 months post- tx	-7.1 ± 2.2 (n=33)	-2.9 ± 1.7 (n=33)	NR	<0.01
		3 months post- tx	-9.6 ± 3.3 (n=33)	-5.4 ± 4.7 (n=33)	NR	<0.01
	Δ from baseline, SF-36 physical function domain	3 months post- tx	18.7 ± 9.2 (n=33)	9.2 ± 4.9 (n=33)	NR	<0.01
	Δ from baseline, SF-36 role physical domain	3 months post- tx	27.6 ± 8.9 (n=33)	18.2 ± 9.3 (n=33)	NR	<0.01

					Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Δ from baseline, SF-36 bodily pain domain	3 months post- tx	13.7 ± 8 (n=33)	8.1 ± 4 (n=33)	NR	0.01
	Δ from baseline, SF-36 general health domain	3 months post- tx	22.3 ± 6.9 (n=33)	14.8 ± 11.9 (n=33)	NR	0.002
	Δ from baseline, SF-36 vitality domain	3 months post tx	22.1 ± 6.6 (n=33)	16.8 ± 6.6 (n=33)	NR	0.002
	Δ from baseline, SF-36 social functioning domain	3 months post tx	16 ± 8.1 (n=33)	9.8 ± 4.7 (n=33)	NR	<0.01
	Δ from baseline, SF-36 role emotion domain	3 months post tx	27.8 ± 10.7 (n=33)	17.5 ± 6.2 (n=33)	NR	<0.01
	Δ from baseline, SF-36 mental health domain	3 months post tx	22.2 ± 6.4 (n=33)	11 ± 6.5 (n=33)	NR	<0.01

F/U: follow-up; GP: general practitioner; IHS: International Headache Society; MD: mean difference; NA: not applicable; NR: not reported; SD: standard deviation; SF-36: Short-Form-36 questionnaire.

*As reported by the authors. Adjusted difference: positive favors acupuncture.

⁺Severity of headaches were recorded 4x/day on a 6-point Likert scale and the total summed to give a headache score.

‡"Days with headache" was defined very liberally as days on which a patient recorded headache severity of at least 1 out of 5 for at least one timepoint. The mean number of days with headache reported by this trial is accordingly larger than that seen in other trials. Therefore, the authors performed the analyses using more conservative definitions of days with headache (i.e., day on which mild or moderate/severe headache was reported); results indicated that differences between groups were not sensitive to the definition of headache day.

Appendix Table G5. Efficacy Outcomes from RCTs Evaluating Acupuncture for Chronic Tension-Type Headache

			Resu (mean ± SD		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
Acupuncture v	vs. Sham					
Karst 2000	VAS pain (mean) (0-10)	Baseline	6.2 ± 2.2 (n=21)	6.3 ± 2.2 (n=18)	NR	NR
		Immediate	4.3 ± 2.6 (n=21)	4.7 ± 2.4 (n=18)	NR	NR
5 week treatment		6 wks post tx	4.0 ± 2.5 (n=21)	3.9 ± 2.7 (n=18)	NR	NR
period	Clinical global impression (CGI)	Immediate	1.6 ± 1.5 (n=21)	0.8 ± 1.5 (n=18)	NR	NR
	(-4 to 4)	6 wks post tx	1.3 ± 1.4 (n=21)	1.1 ± 1.7 (n=18)	NR	NR
	Frequency of headache	Baseline	26.9 ±7.0 (n=21)	27.2 ± 5.9 (n=18)	NR	NR
	attacks/month	Immediate	17.5 ± 12.6 (n=21)	22.8 ± 10.0 (n=18)	NR	NR
		6 wks post tx	22.1 ± 10.6 (n=21)	22.0 ± 9.9 (n=18)	NR	NR
	PPT (Pressure Point Threshold) Left (kPa)	Baseline	329.1 ± 70.5 (n=21)	373.2 ± 28.6 (n=18)	NR	NR
		6 wks post tx	360.0 ± 41.3 (n=21)	366.6 ± 57.1 (n=18)	NR	NR
	PPT (Pressure Point Threshold) Right (kPa)	Baseline	312.9 ± 78.8 (n=21)	354.7 ± 56.8(n=18)	NR	NR
		6 wks post tx	368.2 ± 439.4 (n=21)	358.9 ± 76.6 (n=18)	NR	NR
	Analgesics/month	Baseline	8.3 ± 11.8 (n=21)	10.2 ± 12.0 (n=18)	NR	NR
		Immediate	6.4 ± 11.2 (n=21)	4.3 ± 5.7 (n=18)	NR	NR
		6 wks post tx	13.7 ± 117.2 (n=21)	21.2 ± 27.6 (n=18)	NR	NR
Tavola 1992	Headache intensity (sum of the intensity of the headaches in a month [1 to 4; 1 = slight; 2	Baseline	4.3 ± 3.9 (n=15)	4.5 ± 3.4 (n=15)	NR	NS

				sults 9 or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
8 week treatment period	= medium: 3 = strong: 4 = very strong]/number of headaches)					
	Headache frequency (no. of headaches/month)	Baseline	3.4 ± 2.4* (n=15) (estimated from graph)	3.2 ± 2.5* (n=15) (estimated from graph)	NR	NS
	Duration of headaches (sum of duration of headaches in hrs./no. of headaches)	Baseline	2.8 ± 1.8 * (n=15) (estimated from graph)	3.2 ± 2.6* (n=15) (estimated from graph)	NR	NS
	Headache index (intensity X duration X frequency/30)	Baseline	4.3 ± 3.9 (n=15)	4.5 ± 3.4 (n=15)	NR	NS
		half-way thru tx (tx = 8 wks.)	3.4 ± 2.4* (n=15) (estimated from graph)	3.2 ± 2.5* (n=15) (estimated from graph)	NR	NS
		end of tx (tx = 8 wks.)	2.8 ± 1.8 * (n=15) (estimated from graph)	3.2 ± 2.6* (n=15) (estimated from graph)	NR	NS
		4 wks (1 mo.) after the end end of tx	2.4 ± 1.4 * (n=15) (estimated from graph)	3.0 ± 2.3* (n=15) (estimated from graph)	NR	NS
		26 wks (6 mos.) after the end end of tx	2.2 ± 1.6* (n=15) (estimated from graph)	3.1 ± 2.6* (n=15) (estimated from graph)	NR	NS
		52 wks (12 mos.) after the end end of tx	$3.2 \pm 2.1^*$ (n=15) (estimated from graph)	3.7 ± 2.2* (n=15) (estimated from graph)	NR	NS
	Analgesic consumption (sum	baseline (1 month prior to tx)	11.6 ± 10.2 (n=15)	11.5 ± 12.7 (n=15)	NR	NS
	of the drugs taken per month)	half-way thru tx (tx = 8 wks.)	7.3 ± * (n=15) (estimated from graph)	9.8 ± * (n=15) (estimated from graph)	NR	NS

			_	sults D or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
		end of tx (tx = 8 wks.)	4.3 ± * (n=15) (estimated from graph)	9.3 ± * (n=15) (estimated from graph)	NR	NS
		4 wks (1 mo.) after the end end of tx	5.0 ± * (n=15) (estimated from graph)	9.0 ± * (n=15) (estimated from graph)	NR	NS
		26 wks (6 mos.) after the end end of tx	5.0 ± * (n=15) (estimated from graph)	8.5 ± * (n=15) (estimated from graph)	NR	NS
		52 wks (12 mos.) after the end end of tx	6.5 ± * (n=15) (estimated from graph)	9.5 ± * (n=15) (estimated from graph)	NR	NS
	Mean decrease of episode frequency from baseline to 9 wks.	4 wks (1 mo.) after the end end of tx	44.3%	21.4%	NR	NR
	Mean decrease of headache index from baseline to 9 wks.	4 wks (1 mo.) after the end end of tx	58.3%	27.8%	NR	NR
	Mean decrease of analgesic consumption from baseline to 9 wks.	4 wks (1 mo.) after the end end of tx	57.7%	21.7%	NR	NR
	Responders 33% threshold (Proportion of patients with >33% improvement over baseline on Headache Index)	4 wks (1 mo.) after the end end of tx	86.7% (13/15)	60.0% (9/15)	NR	P=0.125
	Responders 50% threshold (Proportion of patients with >50% improvement over baseline on Headache Index)	4 wks (1 mo.) after the end end of tx	53.3% (8/15)	46.7% (7/15)	NR	P=1
	Responders 33% threshold (Proportion of patients with >33% improvement over baseline on Headache Index)	52 wks (12 mos.) after the end end of tx	53.3% (8/15)	46.7% (7/15)	NR	P=1

			Resi (mean ± SD		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx In	Intervention	Control		
	Responders 50% threshold (Proportion of patients with >50% improvement over baseline on Headache Index)		40.0% (6/15)	26.7% (4/15)	NR	P=0.7
Acupuncture vs. A	ctive Comparator		•			
Soderberg 2006 Headache intensity (VAS 0- 100) Acupuncture vs.	Baseline	26.75 (range, 0.72– 69.6) (n=30)	22.03 (range, 4.66–48.2) (n=30)	NR	NS	
physical training vs. relaxation training		Immediate	21.21 (range, 0.93– 72.45) (n=30)	15.5 (range, 0.30–51.53) (n=30)	NR	NS
10-12 week treatment period		3 mos post tx	18.93 (range, 0.00– 53.38) (n=30)	16.88 (range, 0.00–61.67) (n=30)	NR	NS
		6 mos post tx	17.72 (range, 0.00– 50.27) (n=30)	14.66 (range, 0.00–56.75) (n=30)	NR	NS
	Headache-free periods (0-28 periods/wk.)	Baseline	4.13 (range, 0.00– 18.25) (n=30)	5.74 (range, 0.00–23.25) (n=30)	NR	NS
		Immediate	3.85 (range, 0.00– 26.25) (n=30)	8.33 (range, 0.00–27.50) (n=30)	NR	NS
		3 mos post tx	6.25 (range, 0.00– 28.00) (n=30)	7.46 (range, 0.00–28.00) (n=30)	NR	NS
		6 mos post tx	7.58 (range, 0.00– 28.00) (n=30)	9.37 (range, 0.00–28.00) (n=30)	NR	NS

				ults or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Headache-free days (0-7 days/wk.)	Baseline	0.73 (range, 0.00– 3.25) (n=30)	0.97 (range, 0.00– 5.00) (n=30)	NR	NS
		Immediate	0.68 (range, 0.00– 6.25) (n=30)	1.52 (range, 0.00– 6.75) (n=30)	NR	P=0.01
		3 mos post tx	1.18 (range, 0.00– 7.00) (n=30)	1.23 (range, 0.00– 7.00) (n=30)	NR	NS
		6 mos post tx	1.56 (range, 0.00– 7.00) (n=30)	1.66 (range, 0.00– 7.00) (n=30)	NR	NS
	Headache intensity (VAS 0- 100)	Baseline	26.75 (range, 0.72– 69.6) (n=30)	26.14 (range, 3.77– 61.71) (n=30)	NR	NS
		Immediate	21.21 (range, 0.93– 72.45) (n=30)	16.77 (range, 0.00– 56.24) (n=30)	NR	NS
		3 mos post tx	18.93 (range, 0.00– 53.38) (n=30)	16.14 (range, 0.00– 66.64) (n=30)	NR	NS
		6 mos post tx	17.72 (range, 0.00– 50.27) (n=30)	15.08 (range, 0.00– 70.48) (n=30)	NR	NS
	Headache-free periods (0-28 periods/wk.)	Baseline	4.13 (range, 0.00– 18.25) (n=30)	3.32 (range, 0.00– 19.50) (n=30)	NR	NS
		Immediate	3.85 (range, 0.00– 26.25) (n=30)	6.98 (range, 0.00– 28.00) (n=30)	NR	P=0.024
		3 mos post tx	6.25 (range, 0.00– 28.00) (n=30)	7.67 (range, 0.00– 29.00) (n=30)	NR	NS
		6 mos post tx	7.58 (range, 0.00– 28.00) (n=30)	8.29 (range, 0.00– 29.00) (n=30)	NR	NS
	Headache-free days (0-7 days/wk.)	Baseline	0.73 (range, 0.00– 3.25) (n=30)	0.38 (range, 0.00– 3.00) (n=30)	NR	NS
		Immediate	0.68 (range, 0.00– 6.25) (n=30)	1.44 (range, 0.00– 7.00) (n=30)	NR	P=0.01
		3 mos post tx	1.18 (range, 0.00– 7.00) (n=30)	1.58 (range, 0.00– 7.25) (n=30)	NR	NS
		6 mos post tx	1.56 (range, 0.00– 7.00) (n=30)	1.73 (range, 0.00– 7.25) (n=30)	NR	NS

				Results (mean ± SD or % (n/N))		p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
Soderberg 2011	Proportion of patients with Improved QoL (MSEP)	Immediate	56.7% (17/30)	63.3% (19/30)	NR	NS
Acupuncture vs.		3 mos post tx	56.7% (17/30)	86.7% (26/30)	NR	P=0.036
physical training		6 mos post tx	56.7% (17/30)	80.0% (24/30)	NR	NS
vs. relaxation training	Proportion of patients with	Immediate	36.7% (11/30)	36.7% (11/30)	NR	NS
training	Improved Vitality Dimension	3 mos post tx	26.7% (8/30)	43.3% (13/30)	NR	NS
10-12 week	Score of ≥10 VAS units	6 mos post tx	20.0% (6/30)	33.3% (10/30)	NR	NS
treatment	Proportion of patients with	Immediate	16.7% (15/30)	16.7% (15/30)	NR	NS
period	Improved Vitality Dimension	3 mos post tx	16.7% (15/30)	16.7% (15/30)	NR	NS
	Score (MSEP) of ≥25 VAS units	6 mos post tx	10.0% (3/30)	13.3% (14/30)	NR	NS
	Proportion of patients with Improved Sleep QoL Dimension (MSEP) of ≥10 VAS units	Immediate	26.7% (8/30)	26.7% (8/30)	NR	NS
		3 mos post tx	30.0% (9/30)	30.0% (9/30)	NR	NS
		6 mos post tx	40.0% (12/30)	33.3% (10/30)	NR	NS
	Proportion of patients with	Immediate	13.3% (4/30)	23.3% (7/30)	NR	NR
	Improved Sleep QoL	3 mos post tx	10.0% (3/30)	13.3% (4/30)	NR	NR
	Dimension (MSEP) of ≥25 VAS units	6 mos post tx	13.3% (4/30)	16.7% (5/30)	NR	NR
	Proportion of patients with	Immediate	43.3% (13/30)	26.7% (8/30)	NR	NS
	Improved Contentment	3 mos post tx	30.0% (9/30)	30.0% (9/30)	NR	NS
	Dimension Score (MSEP) of ≥10 VAS units	6 mos post tx	40.0% (12/30)	33.3% (10/30)	NR	NS
	Proportion of patients with	Immediate	10.0% (3/30)	13.3% (4/30)	NR	NS
	Improved Contentment	3 mos post tx	10.0% (3/30)	13.3% (4/30)	NR	NS
	Dimension Score (MSEP) of ≥25 VAS units	6 mos post tx	13.3% (4/30)	16.7% (5/30)	NR	NS
	Proportion of patients with	Immediate	56.7% (17/30)	76.7% (23/30)	NR	NS
	Improved QoL (MSEP)	3 mos post tx	56.7% (17/30)	66.7% (20/30)	NR	NS
		6 mos post tx	56.7% (17/30)	73.3% (22/30)	NR	NS

			Resu (mean ± SD		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Proportion of patients with	Immediate	36.7% (11/30)	36.7% (11/30)	NR	NS
	Improved Vitality Dimension	3 mos post tx	26.7% (8/30)	30.0% (9/30)	NR	NS
	Score of ≥10 VAS units	6 mos post tx	20.0% (6/30)	50.0% (15/30)	NR	P=0.04
	Proportion of patients with	Immediate	16.7% (15/30)	10.0% (3/30)	NR	NS
	Improved Vitality Dimension	3 mos post tx	16.7% (15/30)	10.0% (3/30)	NR	NS
	Score (MSEP) of ≥25 VAS units	6 mos post tx	10.0% (3/30)	33.3% (10/30)	NR	P=0.04
	Proportion of patients with	Immediate	26.7% (8/30)	30.0% (9/30)	NR	NS
	nproved Sleep QoL	3 mos post tx	30.0% (9/30)	36.7% (11/30)	NR	NS
	Dimension (MSEP) of ≥10 VAS units	6 mos post tx	40.0% (12/30)	53.3% (16/30)	NR	P=0.04
	Proportion of patients with	Immediate	13.3% (4/30)	16.7% (5/30)	NR	NS
	Improved Sleep QoL	3 mos post tx	10.0% (3/30)	16.7% (5/30)	NR	NS
	Dimension (MSEP) of ≥25 VAS units	6 mos post tx	13.3% (4/30)	26.7% (8/30)	NR	P=0.04
	Proportion of patients with	Immediate	43.3% (13/30)	40.0% (12/30)	NR	NS
	Improved Contentment	3 mos post tx	30.0% (9/30)	36.7% (11/30)	NR	NS
	Dimension Score (MSEP) of ≥10 VAS units	6 mos post tx	40.0% (12/30)	53.3% (16/30)	NR	NS
	Proportion of patients with	Immediate	10.0% (3/30)	6.7% (2/30)	NR	NS
	Improved Contentment	3 mos. post tx	10.0% (3/30)	16.7% (5/30)	NR	NS
	Dimension Score (MSEP) of ≥25 VAS units	6 mos. post tx	13.3% (4/30)	26.7% (8/30)	NR	NS
Carlsson 1990 (Health Status	Headache intensity (pain on VAS 0-100)	baseline (3-8 wks. before treatment)	41 (n=23) (estimated from graph)	52 (n=29) (estimated from graph)	NR	NR
Acupuncture vs. physical training		4-9 wks. after termination of tx	40 (n=23) (estimated from graph)	28 (n=29) (estimated from graph)	NR	NR

			Resu (mean ± SD (Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
8-12 week treatment		After 7-12 mos. (?after termination of tx?)	52 (n=23) (estimated from graph)	29 (n=29) (estimated from graph)	NR	NR
period	Sickness Impact Profile (SIP) - Overall (0-100, poorer health)	before tx	12.5 (n=23) (estimated from graph)	9.5 (n=29) (estimated from graph)	NR	NR
		after tx	9 (n=23) (estimated from graph)	4.5 (n=29) (estimated from graph)	NR	NR
	Sickness Impact Profile (SIP) - Psychosocial index (0-100, poorer health)	before tx	15.5 (n=23) (estimated from graph)	14 (n=29) (estimated from graph)	NR	NR
		after tx	10 (n=23) (estimated from graph)	4.5 (n=29) (estimated from graph)	NR	NR
	Sickness Impact Profile (SIP) - Emotional Behavior (0-100, poorer health)	before tx	26 (n=23) (estimated from graph)	23 (n=29) (estimated from graph)	NR	NR
		after tx	19 (n=23) (estimated from graph)	7 (n=29) (estimated from graph)	NR	NR
	Sickness Impact Profile (SIP) - Sleep and rest (0-100, poorer health)	before tx	23.5 (n=23) (estimated from graph)	17 (n=29) (estimated from graph)	NR	NR
		after tx	12.5 (n=23) (estimated from graph)	10.5 (n=29) (estimated from graph)	NR	NR
	Mood Adjective Check List (MACL) - Overall scores (1-4,	before tx	2.79 ± 0.37 (n=23)	2.77 ± 0.43 (n=29)	NR	NR
	more positive emotional state)	after tx	2.77 ± 0.48 (n=23)	2.97 ± 0.48 (n=29)	NR	NR
		before tx	2.78 ± 0.50 (n=23)	2.82 ± 0.66 (n=29)	NR	NR

				sults) or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Mood Adjective Check List (MACL) - pleasantness/unpleasantness (1-4, more positive emotional state)	after tx	2.72 ± 0.62 (n=23)	3.01 ± 0.64 (n=29)	NR	NR
	Mood Adjective Check List (MACL) -	before tx	2.86 ± 0.51 (n=23)	2.80 ± 0.56 (n=29)	NR	NR
	activation/deactivation (1-4, more positive emotional state)	after tx	2.77 ± 0.67 (n=23)	3.04 ± 0.58 (n=29)	NR	NR
	Mood Adjective Check List (MACL) - calmness/tension (1-4, more	before tx	2.29 ± 0.63 (n=23)	2.28 ± 0.61 (n=29)	NR	NR
	positive emotional state)	after tx	2.39 ± 0.68 (n=23)	2.60 ± 0.69 (n=29)	NR	NR
	Mood Adjective Check List (MACL) - extraversion/introversion (1-4,	before tx	2.80 ± 0.44 (n=23)	2.89 ± 0.41 (n=29)	NR	NR
	more positive emotional state)	after tx	2.79 ± 0.50 (n=23)	3.03 ± 0.49 (n=29)	NR	NR
	Mood Adjective Check List (MACL) - pos/neg social	before tx	3.14 ± 0.46 (n=23)	3.10 ± 0.47 (n=29)	NR	NR
	oreintation (1-4, more positive emotional state)	after tx	3.07 ± 0.45 (n=23)	3.31 ± 0.47 (n=29)	NR	NR
	Mood Adjective Check List (MACL) - confidence/lack of	before tx	2.89 ± 0.52 (n=23)	2.74 ± 0.41 (n=29)	NR	NR
	confidence (1-4, more positive emotional state)	after tx	2.87 ± 0.52 (n=23)	2.86 ± 0.49 (n=29)	NR	NR
	Headache frequency (1-to-5 scale: almost never, once or twice a month, once a week, several times a week and daily)	after tx			"reduced in both the groups p<0.001" (no data)	NR
		before tx	3.78 ± 0.96 (n=23)	3.72 ± 0.73 (n=29)	NR	NR

			Resu (mean ± SD (Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
Carlsson 1990 (Muscle Tenderness) Acupuncture vs. physical training		after tx	3.24 ± 1.04 (n=23)	2.52 ± 0.80 (n=29)	NR	NR
10-12 week treatment	Proportion of patients NOT TAKING analgesics	before tx	5% (n=23) (estimated from graph)	3% (n=29) (estimated from graph)	NR	NR
period		after tx	7% (n=23) (estimated from graph)	18% (n=29) (estimated from graph)	NR	NR
	Proportion of patients with a LOW intake of analgesics	before tx	4% (n=23) (estimated from graph)	11% (n=29) (estimated from graph)	NR	NR
		after tx	3% (n=23) (estimated from graph)	7% (n=29) (estimated from graph)	NR	NR
	Proportion of patients with a MODERATE intake of analgesics	before tx	11% (n=23) (estimated from graph)	13% (n=29) (estimated from graph)	NR	NR
		after tx	11% (n=23) (estimated from graph)	4% (n=29) (estimated from graph)	NR	NR
	Proportion of patients with a HIGH intake of analgesics	before tx	3% (n=23) (estimated from graph)	2% (n=29) (estimated from graph)	NR	NR
		after tx	2% (n=23) (estimated from graph)	0% (n=29) (estimated from graph)	NR	NR

Appendix Table G6. Efficacy outcomes from RCTs Evaluating Manual Therapy for Chronic Migraine and Chronic Tension-Type Headache

			Resul (mean ± SD o		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
Manipulation v	s. Amitriptyline					
Nelson 1998	4 wks.) (0-70; weekly sum of pt's headache pain scores [VAS 0-10]) on	last 4 wks. of the treatment period (8 wks. from randomization)	9.8 ± 6.3 (n=59)	9.1 ± 6.3 (n=49)	Adj. diff -0.7 (-4.2, 2.1)	NR
8 week treatment period	days they had experienced a headache) (adj = baseline values)	4 wks. after the end of treatment (12 wks. after randomization)	9.8 ± 7.0 (n=58)	12.6 ± 7.0 (n=50)	Adj. 2.8 (-0.07, 6.3)	NS
		Last 4 wks. of the treatment period (8 wks. from randomization)	1.1 ± 1.1 (n=59)	0.9 ± 1.0 (n=49)	Adj0.2 (-0.7, 0.2)	NR
		4 wks. after the end of treatment (12 wks. after randomization)	1.1 ± 1.3 (n=58)	1.4 ± 1.3 (n=50)	Adj.0.4 (-0.2, 0.9)	NS
	SF-36 scores (global), %	4 wks. after the end of treatment (12 wks. after randomization)	73.6 ± 10.7 (n=58)	71.2 ± 10.5 (n=50)	Adj2.5 (-8.0, 3.1)	NS
	Headache frequency (% of days with headache)	baseline	53.1% ± 26.3% (n=58)	51.8% ± 24.4% (n=47)	NR	NR
		Last 4 wks. of the treatment period (8 wks. from randomization)	37.5% ± 25.9% (n=58)	26.8% ± 22.6% (n=47)	NR	NR
		4 wks. after the end of treatment (12 wks. after randomization)	36.9% ± 29.3% (n=58)	40.5% ± 23.3 (n=47)	NR	NS
	Headache severity on the days with	baseline	5.0 ± 1.3 (n=56)	4.6 ± 1.1 (n=44)	NR	NR
		Last 4 wks. of the treatment period (8 wks. from randomization)	4.3 ± 1.5 (n=56)	4.3 ± 1.6 (n=44)	NR	NR
		4 wks. after the end of treatment (12 wks. after randomization)	4.4 ± 1.7 (n=56)	4.5 ± 1.3 (n=44)	NR	NS

			Results (mean ± SD or % (n/N))		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Proportion of patients with >20% reduction in HI scores	Last 4 wks. of the treatment period (8 wks. from randomization)	85% (50/59)	80% (39/49)	NR	NR
		4 wks. after the end of treatment (12 wks. after randomization)	58% (34/59)	69% (34/49)	NR	NR
	Proportion of patients with >40% reduction in HI scores	Last 4 wks. of the treatment period (8 wks. from randomization)	22% (13/59)	49% (24/49)	NR	NR
		4 wks. after the end of treatment (12 wks. after randomization)	74% (43/58)	44% (22/50)	RR 1.68, NNT 3.3	NR
	Proportion of patients with >60% reduction in HI scores	last 4 wks. of the treatment period (8 wks. from randomization)	60% (35/58)	36% (18/50)	RR 1.67, NNT 4.1	NR
		4 wks. after the end of treatment (12 wks. after randomization)	22% (13/58)	16% (8/50)	RR 1.40, NNT 15.6	NR
Manipulation v	vs. Routine Care					
Castien 2011	Proportion of patients with 50% reduction in headache frequency	immediately after tx period	87.5% (35/40)	27.5% (11/40)	RR 3.2 (95% CI 1.9, 5.3) NNT 2 (95% CI 1.3, 2.2)	
8 week treatment period		26 wks. after randomization (18 wks. after end of tx)	81.6% (31/38)	40.5% (15/37)	RR 2.0 (95% CI 1.3, 3.0) NNT 3 (95% CI 1.6, 4.8)	
	Δ from baseline, mean headache frequency (days/14 days (headache diary))	immediately after tx period	-9.1 ± 3.8 (n=40)	-2.7 ± 4.3 (n=40)		<0.001
	Mean difference in Δ scores from baseline, mean headache frequency (days/14 days (headache diary))	immediately after tx period			-6.4 ± 0.92 (95% Cl -8.32, -4.56)	<0.001
	Δ from baseline, mean headache pain intensity (0-10 NRS)	immediately after tx period	-2.7 ± 0.9 (n=40)	-0.9 ± 2.4 (n=40)		0.003

			Results (mean ± SD or % (n/N))		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Mean difference in Δ scores from baseline, mean headache pain intensity (0-10 NRS)	immediately after tx period			-1.8 ± 0.6 (95% Cl -3.07, -0.67)"	0.003
	Δ from baseline, mean headache duration (hrs./day)	immediately after tx period	–5.9 ± 8.7 (n=40)	-0.6 ± 10.0 (n=40)		0.013
	Mean difference in Δ scores from baseline, mean headache duration (hrs./day)	immediately after tx period			-5.3 ± 2.1 (95% Cl -9.51, -1.15)	0.013
	Δ from baseline, Headache Impact Test-6 (36-78)	immediately after tx period	-8.9 ± 7.1 (n=40)	-2.4 ± 6.5 (n=40)		<0.001
	Mean difference in Δ scores from baseline, mean Headache Impact Test-6 (36-78)	immediately after tx period			-6.5 ± 1.5 (95% Cl -9.62, -3.52)	<0.001
	Δ from baseline, mean Headache Disability Inventory (0-100)	immediately after tx period	-17.4 ± 16.1 (n=40)	-5.8 ± 12.8 (n=40)		0.001
	Mean difference in Δ scores from baseline, mean Headache Disability Inventory (0-100)	immediately after tx period			-11.6 ± 3.2 (95% Cl -18.1, -5.1)	0.001
	Δ from baseline, mean headache frequency (days/14 days (headache diary))	26 wks. after randomization (18 wks. after end of tx)	-9.1 ± 4.2 (n=38)	-4.1 ± 4.4 (n=37)		<0.001
	Mean difference in Δ scores from baseline, mean headache frequency (days/14 days (headache diary))	26 wks. after randomization (18 wks. after end of tx)			-4.9 ± 0.99 (95% CI -6.95, -2.98)	<0.001
	Δ from baseline, mean headache pain intensity (0-10 NRS)	26 wks. after randomization (18 wks. after end of tx)	-3.1 ± 2.8 (n=38)	-1.7 ± 2.5 (n=37)		0.027
	Mean difference in Δ scores from baseline, mean headache pain intensity (0-10 NRS)	26 wks. after randomization (18 wks. after end of tx)			-1.4 ± 0.63 (95% CI -2.69, -0.16)	0.027
	Δ from baseline, mean headache duration (hrs./day)	26 wks. after randomization (18 wks. after end of tx)	-7.0 ± 10.4 (n=38)	-3.5 ± 7.3 (n=37)		0.095

			Results (mean ± SD or % (n/N))		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Mean difference in Δ scores from baseline, mean headache duration (hrs./day)	26 wks. after randomization (18 wks. after end of tx)			-3.5 ± 2.1 (95% CI -7.71, -0.63)	0.095
	Δ from baseline, Headache Impact Test-6 (36-78)	26 wks. after randomization (18 wks. after end of tx)	-10.6 ± 8.4 (n=38)	-5.5 ± 8.6 (n=37)		0.012
	Mean difference in Δ scores from baseline, mean Headache Impact Test-6 (36-78)	26 wks. after randomization (18 wks. after end of tx)			-5.0 ± 1.97 (95% Cl -9.02, -1.16)	0.012
	Δ from baseline, Headache Disability Inventory (0-100)	26 wks. after randomization (18 wks. after end of tx)	-20.0 ± 22.6 (n=38)	-9.9 ± 18.0 (n=37)		0.037
	Mean difference in Δ scores from baseline, mean Headache Disability Inventory (0-100)	26 wks. after randomization (18 wks. after end of tx)			-10.1 ± 4.74 (95% CI -19.5, -0.64)	0.037
	Perceived recovery: proportion who considered themselves improved/much improved	immediately after tx period	87.5% (35/40)	25.0% (10/40)	Diff: 62.5% (95% Cl 48.4%, 79.3%)	<0.05
	Proportion who used ≥1 sick leave day	26 wks. after randomization (18 wks. after end of tx)	7.9% (3/38)	32.4% (12/37)	Diff: 49% (95% Cl 30.0%, 67.9%)	<0.05
	Proportion who used any additional health care (i.e., physical therapy, medical specialists, other)	26 wks. after randomization (18 wks. after end of tx)	13.2% (5/38)	59.4% (22/37)	Diff: 46.3% (95% Cl 27.1%, 65.4%)	<0.05
	Proportion who used additional physical therapy	26 wks. after randomization (18 wks. after end of tx)	2.6% (1/38)	40.5% (15/37)	Diff: 37.9% (95% Cl 21.2%, 54.3%)	<0.05
	Proportion who used additional medical specialist care	26 wks. after randomization (18 wks. after end of tx)	2.6% (1/38)	16.2% (6/37)	Diff: 13.5% (95% Cl 0.7%, 26.5%)	<0.05
	Proportion who used additional "other" health care	26 wks. after randomization (18 wks. after end of tx)	7.8% (3/38)	2.7% (1/37)	Diff: 5.1% (95% CI -4.8%, -15.2%)	<0.05

				Results (mean ± SD or % (n/N))		p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Use of analgesics/NSAIDs (decreased, no change, increased intake of tablets)	26 wks. after randomization (18 wks. after end of tx)	Data NR: "differences were not stat. diff. b/w groups"			NS
	Use of analgesics/NSAIDs (decreased, no change, increased intake of tablets)	26 wks. after randomization (18 wks. after end of tx)	Data NR: "differences were not stat. diff. b/w groups"			0.92

Appendix Table G7. Efficacy Outcomes from RCTS Evaluating Massage Therapy for Chronic Daily Headache

			Resi (mean ± SD		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
Massage vs. Sh	am					
Chatchawan	Headache intensity (pain during past 24 hrs. on	baseline	5.54 ± 2.16 (n=36)	4.66 ± 2.40 (n=36)	NR	NR
2014	VAS 0-10)	end of tx (after 3 wks. of tx)	1.66 (n=36)	2.60 (n=36)	Diff (95% Cl): -0.94 (- 1.95 to 0.07)	0.066
3 week treatment		3 wks. after last tx	2.32 (n=36)	2.93 (n=36)	Diff (95% Cl): -0.61 (- 1.77 to 0.56)	0.3
period		9 wks. after last tx	2.63 (n=36)	2.70 (n=36)	Diff (95% Cl): -0.07 (- 1.18 to 1.04)	0.9
	Headache frequency (time/mo) (adjusted mean, for baseline)	baseline	16.26 ± 2.02 (n=36)	16.35 ± 6.68 (n=36)	NR	NR
		end of tx (after 3 wks. of tx)	3.16 (n=36)	3.86 (n=36)	Diff (95% Cl): -0.70 (- 1.84 to 0.43)	0.219
		3 wks. after last tx	2.46 (n=36)	5.02 (n=36)	Diff (95% Cl): -2.56 (- 5.17 to 0.04)	0.054
		9 wks. after last tx	3.07 (n=36)	2.91 (n=36)	Diff (95% CI): 0.16 (- 1.10 to 0.78)	0.733
	Headache duration (hours by average/time)	baseline	8.28 ± 13.81 (n=36)	4.65 ± 4.67 (n=36)	NR	NR
	(adjusted mean, for baseline)	end of tx (after 3 wks. of tx)	6.76 (n=36)	8.54 (n=36)	Diff (95% Cl): -1.78 (- 9.07 to 5.53)	0.629
		3 wks. after last tx	6.88 (n=36)	10.38 (n=36)	Diff (95% Cl): -3.50 (- 12.90 to 5.90)	0.459
		9 wks. after last tx	2.98 (n=36)	7.70 (n=36)	Diff (95% Cl): -4.72 (- 10.27 to 0.83)	0.094
	Headache Disability Index (HDI) score (0-100) (adjusted mean, for baseline)	baseline	37.47 ± 19.68 (n=36)	32.28 ± 17.96 (n=36)	NR	NR
		end of tx (after 3 wks. of tx)	29.95 (n=36)	29.83 (n=36)	Diff (95% Cl): 0.12 (- 6.62 to 6.85)	0.972
		3 wks. after last tx	26.40 (n=36)	28.25 (n=36)	Diff (95% Cl): -1.85 (- 9.97 to 6.25)	0.649

			Results (mean ± SD or % (n/N))		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
		9 wks. after last tx	28.12 (n=36)	27.77 (n=36)	Diff (95% Cl): 0.35 (- 7.32 to 8.01)	0.929
	PPT (pounds/cm2) (adjusted mean, for baseline)	baseline	2.71 ± 1.22 (n=36)	2.85 ± 1.20 (n=36)		
		end of tx (after 3 wks. of tx)	3.57 ± 1.41 (n=36)	2.62 ± 1.07 (n=36)	Diff (95% CI): 1.03 (0.54–1.53)	0.001
		3 wks. after last tx	3.72 ± 1.46 (n=36)	2.58 ± 1.05 (n=36)	Diff (95% CI): 1.22 (0.69–1.76)	0.001
		9 wks. after last tx	3.42 ± 1.46 (n=36)	2.63 ± 0.94 (n=36)	Diff (95% Cl): 0.84 (0.28–1.40)	0.004
	Analgesic medication use	baseline	25 (69.4%)	25 (66.7%)	NR	NR
		Not reported	10 (27.8%)	9 (25.0%)	NR	NR

Appendix Table G8. Efficacy Outcomes from RCTS Evaluating Transcranial Magnetic Stimulation for Chronic Migraine

				sults) or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
TMS vs. Sham						
Misra 2013	Proportion of patients with >50% improvement in headache frequency	4 wks. from end of tx	78.7% (37/47)	33.3% (16/48)	NR	P<0.0001
5 day treatment period	Proportion of patients with >50% improvement in pain frequency and mean severity (VAS 0-100)	4 wks. from end of tx	76.6% (36/47)	27.1% (13/48)	NR	P<0.0001
	Proportion of patients - headache severity - Normal (0)	4 wks. from end of tx	6.4% (3/47)	0% (0/48)	NR	NR
	Proportion of patients - headache severity - Mild (1)	4 wks. from end of tx	38.3% (18/47)	14.6% (7/48)	NR	NR
	Proportion of patients - headache severity - Moderate (2)	4 wks. from end of tx	46.8% (22/47)	45.8% (22/48)	NR	NR
	Proportion of patients - headache severity - Severe (3)	4 wks. from end of tx	8.5% (4/47)	39.6% (19/48)	NR	NR
	Proportion of patients - functional disability - Normal (0)	4 wks. from end of tx	13.3% (6/45)	0% (0/48)	NR	NR
	Proportion of patients - functional disability - Mild (1)	4 wks. from end of tx	51.1% (23/45)	25.0% (12/48)	NR	NR
	Proportion of patients - functional disability - Moderate (2)	4 wks. from end of tx	33.3% (15/45)	43.8% (21/48)	NR	NR
	Proportion of patients - functional disability - Severe (3)	4 wks. from end of tx	2.2% (1/45)	31.3% (15/48)	NR	NR
	Analgesic use/mo.	baseline	20.58 ± 16.76 (n=50)	17.52 ± 18.10 (n=50)	NR	NS
		4 wks. from end of tx	5.09 ± 5.94 (n=47)	6.71 ± 5.75 (n=48)	NR	P=0.18
		baseline	20.8 ± 9.5 (n=50)	17.0 ± 10.3 (n=50)	NR	NS

				esults D or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
	Headache frequency (attacks/mo.)	4 wks. from end of tx	5.2 ± 4.9 (n=47)	8.9 ± 6.6 (n=48)	NR	P<0.0001
	Headache severity (0-3, worse)	baseline	3 ± 0 (n=50)	3 ± 0 (n=50)	NR	NS
		4 wks. from end of tx	1.57 (n=47)	2.25 (n=48)	NR	P<0.0001
	Functional disability (0-3, worse)	baseline	3.26 ± 0.44 (n=50)	3.24 ± 0.43 (n=50)	NR	NS
		4 wks. from end of tx	1.24 (n=47)	2.06 (n=48)	NR	P<0.0001
	Proportion of patients who were satisfied	4 wks. from end of tx	78.7% (37/47)	29.2% (14/48)	NR	P<0.0001
•	Headache frequency (mean attacks/8 wks.; days)	baseline (8 wks. prior to tx)	9.36 ± 2.82	9.2 ± 2.6* (estimated from graph)	NR	NR
5 day treatment period		8 wks. from end of tx	6.79 ± 4.28	7.7 ± 4.2* (estimated from graph)	NS	NR
	Headache frequency (mean headache	baseline (8 wks. prior to tx)	14.3 ± 5.07	17.69 ± 11.63	NR	NR
	days/8 wks.)	8 wks. from end of tx	9.50 ± 6.80	13.15 ± 9.27	NR	NS
	Headache frequency (mean headache hrs./8 wks.)	baseline (8 wks. prior to tx)	125.93 ± 80.31	134 ± 100* (estimated from graph)	NR	NR
		8 wks. from end of tx	85.36 ± 72.27	103 ± 77* (estimated from graph)	NS	NR
	Headache severity (mean pain	baseline (8 wks. prior to tx)	6.26 ± 1.33	5.52 ± 1.72	NR	NR
	intensity/8 wks.; VAS 0-10)	8 wks. from end of tx	6.11 ± 1.26	5.17 ± 2.51	NR	NS
	Headache severity (mean number of pills)	baseline (8 wks. prior to tx)	15.15 ± 11.24	14.21 ± 10.13	NR	NR
		8 wks. from end of tx	11.81 ± 9.89	12.50 ± 14.65	NR	NS

Appendix Table G9. Efficacy Outcomes Results from RCTs Evaluating Trigger Point Injections for Chronic Tension-Type Headache

			Res (mean ± SD	ults or % (n/N))	Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
TPI vs. Placebo		•				
Karadas 2013	Number of painful days/mo.	baseline	20.2 ± 3.9 (n=24)	19.1 ± 3.5 (n=23)	NR	NR
1 wk (1 session every 3 days for a		12 wks. (3 mos.) after tx	7.5 ± 3.7 (n=24)	17.6 ± 4.0 (n=23)	NR	P<0.001
total of 3 sessions)	Δ from baseline, Number of painful days/mo.	12 wks. (3 mos.) after tx	-12.7 ± 3.6 (n=24)	-1.5 ± 3.1 (n=23)	NR	P<0.001
	Pain severity (VAS 0-100)	baseline	77.5 ± 6.1 (n=24)	76.2 ± 6.1 (n=23)	NR	NR
		12 wks. (3 mos.) after tx	38.7 ± 11.0 (n=24)	70.0 ± 10.3 (n=23)	NR	P<0.001
	Δ from baseline, Pain severity (VAS 0-100)	12 wks. (3 mos.) after tx	-38.8 ± 10.5 (n=24)	-6.2 ± 9.0 (n=23)	NR	P<0.001
	Medication use (no. analgesic drugs/mo., tablets)	baseline	9.8 ± 2.1 (n=24)	10.1 ± 2.6 (n=23)	NR	NR
		12 wks. (3 mos.) after tx	3.9 ± 2.1 (n=24)	9.0 ± 1.9 (n=23)	NR	P<0.001
	Δ from baseline, Medication use (no. analgesic drugs/mo., tablets)	12 wks. (3 mos.) after tx	-5.9 ± 1.4 (n=24)	-1.1 ± 1.6 (n=23)	NR	P<0.001
	Hamilton Depression Scale scores	baseline	20.0 ± 7.9 (n=24)	20.2 ± 7.3 (n=23)	NR	NR
		12 wks. (3 mos.) after tx	14.8 ± 5.9 (n=24)	19.2 ± 7.3 (n=23)	NR	P<0.001
	Δ from baseline, Hamilton Depression Scale scores	12 wks. (3 mos.) after tx	-5.2 ± 4.0 (n=24)	-1.0 ± 1.8 (n=23)	NR	P<0.001
	Hamilton Anxiety Scale scores	baseline	21.9 ± 5.6 (n=24)	21.7 ± 4.2 (n=23)	NR	NR
		12 wks. (3 mos.) after tx	14.6 ± 4.5 (n=24)	20.3 ± 4.1 (n=23)	NR	P<0.001
	Δ from baseline, Hamilton Anxiety Scale scores	12 wks. (3 mos.) after tx	-7.3 ± 4.0 (n=24)	-1.4 ± 2.2 (n=23)	NR	P<0.001

CI, confidence interval; F/U, follow-up; Mo., month; mos., months; NOS, not otherwise stated; NR, not reported; NS, not statistically significant; SD, standard deviation; tx, treatment; VAS, visual analog scale; wk., week; wks., weeks.

APPENDIX H. Data Abstraction Tables: Safety Outcomes

NOTE Additional safety outcomes information can be found in the report text. See section that follows these tables for safety information from unpublished trials from clinicaltrials.gov.

Appendix Table H1. Safety Outcomes from RCTs Evaluating BoNTA in Included Studies

			Re	sults n/N (%)	Effect Size (95% CI)	p-value
Author	Outcome	F/U post-tx	Intervention	Comparator		
BoNTA vs. Placebo						
Freitag 2008	Fever	16 wks.	0 (0.0)	2/21 (9.5%)	NR	NR
16 week study period	Backache	16 wks.	0 (0.0)	1/20 (4.8%)	NR	NR
io weekstaay period	Panic attack	16 wks.	0 (0.0)	1/20 (4.8%)	NR	NR
	Heaviness of arms	16 wks.	0 (0.0)	1/20 (4.8%)	NR	NR
	Confusion	16 wks.	0 (0.0)	1/20 (4.8%)	NR	NR
	Chest heaviness	16 wks.	0 (0.0)	1/20 (4.8%)	NR	NR
	Stiff neck	16 wks.	1/20 (5.0%)	1/20 (4.8%)	NR	NR
	Dizziness	16 wks.	0 (0.0)	1/20 (4.8%)	NR	NR
	Sinus infection	16 wks.	2/20 (10%)	0 (0.0)	NR	NR
	Hair loss	16 wks.	1/20 (5.0%)	0 (0.0)	NR	NR
	Amenorrhea	16 wks.	1/20 (5.0%)	0 (0.0)	NR	NR
Hamdy 2009	Hematoma at site of injection	12 wks.	1/14 (7.1%)	1/14 (7.1%)	NR	NR
16 week study period	Blepharoptosis	12 wks.	1/14 (7.1%)	0/14 (0.0%)	NR	NR
io week study period	Itching at site of injection	12 wks.	0/14 (0.0%)	1/14 (7.1%)	NR	NR
	Pain at site of injection	12 wks.	1/14 (7.1%)	1/14 (7.1%)	NR	NR
Kokoska 2004	Ptosis	24 wks.	3/20 (15%)	0 (0.0)	NR	NR
24 week study period	Diplopia	24 wks.	0 (0.0)	0 (0.0)	NR	NR
24 week study period	Facial nerve/expression problems	24 wks.	0 (0.0)	0 (0.0)	NR	NR

			Results	Effect Size (95% CI)	p-value	
Author	Outcome	F/U post-tx	Intervention	Comparator		
	Autonomic/systemic side problems	24 wks.	0 (0.0)	0 (0.0)	NR	NR
	Keratopathy	24 wks.	0 (0.0)	0 (0.0)	NR	NR
	Idiosyncratic or allergic reactions	24 wks.	0 (0.0)	0 (0.0)	NR	NR
Padberg 2004	Hematoma at injection site	12 wks.	0 (0.0)	2/21 (9.5%)	NR	NR
12 week study period	Frontal muscle weakness	12 wks.	1/19 (5.3%)	0 (0.0)	NR	NR
	Nausea	12 wks.	1/19 (5.3%)	1/21 (4.8%)	NR	NR
	Neck numbness	12 wks.	1/19 (5.3%)	0 (0.0)	NR	NR
Schmitt 2004	Increased headache	4 wks.	4/30 (13.3%)	4/29 (13.8%)	NR	NR
8 week study period	Increased headache	8 wks.	3/30 (10.0%)	0 (0.0)	NR	NR
o week study period	Other	4 wks.	4/30 (13.3%)	2/29 (6.9%)	NR	NR
	Other	8 wks.	0 (0.0)	0 (0.0)	NR	NR
Silberstein 2006 8 week study period	All adverse events	8 wks.	150U: 29/47 (61.7%) 100U: 33/51 (64.7%) 100U 3s: 33/52 (63.5%) 86U 3s: 28/51 (54.9%) 50U: 25/49 (51.0%)	26/50 (52.0%)	NR	NR
Ondo 2004	All adverse events	12 wks.	33	39	NR	NR
8 week study period						

Appendix Table H2. Safety Outcomes from RCTs Evaluating Acupuncture

			Resul (mean ± SD o		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
Chronic Migraine	9					
Vickers 2004	Headache after treatment	Unclear: "after treatment"	2.2% (4/186) (5 cases in 4 pts.)	NR	NR	NR
3 month treatment period	Withdrawal at 3 months due to adverse effects (NOS) (unclear if this patient is included in the count above)	12 wks.	0.6% (1/173)	0% (0/140)	NR	NR
	No serious adverse events (assumed based on statement "Confirming the excellent safety profile of acupuncture, the only adverse event reported was five cases of headache after treatment in four subjects.")	36 wks.	0% (0/186)	0% (0/193)	NR	NR
Yang 2011	"Serious adverse events"	Immediate	0% (0/33)	0% (0/33)	NS	NR
	Death	Immediate	0% (0/33)	0% (0/33)	NS	NR
	"Non-serious adverse events/side effects" (primarily related to local insertion of needles, i.e., local pain after tx, ecchymosis, local paresthesia during tx)	Immediate	6% (2/33)	NR	NR	NR
	Any non-serious adverse event (mostly mild and self- limiting)	Immediate	NR	66% (22/33)	NR	NR
	Paresthesia	Immediate	NR	48.4% (16/33)	NR	NR
	Difficulty with memory	Immediate	NR	36.3% (12/33)	NR	NR
	Dyspepsia	Immediate	NR	36.3% (12/33)	NR	NR
	Fatigue	Immediate	NR	24.2% (8/33)	NR	NR
	Dizziness	Immediate	NR	21.2% (7/33)	NR	NR
	Somnolence	Immediate	NR	18.1% (6/33)	NR	NR
	Nausea	Immediate	NR	12.1% (5/33)	NR	NR
	Adverse events leading to withdrawl from treatment	Immediate	0% (0/33)	9.1% (3/33)	NR	NR
Chronic Tension-	Type Headache					
Karst 2000	NR					
Soderberg 2006	NR					

			Results (mean ± SD or % (n/N))		Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
Tavola 1992	NR					
Carlsson 1990	"In a few patients, a slight vasovagal reaction was seen at the first treatment [in the acupuncture group]. Otherwise, no complications were noted."					

Appendix Table H3. Safety Outcomes from RCTs Evaluating Manual Therapy for Chronic Migraine and Chronic Tension-Type Headache

			Results (mean ± SD or % (n	Results (mean ± SD or % (n/N))		
Author	Outcome	F/U post-tx	Intervention	Control		
Nelson 1998 8 wk treatment period	Withdrawal due to side effects (NOS)	4 wks.	0% (0/58) ("Side effects in the SMT group were much more benign infrequent, mild and transitory (NOS); none required withdrawal from the study")	14.0% (7/50)	NR	NR
Castien 2011	"No adverse events were reported in both intervention groups."					

CI, confidence interval; NOS, not otherwise stated; NR, not reported; NS, not statistically significant; tx, treatment; SD, standard deviation; SMT, spinal manipulation therapy; U, units; wks., weeks;

Appendix Table H4. Safety Outcomes from RCTS Evaluating Massage Therapy for Chronic Daily Headache

					Effect Estimate (95% CI)*	p-value*
Author	Outcome	F/U post-tx	Intervention	Control		
Chatchawan 2014	Mild fever/mild soreness/other mild discomfort	9 wks.	16.7% (6/36)		"All (both groups) resolved w/in 15- 60 mins. without using meds."	NR

Appendix Table H5. Safety Outcomes from RCTs Evaluating Transcranial Magnetic Stimulation for Chronic Migraine

	Outcome	F/U post-tx	Results (mean ± SD or % (n/N))		Effect Estimate (95% CI)*	p-value*
Author			Intervention	Control		
TMS vs. Sham						
Misra 2013	Drowsiness	4 wks.	2.1% (1/47)	0% (0/48)	NR	P=0.5
5 day treatment period	Discomfort during treatment (mean on Face pain scale (0-5))	4 wks.	100% (47/47) (3.10 ± 0.71)	14.6% (7/48) (0.14 ± 0.35)	NR	P<0.0001
	Study withdrawal due to side effect (NOS; unclear if this is the same patient as above)	4 wks.	2.1% (1/47)	0% (0/48)	NR	NS
Teepker 2010	Assessment of visual motor threshold is uncomfortable	during tx	35.7% (5/14)	30.8% (4/13)	NR	NS
5 day treatment	Sitting is long-lasting and uncomfortable	during tx	7.1% (1/14)	7.7% (1/13)	NR	NS
period	Sleepiness	during tx	7.1% (1/14)	7.7% (1/13)	NR	NS
	Headache	during tx	14.3% (2/14)	0% (0/13)	NR	NS
	Amyostasia	"after treatment"	7.1% (1/14)	7.7% (1/13)	NR	NS
	Testiness	"after treatment"	7.1% (1/14)	7.7% (1/13)	NR	NS
	Vigorous dreams	"after treatment"	0% (0/14)	7.7% (1/13)	NR	NS
	Phonophobia	"after treatment"	0% (0/14)	7.7% (1/13)	NR	NS
	Withdrawal due to side effect (NOS)	"after treatment"	7.1% (1/14)	7.7% (1/13)	NR	NS

Appendix Table H6. Safety Outcomes from RCTS Evaluating Trigger Point Injections for Chronic Tension-Type Headache

			-	Results (mean ± SD or % (n/N))		
Author	Outcome	F/U post-tx	Intervention	Control	Effect Estimate (95% CI)*	p-value*
TPI vs. Placebo						
Karadas 2013	"no serious side effects [in any patient] observed before or after the applications"	NR	0% (0/24)	0% (0/24)	NR	NR
1 week (1 session every	Injection site and injection pain	NR	12.5% (3/24)	16.7% (4/24)	NR	NR
3 days for a total of 3 sessions)	Dizziness	NR	8.3% (2/24)	8.3% (2/24)	NR	NR
	Back pain	NR	8.3% (2/24)	12.5% (3/24)	NR	NR
	Cervical muscle spasm	NR	0% (0/24)	4.2% (1/24)	NR	NR

The following Tables contain safety information from unpublished trials from clinicaltrials.gov. Data in this section are included for completeness only and have not been addressed in this report as they do not meet the inclusion criteria.

NCT01432379: BOTOX[®] Prophylaxis in Patients with Chronic Migraine

Baseline n=1168 Completed n=783 Date completed: May 2015 155-195 U of BoNTA administered to the face, head, and neck areas approximately every 12 weeks for 1 year

Appendix Table H7. Unpublished Safety Outcomes from NCT01432379: BOTOX[®] Prophylaxis in Patients with Chronic Migraine, Primary and Secondary Outcomes.

Outcome Type	Follow-up	Outcome Title	Description	Incidence Rate* Number (95% Cl)
Primary	64 weeks	Incidence rate of dysphagia	Incidence rates reported for subjects with events 1,000 person-months, based on the first reported occurrence of dysphagia from study enrollment up to 64 weeks. Dysphagia was defined as difficulty or discomfort in swallowing	0.4 (0.1, 0.9)
Secondary	64 weeks	Incidence rate of intractable migraine	Incidence rates reported for subjects with events 1,000 person-months, based on the first reported occurrence of intractable migraine from study enrollment to 64 weeks. Intractable migraine was defined as a migraine that does not seem to go away	1.6 (0.9, 2.4)

*units were events per 1,000 person-months

Appendix Table H8. Unpublished Safety Outcomes from NCT01432379: BOTOX[®] Prophylaxis in Patients with Chronic Migraine, Serious Adverse Events.

Adverse Event	Rate of occurrence in BoNTA group n/N (%)	
Total # serious adverse events	61/1160 (5.26%)	
Blood and lymphatic system disorders	1/1160 (0.09%)	
Angina pectoris	1/1160 (0.09%)	
Myocardial infarction	1/1160 (0.09%)	
Pericarditis	1/1160 (0.09%)	
Vertigo positional	1/1160 (0.09%)	
Retinal detachment	1/1160 (0.09%)	
Upper abdominal pain	2/1160 (0.17%)	
Gastric Ulcer	1/1160 (0.09%)	
Gastrointestinal pain	1/1160 (0.09%)	
Incarcerated umbilical hernia	1/1160 (0.09%)	
Inguinal hernia	1/1160 (0.09%)	
Intestinal obstruction	1/1160 (0.09%)	
Device malfunction	1/1160 (0.09%)	
Cholecystitis	1/1160 (0.09%)	
Cholecystitis chronic	1/1160 (0.09%)	
Chronic sinusitis	1/1160 (0.09%)	
Gastroenteritis viral	1/1160 (0.09%)	
Herpes zoster	1/1160 (0.09%)	
Meningitis	1/1160 (0.09%)	
Pneumonia	1/1160 (0.09%)	
Pneumonia pneumococcal	1/1160 (0.09%)	
Urinary tract infection	1/1160 (0.09%)	
Craniocerebral injury	1/1160 (0.09%)	
Femoral neck fracture	1/1160 (0.09%)	
Hip fracture	1/1160 (0.09%)	
Post lumber puncture syndrome	1/1160 (0.09%)	
Radius fracture	1/1160 (0.09%)	
Intervertebral disc protrusion	1/1160 (0.09%)	
Musculoskeletal chest pain	1/1160 (0.09%)	
Rotator cuff syndrome	1/1160 (0.09%)	

Adverse Event	Rate of occurrence in BoNTA group n/N (%)
Breast cancer	1/1160 (0.09%)
Gastrointestinal carcinoma	1/1160 (0.09%)
Leiomyoma	1/1160 (0.09%)
Lipoma	1/1160 (0.09%)
Lung neoplasm malignant	1/1160 (0.09%)
Metastases to central nervous system	1/1160 (0.09%)
Metastases to lymph nodes	1/1160 (0.09%)
Migraine	11/1160 (0.95%)
Headache	3/1160 (0.26%)
Intracranial pressure increased	2/1160 (0.17%)
Cerebrovascular accident	1/1160 (0.09%)
Hemiplegic migraine	1/1160 (0.09%)
Migraine with aura	1/1160 (0.09%)
Monoparesis	1/1160 (0.09%)
Vllth nerve paralysis	1/1160 (0.09%)
Abortion	1/1160 (0.09%)
Abortion spontaneous	1/1160 (0.09%)
Depression	3/1160 (0.26%)
Bipolar disorder	1/1160 (0.09%)
Post-traumatic stress disorder	1/1160 (0.09%)
Nephrolithiasis	1/1160 (0.09%)
Urge incontinence	1/1160 (0.09%)
Breast hematoma	1/1160 (0.09%)
Breast mass	1/1160 (0.09%)
Cervical dysplasia	1/1160 (0.09%)
Pulmonary embolism	1/1160 (0.09%)

NCT02147561: A Safety and Efficacy Study of BOTOX[®] in Korean Adults with Chronic Migraine

Baseline n=280

Completed n=276

Date completed: February 2015

BoNTA injected across specific head and neck muscles on day 0

Appendix Table H9. Unpublished Safety Outcomes from NCT02147561: A Safety and Efficacy Study of BOTOX[®] in Korean Adults with Chronic Migraine, Primary Outcome

Outcome Type	Follow-up	Outcome Title	Description	Results, % or Mean $\Delta \pm$ SD
Primary	4 weeks	Percentage of patients with adverse events	An adverse event was considered any unfavorable or unintended sign, symptom, or diseases associated with the use of the study drug, whether or not considered related to the study drug	24.37%

Appendix Table H10. Unpublished Safety Outcomes from NCT02147561: A Safety and Efficacy Study of BOTOX[®] in Korean Adults with Chronic Migraine, Serious and Nonserious Adverse Events

Adverse Event	Rate of occurrence in BoNTA group n/N (%)
Total # serious adverse events	4/279 (1.43%)
Diarrhea	1/279 (0.36%)
Fever	1/279 (0.36%)
Common cold	1/279 (0.36%)
Migraine	1/279 (0.36%)
Hemoptysis	1/279 (0.36%)
Total # non-serious adverse events	38/279 (13.62%)
Muscle weakness	24/279 (8.60%)
Ptosis	14/279 (5.02%)

APPENDIX I. Clinical Experts

Janna Friedly, MD

Physiatry, Physical Medicine and Rehabilitation Assistant Professor Department of Rehabilitation Medicine University of Washington Seattle, WA

Robert Nicholson, PhD, LCP, FAHS Psychologist Mercy Hospital Center for Quality and Safety Chesterfield, MO